前往化源商城

129-20-4 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: SNCA-p-activity-luciferase
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION

1; Cells; 4 uL; Dispense 1500 HEK-293-SNCA-luc cells/well into Greiner 1536-well white / solid bottom tissue culture treated plate. The plate was covered with metal lids with gas-exchange holes.
2; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
3; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array. The plate was covered with metal lids with gas-exchange holes.
4; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
5; Dispense; 1 uL; Dispense Gly-Phe-7-amino-4-trifluoromethylcoumarin (GF-AFC, prepared at 125 uM in PBS) was added. The plate was covered with metal lids with gas-exchange holes.
6; Incubate; 30 min; Incubate at 37C, 5% CO2.
7; Detector; Fluorescence; Measure fluorescence with ViewLux microplate reader (PerkinElmer) equipped with 405/10 excitation and 540/25 emission filters.
8; Dispense; 3 uL; Dispense ONE-Glo (PerkinElmer) lucifase detection reagent was added to each well. Plates were covered with metal lids with gas-exchange holes.
9; Incubate; 15 min; Incubate at room temperature.
10; Detector; Luminescence; Measure luminescence with ViewLux microplate reader (PerkinElmer) equipped with clear filters.

NOTES (numbers refer to sequence above)
1; HEK-293-SNCA-luc were cultured and suspended in phenol-red free DMEM (4.5 g/L glucose, 25 mM HEPES, cat #21063 (Thermo)).
3; Compounds were added to the assay plate in an 11-point intra plate dose response, 1:3 titration in DMSO with a final concentration range of xxx - yyy uM. Vehicle-only plates, with DMSO being pin-transferred to every well, were inserted at the beginning of screening runs to confirm expected assay performance. Activity was normalized to wells containing medium only (-100% activity, full inhibition) and SNCA-luc cells treated with DMSO vehicle control (0% activity), contained on the same plate as test samples.
10; Signals were analyzed, and dose-response curves were fit using the Hill equation. Compounds in curve classes -1.1, -1.2, -2.1, -2.2 in the SNCA-luc assay were considered active. Compounds were eliminated from further consideration if also active (curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4) in the GF-AFC cytotoxicity assay.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0001896372 uMActivity at 0.0004510146 uMActivity at 0.0007501981 uMActivity at 0.0009728036 uMActivity at 0.00288 uMActivity at 0.00508 uMActivity at 0.00871 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.232 uMActivity at 0.457 uMActivity at 0.692 uMActivity at 1.068 uMActivity at 2.292 uMActivity at 3.859 uMActivity at 11.39 uMActivity at 17.02 uMActivity at 25.62 uMActivity at 57.25 uMActivity at 87.55 uMActivity at 183.4 uMActivity at 286.0 uMCompound QC
Inactive0-6.754.95490.97270.090117.540 0 0 18.940815.9527-1.59161.49698.9408QC'd by Sytravon
Inactive0-5.34.0950.99965.5-7.782340 0 0 1-11.1081-7.5736-7.73535.034-11.1081QC'd by Sytravon
Inactive0-5.154.95490.907-15.92079.540 0 0 117.87255.287413.9021-13.683917.8725QC'd by Sytravon
Activator35.481346.40950Single point of activity-4.452.5884145.9404-0.469131 0 0 035.59340.1678-0.39091.93335.593QC'd by Sytravon
Activator39.810772.26460Single point of activity-4.44.95490.951568.1912-4.073330 0 0 058.01175.8738-9.2278-8.522458.0117QC'd by Sytravon
Activator14.125445.33190Partial curve; partial efficacy; poor fit-4.852.40640.998240.7728-4.55912.41 0 0 040.0933-24.9557-3.884511.525440.0933QC'd by Sytravon
Inactive0-5.754.95490.9291-20.608633.154541 0 0 0-12.846445.456928.2161-28.42-12.8464QC'd by Sytravon
Inactive0-4.354.95490.855-24.2184-0.540 0 0 0-18.932-3.6477-2.4094.988-18.932QC'd by Sytravon
Inactive0-4.73.62720.862515-8.552340 0 0 014.477-2.951-13.7936-5.964614.477QC'd by Sytravon
Inactive0-6.74.95490.66373-16.86440 0 0 08.8169-15.726.3794-6.35998.8169QC'd by Sytravon
Inactive0-4.752.40640.999921.5-2.410141 0 0 020.218433.3778-2.42513.577120.2184QC'd by Sytravon
Inactive0-4.44.95490.81172.5-8.34540 0 0 01.096-8.966-5.5054-11.12091.096QC'd by Sytravon
Activator39.810738.79450Single point of activity-4.44.95490.624141.75572.961230 0 0 036.203921.355-6.3904-4.532536.2039QC'd by Sytravon
Inactive0-6.054.0950.9994-6.05182040 0 0 120.515619.73771.4122-6.293220.5156QC'd by Sytravon
Inactive0-5.24.095110.5-10.168341 0 0 1-15.988436.1362-10.14028.7939-15.9884QC'd by Sytravon
Inactive0-6.51.39050.9999-24.2410.274540 0 0 1-5.5981-4.3546-20.7587-23.9509-5.5981QC'd by Sytravon
Inactive0-6.84.95490.711-2.44592140 0 0 0-3.345317.3219-9.95495.5495-3.3453QC'd by Sytravon
Activator39.810747.8090Partial curve; partial efficacy; poor fit-4.44.95490.521250.23992.43092.40 0 0 043.472230.2363-10.9855-11.514343.4722QC'd by Sytravon
Activator22.387275.50810Partial curve; high efficacy; poor fit-4.651.96730.982996.532421.02432.30 0 0 086.498526.093216.336536.261386.4985QC'd by Sytravon
Inactive0-6.84.95490.7429-1-13.073840 0 0 01.8063-11.31150.8702-5.17571.8063QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_AG_FLUO8_1536_1X%ACT PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as agonists of the human M1 muscarinic receptor (CHRM1; M1). In this assay, CHO-K1 cells stably expressing human M1 are loaded, intracellularly with the calcium indicator dye, Fluo-8, followed by treatment with agonist control or test compounds. As designed, compounds that act as CHRM1 agonists will increase intracellular calcium mobilization, resulting in increased relative fluorescence of the indicator dye and well fluorescence. Compounds are tested in singlicate at a final nominal concentration of 3 uM.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 ug/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 uL of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 uL of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were dispensed to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470-495 nm excitation and 515-575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices). Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay. A ratio for each well was calculated to normalize assay data, according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read.
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent activation was calculated from the median ratio as follows:

%_Activation = ( ( Ratio_Test_Compound - Median_Ratio_Low_Control ) / ( Median_Ratio_High_Control - Median_Ratio_Low_Control ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing DMSO.
High_Control is defined as wells containing Acetylcholine (EC100) and DMSO.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally activating compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent activation of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter for the entire run, i.e. any compound that exhibited greater % activation than the entire screen's cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed primary activation. Negative % activation values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-1, and for inactive compounds 1-0.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50 ug/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250 mM (pH 8.0); (Sigma P8761)
Agonist: Acetylcholine (50 mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Activation at 3 uM
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CYP273
Protocol: Tox21 Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a BioRaptr Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). Compounds dissolved in DMSO and positive control (furafyllline) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000075213 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000689059 uM-Replicate_1Activity at 0.0001619730 uM-Replicate_1Activity at 0.0003751800 uM-Replicate_1Activity at 0.0007781017 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00657 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-3.5643-2.3504-2.9312-2.3657-2.8224-2.60180.03942.8539-0.9099-0.8614-3.0049-2.5808-0.7-3.5643QC'd by SIGMAInactive0
Inactive0004-4.9449-1.1401-4.88281.72781.7167-2.1117-5.69640.39330.89390.1314-2.73353.195-4.9521-4.9449QC'd by SIGMAInactive0
Inactive00042.7107-2.18841.39851.45820.7693-2.47871.522.89860.9702-0.02532.12932.77661.5392.7107QC'd by EnamineInactive0
Inactive0004-2.1522-2.3143-3.894-2.36983.0635-2.9724-0.6981.807-0.3874-2.23870.0851-4.19653.0171-2.1522QC'd by SIGMAInactive0
Inactive0-4.34892.25260.8543-15.2749-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.3957-1.8486-1.8251-1.3415-0.2999-5.8043-1.46250.1520.0394-2.6869-2.4228-2.2664-9.6519-14.3957QC'd by SIGMAInactive0-4.09892.18760.881
Inactive0-4.39891.34430.8661-18.2112-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.0093-2.34660.81450.3878-0.5249-2.2045-0.0596-0.3675-2.1137-2.5302-0.6582-8.8446-8.7305-16.0093QC'd by AcrosInactive0-4.19891.62660.9372
Inactive0-4.37131.3310.7782-33.4439-3.50340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.5366-4.0189-0.7745-2.4487-0.7353-13.4714-1.9963-2.0808-1.5803-2.9931-5.0804-13.0346-7.2628-16.8143-29.5366QC'd by LightBiologicalsInactive0-4.37131.22210.9463
Inactive0-4.14891.62660.9461-28.1716-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.143-1.7608-0.23880.22480.5264-2.4986-0.1313-2.2365-0.2423-3.4362-3.0971-3.2181-11.2156-20.143QC'd by EnamineInhibitor79.640731.491610Partial curve; partial efficacy; poor fit-4.09892.58840.988
Inhibitor79.640737.878410Partial curve; partial efficacy; poor fit-4.09892.33320.6037-41.3784-3.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.14860.0477-0.2424-0.1109-17.1482-2.60430.09871.3021-8.8121-0.6811-2.6079-6.0005-11.8578-31.1486QC'd by LightBiologicalsInhibitor70.979933.811310Partial curve; partial efficacy; poor fit-4.14891.47870.9532
Inactive0-4.14891.3310.6595-35.6335-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.36121.8269-1.26512.0528-1.3342-1.1508-1.3078-0.329-8.12350.9213-0.3901-8.3475-13.4823-26.3612QC'd by LightBiologicalsInhibitor63.260940.716221Partial curve; partial efficacy-4.19891.55790.9889
Inhibitor31.7055100.219240Partial curve; high efficacy-4.49891.41630.9793-102.2947-2.0755-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.79751.59931.9578-0.4182-5.9156-12.3257-6.81250.6301-0.9357-7.8675-21.9718-39.1747-68.2733-88.7975QC'd by SIGMAInhibitor28.2576108.402740Partial curve; high efficacy-4.54891.24750.9984
Inactive0-4.44891.53860.9285-23.7863140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.48852.58192.144-0.92281.57780.3813-0.7273-0.01780.48032.4385-0.728-9.9293-11.8247-21.4885QC'd by SIGMAInactive0-4.39891.62590.9598
Inhibitor9.333739.896721Complete curve; partial efficacy-5.02992.04370.9899-39.89670-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.3129-0.2423-0.4463-0.29990.64780.36361.006-0.49871.2825-1.1546-7.8589-17.895-35.8398-36.3129QC'd by LightBiologicalsInhibitor11.750456.388421Partial curve; partial efficacy-4.92991.1110.9845
Inhibitor31.7055101.457340Partial curve; high efficacy-4.49891.1110.9982-102.7597-1.3024-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-82.349-1.7206-3.1014-1.0307-0.462-0.0614-0.5481-3.1286-4.6801-13.1432-23.5612-42.1146-67.192-82.349QC'd by SIGMAInhibitor25.184689.509140Partial curve; high efficacy-4.59891.37230.9943
Inactive0-4.39891.37230.9408-30.7143-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.2619-3.9038-4.25970.95220.2767-0.086-3.7725-0.0863-0.3476-4.4856-5.6587-11.4378-17.5999-27.2619QC'd by EnamineInactive0-4.39891.37230.9104
Inhibitor0.0291.537495Complete curve; high efficacy-7.69891.210.9985-95.5053-3.9679-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.9758-10.1145-26.2532-42.3865-67.4835-79.9456-90.8539-91.593-94.2489-95.4721-96.0956-96.1267-97.0582-96.9758QC'd by SIGMAInhibitor0.141694.840291Complete curve; high efficacy-6.84891.210.9987
Inhibitor70.979957.401421Partial curve; partial efficacy-4.14891.46410.9678-60.4859-3.0846-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-45.8227-1.5241-1.1304-2.119-3.4583-2.7138-4.9163-1.3699-5.0741-7.7268-8.2608-10.3758-24.1789-45.8227QC'd by TCIInhibitor63.260959.370621Partial curve; partial efficacy-4.19891.82650.9826
Inhibitor31.705588.458340Partial curve; high efficacy-4.49891.24750.9907-90.0614-1.6031-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-73.0646-2.1792-0.7242-0.9217-2.0267-1.1711-1.4022-1.5555-4.0648-12.1704-19.1709-32.2561-64.0802-73.0646QC'd by SIGMAInhibitor31.705586.838540Partial curve; high efficacy-4.49891.1110.9934
Inhibitor7.09899.944883Complete curve; high efficacy-5.14891.34430.9949-102.6257-2.681-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-98.8687-2.2636-1.9377-0.2674-0.3864-3.2139-8.5636-4.0834-14.5383-36.543-60.2337-91.3595-96.848-98.8687QC'd by TCIInhibitor5.638199.072784Complete curve; high efficacy-5.24891.62660.998
Inhibitor14.162399.52242Partial curve; high efficacy-4.84890.70.9894-100.6417-1.1197-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.2822-1.4919-2.9847-0.2649-1.6478-3.8502-2.8959-7.6423-18.6375-36.1235-44.1844-53.91-71.7844-88.2822QC'd by SIGMAInhibitor17.829395.774281Complete curve; high efficacy-4.74891.210.9995
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Mus musculus
External ID: CHEMBL1106141
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2010
Volume: 20
Issue: 8
First Page: 2546
Last Page: 2548
DOI: 10.1016/j.bmcl.2010.02.093

Target ChEMBL ID: CHEMBL375
ChEMBL Target Name: Mus musculus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition>50%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Mus musculus
External ID: CHEMBL1106140
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2010
Volume: 20
Issue: 8
First Page: 2546
Last Page: 2548
DOI: 10.1016/j.bmcl.2010.02.093

Target ChEMBL ID: CHEMBL375
ChEMBL Target Name: Mus musculus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition>20%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Mus musculus
External ID: CHEMBL1106139
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2010
Volume: 20
Issue: 8
First Page: 2546
Last Page: 2548
DOI: 10.1016/j.bmcl.2010.02.093

Target ChEMBL ID: CHEMBL375
ChEMBL Target Name: Mus musculus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=29%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:Burkholderia multivorans
External ID: HMS1625
Protocol: The fix-reporter plasmid was conjugated into this strain which the stably integrates into the chromosome using the mini-Tn7 system (PMID: 15908923). This plasmid consists of the fixK promoter, which is a target of the fixLJ pathway driving expression of GFP.
The day before screen an overnight culture of B. multivorans strain VC7102, with fix reporter, is set up in tryptic soy broth (TSB) at 37 degrees C with shaking. The day of the screen the overnight culture is diluted 1:100 in fresh tryptic soy broth.
The day of the screen, 30 microL of tryptic soy broth (TSB) is pipetted into columns 1-22 of a 384-well plate (Corning 3764) using the Combi multidrop dispenser. To column 24, 30 microL of TSB containing 78 microM of Benserazide TSB is added for a positive control. To column 23, 30 microL of TSB containing with DMSO (0.078% v/v in TSB) is added for a negative control. 300 nL of each compound are pin-transferred to each plate. For every compound plate 2 replicate assay plates are set up. 30 microL of the 1:100 diluted-B. multivorans strain VC7102 is added to each well using the Combi. Initial OD600 and GFP are measured using the PerkinElmer EnVision. Plates are stacked 5 high, covered with lids and incubated at 37 degrees C overnight (~18 h).
The following day, assay plates are read using a PerkinElmer EnVision (600 nm filter and GFP).
Positive control: Benserazide 39 microM in column 24 (No positive control was used for plates 2089 & 2090; Plates 2091-2093: columns 1 & 24)
Negative control: DMSO 300 nL/well in column 23 (For plates 2089 & 2090 negative controls were located in columns 2 & 24; plates 2091-2093: columns 2 & 23)
Comment: Analysis method:
For each compound well, the initial GFP value was subtracted from overnight GFP value to calculate the deltaGFP. The mean and standard deviation of the negative control wells deltaGFP (column 23) on both replicate plates was calculated. Wells with replicate average deltaGFP at least 3 standard deviations above the plate negative control deltaGFP average were scored as potential positives.

To determine activity scores, Z-scores were calculated for each replicate separately based on the replicate negative control deltaGFP plate average and standard deviation. The replicate average deltaGFP Z-scores were used for activity scores, with activity score of 100 set to Z-score = 4 and activity score = 0 (no activity) set to Z-score = 0. Z-scores > 4 were considered activity score = 100, and Z-scores < 0 were considered activity score = 0.
Avg_deltaGFP_Z-scoreAbsorbance_T0_AGFP_T0_AAbsorbance_T0_BGFP_T0_BAbsorbance_AGFP_AAbsorbance_BGFP_BdeltaGFP_AdeltaGFP_BAvg_deltaGFPdeltaGFP_A_Z-scoredeltaGFP_B_Z-score
-1.270.05825403560.05725477650.32326537670.3242670642113411122877118144-1.02538-1.51489
0.670.0624266120.0624127100.33225889350.33425870491623231743391683310.3877340.95318
-0.330.05925207730.05925090750.35426732820.3532672667152509163592158050-0.303321-0.354548
10.05924689030.0624661270.34126393810.34326573121704781911851808320.7401411.26456
0.740.10620472210.10720465420.56826607620.57126491096135416025676080540.5436960.932316
-0.660.09221234000.09121483410.52927175620.5272686607594162538266566214-0.115128-1.20669
-2.80.08421991470.08622312650.51327273860.512708166528239476901502570-2.3563-3.24802
-1.960.1121445580.10921539230.526876750.4922666280543117512357527737-1.8505-2.06856
-1.140.10420993670.10121425170.52326817780.5182664243582411521726552068-0.514625-1.7569
-1.270.0621639510.0621890320.47927247140.4792724846560763535814548288-1.25059-1.28825
0.440.11220635890.1121021270.54826852200.53626783436216315762165989240.8187310.0557383
-2.910.0821580040.07921702680.45726695940.4572657682511590487414499502-2.92231-2.8983
-0.490.09520760050.09621319850.52626668050.5242683829590800551844571322-0.229425-0.755007
-0.90.06220905540.06221416370.49726735090.4912677205582955535568559262-0.496131-1.29644
-0.250.11620795900.11521215660.52426775490.52526804075979595588415784000.0139578-0.522249
-2.520.06222558760.06122872190.51327838280.5092781307527952494088511020-2.36606-2.67629
-0.990.06521568750.06421851480.51427183540.5142737090561479551942556710-1.22625-0.751747
0.20.07622487490.07422362870.49828542360.49428440086054876077216066040.425044-0.0214336
-0.390.05921551930.06121585430.5327397010.5262750103584508591560588034-0.243403-0.538384
2.080.0821516730.07921560070.52828023590.52528361806506866801736654301.865212.29612
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Mus musculus
External ID: CHEMBL1106143
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2010
Volume: 20
Issue: 8
First Page: 2546
Last Page: 2548
DOI: 10.1016/j.bmcl.2010.02.093

Target ChEMBL ID: CHEMBL375
ChEMBL Target Name: Mus musculus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityNon-toxic
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_PAM_FLUO8_1536_1X%ACT PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as positive allosteric modulators (PAMs) and increase activity of the human M1 muscarinic receptor (CHRM1; M1) in cells pre-treated with a known agonist. In this assay, CHO-K1 cells stably expressing human M1 are loaded with the Fluo-8 calcium indicator dye, followed by addition of test compounds and subsequent treatment with the activator acetylcholine at a concentration that results in 20% activation (EC20). As designed, compounds that act as CHRM1 PAMs will increase calcium mobilization, resulting in increased intracellular calcium and relative fluorescence of the indicator dye beyond that of the EC20 of acetylcholine. Compounds are tested in singlicate at a final nominal concentration of 3 micromolar.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 degrees C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 micrograms/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 microliters of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 degrees C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 microliters of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 degrees C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were transferred to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470-495 nm excitation and 515-575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices) prior to all wells being treated with an EC20 concentration of acetylcholine. Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay. A ratio for each well was calculated to normalize assay data, according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read and;
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent activation was calculated from the median ratio as follows:

% Activation = ( ( Ratio_Test_Compound - Median_Ratio_Low_Control ) / ( Median_Ratio_High_Control - Median_Ratio_Low_Control ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing Acetylcholine at EC20 and DMSO.
High_Control is defined as wells containing Acetylcholine (EC100) and DMSO.

A mathematical algorithm was used to determine nominally activating compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent activation of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter on an individual plate basis, i.e. any compound that exhibited greater % activation than the plate based cutoff parameter was declared active.

PubChem Activity Outcome and Score:

The inactive compounds of this assay have an activity score range of 0 to 78 and the active compounds have an activity score range of 50 to 100.

The reported PubChem Activity Score has been normalized to 100% observed primary activation. Negative % activation values are reported as activity score zero.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50?g/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250mM (pH 8.0); (Sigma P8761)
Potentiator: Acetylcholine (50mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Activation at 3 uM
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.74
9.74
9.74
9.74
9.74
9.74
9.74
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: HERG01
Protocol: NCGC Assay Protocol Summary:

HERG assay (FluxORTM thallium flux assay) was initially developed by Invitrogen/Molecular Probes, and then miniaturized into 1536-well plate in a homogeneous format by NCGC. This assay measures the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells with a FDSS-7000 kinetic plate reader (Hamamatsu Corp., Hamamatsu City, Japan). The hERG ion channel is transduced into mammalian cells (U2OS) using a baculovirus (Bacmam) construct harboring the hERG K+ ion channel. So far we screened LOPAC1280 library (Sigma), the NTP collection of 1408 compounds, and the NCGC Pharmaceutical Collection (NPC), in which many well defined HERG blockers are present. The rank order potencies of many of these compounds are similar to that of other HERG assays (membrane potential, Rb+ flux, patch clamp, etc). This quick and homogeneous assay is also found to be sensitive, specific, and robust.

Using the FluxORTM thallium flux assay, the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells was measured in the U2OS cell line transduced with hERG K+ ion channel using a baculovirus (Bacmam) using Opti-MEM medium (Invitrogen) containing 2% fetal calf serum (FCS, HyCone) following loading buffer addition, compound treatment for around 10 minutes and finally adding stimulation buffer. The assay was performed in black clear Kalypsys 1536-well plates. In the screen, Astemizole was used as positive controls. Library compounds were measured for their ability to cause hERG channel blockage in the cell line, as reflected by a decrease in fluorescence intensity, in a concentration-dependent manner. Data were normalized to the controls for basal activity (DMSO only) and 100% inhibition (5uM Astemizole). AC50 values were determined from concentration-response data modeled with the standard Hill equation.

qHTS protocol for hERG-U2OS cellular assay

[Step] [Parameter] [Value] [Description]

1. Day 1: Replace medium in 70-80% confluent T225 flask with 2.5 mL of hERG-BacMam virus plus 12.5 mL of phosphate buffered saline (PBS) (corresponding roughly to a multiplicity of infection ratio of 100 virus particles/cell)
2. Incubation: 4 hrs @ room Temperature in Dark
3. Reagent; Remove virus; wash once with 25 ml DPBS
4. Reagent; 35 ml culture medium
5. Incubation; 37oC overnight
6. Day2: Reagent; 3 uL; 2000 U2OS cells/well
7. Time; 4 hr; 37oC incubation
8. Loading buffer; 1 uL; 0.7X;
9. Incubation: 1hr @ RT in Dark.
10. Compounds; 23 nL; 0.59 nM to 92 uM
11. Controls; 23 nL; Astemizole 1.4 nM to 92 uM
12. Time; 10min; 37oC incubation
13. Read fluorescence Intensity on FDSS for 10 Sec with 1 sec interval
14. Reagent; 1 uL; stimulation buffer
15. Read fluorescence Intensity on FDSS for 2 min with 1 sec interval
16. Detection; Fluorescence Intensity; FDSS
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001000000 uMActivity at 0.0003000000 uMActivity at 0.0006116734 uMActivity at 0.00133 uMActivity at 0.00297 uMActivity at 0.00673 uMActivity at 0.015 uMActivity at 0.033 uMActivity at 0.075 uMActivity at 0.167 uMActivity at 0.369 uMActivity at 0.412 uMActivity at 0.836 uMActivity at 1.842 uMActivity at 2.061 uMActivity at 4.179 uMActivity at 9.216 uMActivity at 20.61 uMActivity at 46.08 uMActivity at 92.17 uMCompound QC
Inactive04.0950.5622-0.5-17.405541 0 0 0 0 0 1 0 0 0 0 0 0 04.0358-8.1088-16.5879-0.7265-5.65844.3730.1327-9.70320.36854.1527-0.141-3.5272-0.9713-9.32034.0358QC'd by NIEHS/NTP
Activator15.848952.39750Single point of activity-4.80.40.510848.9806-3.416930 0 0 0 0 1 0 0 0 0 0 1 0 1 038.06212.0116-8.9739-7.06230-7.0944-39.2396018.733825.780800-59.539411.623748.215338.0621QC'd by NIEHS
Inactive04-1.0832-10.89741.0031-11.058-11.8883.65680.91825.31740.029-1.48932.17113.0788-19.8367-2.8584-1.0832QC'd by NIEHS/NTP
Inactive042.45982.223-1.63678.778-0.11389.22693.440711.6742-2.146511.8823-1.8078-2.0833.78254.49092.4598QC'd by NIEHS
Inactive01.85790.45754.5-21.089940 0 0 0 0 0 0 0 0 0 0 0 0 012.886-15.90830.10180.3771-0.02467.9993-3.79713.097311.63728.3022-2.66639.3202-2.3421-0.285412.886QC'd by NIEHS/NTP
Inactive04.95490.5492-6.77071.540 0 0 0 0 0 0 0 0 0 1 0 0 11.3669-1.0856-0.77651.12421.70580.7901-1.98696.09015.26593.2331-7.9279-28.3694-1.3017-10.22551.3669QC'd by NIEHS/NTP
Inactive04-5.5826-4.0359-4.4476-11.3473-11.9097-1.5507-10.1535-3.36261.3234-0.4426-13.9824-5.2512-18.0387-15.3022-5.5826QC'd by NIEHS/NTP
Inhibitor39.810751.900420Partial curve; partial efficacy-4.43.990.9828-50.13811.7623-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0-49.45943.1993-0.02692.7134-1.98075.29460.2133-0.1387-0.26252.47080.17772.53720.4925-30.4729-49.4594QC'd by NIEHS/NTP
Inactive02.33320.6977-10.8456140 0 0 0 0 0 1 0 0 0 0 1 0 1-1.1266-1.46111.2528-0.03690.02955.5889-3.03576.75064.5747-1.4797-0.1821-9.6414-1.4402-9.8713-1.1266QC'd by NIEHS/NTP
Inactive0414.60080.5397-1.6708-0.4130.96947.4259-2.25855.08697.9351-2.4752-5.6365.39961.849-2.487114.6008QC'd by NIEHS/NTP
Inactive00.70.5791-8.9231440 0 0 0 0 0 1 0 0 0 0 0 0 12.80633.51535.19381.41166.33634.612.742912.44016.0481-0.14110.3707-1.47812.4968-5.76932.8063QC'd by NIEHS/NTP
Inactive04-17.8369-10.5115-2.5586-8.8158-26.0957-0.4819-9.7892-2.01490.27332.7166-17.2183-0.47591.0932-12.7028-17.8369QC'd by NIEHS/NTP
Inactive04.95490.4427-9.7222-1.541 0 1 0 0 0 0 0 0 0 0 0 0 0-13.1018-5.53920.00687.73370.45884.0455-12.3759-6.57240.92181.9145-11.3469-7.6261-8.5179-8.6226-13.1018QC'd by NIEHS/NTP
Inactive03.1320.7434-16.07841.540 0 0 0 0 0 0 0 0 0 0 0 0 13.99653.3921-1.15561.97152.01773.8894-2.6092.87572.72384.1025-3.54462.1635-3.6983-12.9823.9965QC'd by NIEHS/NTP
Inactive047.53724.3881-20.20115.5178-1.37582.0045-1.44014.9593-2.11221.3726-3.0011-3.06771.18832.18177.5372QC'd by NIEHS/NTP
Inactive0411.45250.2692-0.1403-0.3748-11.74892.8347-5.054616.89840.0513.829-3.6094-0.51978.0326-1.547611.4525QC'd by NIEHS/NTP
Inactive049.99361.71397.16916.3352-0.34329.148-5.8673-1.564112.6111.82378.2616-0.66541.73632.63199.9936QC'd by NIEHS/NTP
Inactive0410.2340.52521.3877-1.9626-0.9425.6494-0.276911.70528.3766.8657-0.149-0.19442.6788-6.419210.234QC'd by NIEHS/NTP
Activator22.387233.89380Complete curve; partial efficacy; poor fit-4.652.25260.715133.99630.10251.40 0 0 0 0 0 0 0 0 0 0 0 0 025.52240.4272-0.9219-0.128-2.10618.1765-1.5863-10.226512.16486.8628-0.3193-6.515517.608732.268925.5224QC'd by NIEHS/NTP
Inactive049.98485.58260.0396-1.5504-1.30043.2953.988212.27428.06469.11922.031.29227.4225-2.99749.9848QC'd by NIEHS/NTP
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: SMAD3201
Protocol: Suspensions of trypsinized HEPG2 CAGA-GFP cells were dispensed into white, tissue culture-treated, solid 1536-well plates at 5uL/well (1000 cells/well final concentration) in DMEM medium supplemented with 1% FBS. Plates were incubated at 37 degrees C for 2 hours, after which 23 nL of compounds or DMSO were delivered to each well using a pin tool. One uL of recombinant TGF-beta in DMEM (1% FBS) was then dispensed (500 pg/mL final concentration), and plates were incubated at 37 degrees C for 18 hours. Two uL of CellTiter Glo (Promega), a luminescence-based viability reagent, was dispensed, followed by a 10 minute room temperature incubation. The plates were then measured on a PerkinElmer ViewLux plate reader for luminescence (clear filter) using a 5 second exposure. The %Activity was determined from the corrected luminescence values. Wells containing media only (no cells) were used to normalize %Activity of identified toxic compounds; media-only wells corresponded to 100%Activity (complete cell-killing), while DMSO-dosed cell controls were used to normalize 0%Activity (no toxicity).

Concentration-response curves were fitted to the signals arising from the resulting luminescence. The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity, and compounds were subsequently categorized based on their curve class. Toxic compounds showed concentration-dependent decreases in luminescence, concordant with a decrease in intracellular ATP concentration (CellTiter Glo's marker of viability), and thus a decrease in the number of viable cells. Inactive (non-toxic) compounds showed no effect on luminescence signal. Active (toxic) compounds showed concentration dependent decrease in luminescence.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description".

2. For all inactive (non-toxic) compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active (toxic) compounds, a score range was given for each curve class type given above. Active (toxic) compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.018 uMActivity at 0.037 uMActivity at 0.074 uMActivity at 0.164 uMActivity at 0.369 uMActivity at 0.461 uMActivity at 0.737 uMActivity at 0.922 uMActivity at 1.840 uMActivity at 2.300 uMActivity at 3.690 uMActivity at 4.610 uMActivity at 9.233 uMActivity at 20.57 uMActivity at 46.10 uMActivity at 92.20 uMCompound QC
Inactive40 0 0 0 00.259610.7694.1255-1.6909-0.74870.2596QC'd by "Chem Div"
Inactive40 0 0 0 0-0.8876-5.2018-3.67070.33032.9155-0.8876QC'd by "Chem Div"
Inactive40 0 0 0 0-4.2306-10.0984-0.7957-0.93222.0609-4.2306QC'd by "Chem Div"
Inactive45.8218-1.6618-3.05539.7773-4.1735.8218QC'd by "Chem Div"
Inactive4-3.265111.605-17.88485.978514.3087-3.2651QC'd by "Chem Div"
Inactive40 0 0 0 0-7.2413.20083.9728-4.51213.9811-7.241QC'd by "Chem Div"
Inactive40 0 0 0 0-9.8078.98690.34840.37287.0197-9.807QC'd by "Chem Div"
Cytotoxic17.782835.5846Partial curve; partial efficacy-4.752.30310.9974-42.6167-7.0321-2.20 0 0 0 0-39.1036-6.2767-6.4175-8.2439-13.6777-39.1036QC'd by "Chem Div"
Cytotoxic3.548140.0619Single point of activity-5.454.95490.8999-40.3659-0.3039-30 0 0 0 12.6367-8.3337.8061-1.7484-40.23322.6367QC'd by "Chem Div"
Inactive40 0 0 0 10.54241.65919.664714.274915.58960.5424QC'd by "Chem Div"
Inactive40 0 0 0 05.9628-8.298-2.31046.1361-3.44285.9628QC'd by "Chem Div"
Inactive40 0 0 0 0-1.0151-4.6247-5.8885-4.492-0.7127-1.0151QC'd by "Chem Div"
Inactive4-0.9022-1.288913.9053-1.0794.3101-0.9022QC'd by "Chem Div"
Inactive40 0 0 0 0-23.5202-1.57517.1469-12.67219.6037-23.5202QC'd by "Chem Div"
Inactive40 0 0 0 1-0.075-0.6173-0.87325.1352.1913-0.075QC'd by "Chem Div"
Cytotoxic35.481333.3813Single point of activity-4.454.95490.4913-37.3813-4-30 0 0 0 0-30.3178-0.6381-23.6633-3.83866.0591-30.3178QC'd by "Chem Div"
Inactive40 0 0 0 0-17.4140.1464-4.8771-5.0687-7.6162-17.414QC'd by "Chem Div"
Inactive4-4.6673-7.1501-3.3264-4.1232-3.249-4.6673QC'd by "Chem Div"
Inactive40 0 0 0 0-17.38786.57262.9374-7.8375-3.1433-17.3878QC'd by "Chem Div"
Inactive40 0 0 0 1-10.2269-7.0609-5.5812-5.82172.0518-10.2269QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Burnham Center for Chemical Genomics 靶标:cystic fibrosis transmembrane conductance regulator [Homo sapiens]
External ID: SBCCG-A764-CF-PAF-Primary-Assay
Protocol: Assay Materials:
KKLEB-NFkB-GFP cells (Assay Provider)
PAF(Assay Provider)
Fetal Bovine Serum (Hyclone SH30396.03)
Penicillin Streptomycin solution
L-glutamine (100X)
TrypLE (Invitrogen 12563)
DPBS without calcium and magnesium (1X)
Corning culture flasks
Black CellBind 1536-well plates (Corning 3833)
ATPlite (Perkin Elmer 6016739)

I. Cell Suspension
1- Dispense 3 uL/well of cells at 5X10;5 cells/mL to the whole plate (plate cells in 2% FBS assay media).
2- Spin down plates on Eppendorf centrifuge 5810 at 500 rpm for 1 minute.

II. Compound Addition:
3- Transfer test compounds to columns 5-48 and DMSO to columns 1-4 using the Labcyte ECHO 555.
4- Transfer volume of test compound and DMSO is 15nL, making 5uM compound concentration at 0.25% DMSO final.
5-Spin down plates on Vspin at 1000 rpm for 1 minute.
6-Put Kalypsys metal lids on plates, incubate plates at 37 degrees C with 5% CO2 for 2 hours.

III. Reagent Addition
7- Dispense 3 uL/well of serum free assay media to columns 1 and 2.
8- Dispense 3 uL/well of PAF (dilute in serum free assay media) to columns 3-48.
9- Spin down plates without lids on Vspin at 2000 rpm for 2 min
10- Put Kalypsys metal lids on plates, and incubate plates at 37 degrees C with 5% CO2 overnight.

IV. Reading plates:

11-Spin plates upside down with a container at 1000 rpm for 15 sec. Dab them with a tissue to dry them and Read immediately on envision for GFP fluorescence.
12-Dispense 6 uL/well of ATPlite (diluted in DPBS 1:1).
13-Spin down plates on Eppendorf centrifuge 5810 at 2000 rpm for 2 minutes without lids.
14-Incubate plates for 10 min at RT and run Luminescence read on Viewlux.
Comment: Compounds that demonstrated a corrected %Activity of >= 50% at 5 uM concentration are defined as actives in this assay.

The experimental values were normalized by the difference between values from neutral and stimulator control wells in each plate. Then normalized data was corrected to remove systematic plate patterns due to artifacts such as dispensing tip issues etc. Further information about data correction is available at http://www.genedata.com/products/screener.html.

To simplify the distinction between the inactives of the primary screen and of the confirmatory screening stage, the Tiered Activity Scoring System was developed and implemented. Its utilization for the assay is described below.

Activity Scoring
Activity scoring rules were devised to take into consideration compound efficacy, its potential interference with the assay and the screening stage that the data was obtained. Details of the Scoring System will be published elsewhere. Briefly, the outline of the scoring system utilized for the assay is as follows:
1) First tier (0-40 range) is reserved for primary and single-concentration confirmation screening data.
a. If outcome of the primary screen is inactive, then the assigned score is 0
b. If outcome of the primary screen is inconclusive, then the assigned score is 10
c. If outcome of the primary screen is active, then the assigned score is 20
d. If outcome of the single-concentration confirmation screen is inactive, then the assigned score is 21
e. If outcome of the single-concentration confirmation screen is inconclusive, then the assigned score is 25
f. If outcome of the single-concentration confirmation screen is active, then the assigned score is 30.
This scoring system helps track the stage of the testing of a particular SID. For the primary hits which are available for confirmation, their scores will be greater than 20. For those which are not further confirmed, their score will stay under 21.

2) Second tier (41-80 range) is reserved for dose-response confirmation data and is not applicable in this assay

3) Third tier (81-100 range) is reserved for resynthesized true positives and their analogues and is not applicable in this assay
%Activity at 5 uMValueMean LowStd Deviation LowMean High Std Deviation High
17.71388986164067.888625.22080144.63200104.91
-5.52023753164067.888625.22080144.63200104.91
-1.91947331164067.888625.22080144.63200104.91
4.91776516164067.888625.22080144.63200104.91
4.41681435164067.888625.22080144.63200104.91
7.11654104164067.888625.22080144.63200104.91
-16.92220014164067.888625.22080144.63200104.91
5.51825441164067.888625.22080144.63200104.91
-10.22135725164067.888625.22080144.63200104.91
13.11722580164067.888625.22080144.63200104.91
0.11996001164067.888625.22080144.63200104.91
-1.51994666164067.888625.22080144.63200104.91
12.61687553164067.888625.22080144.63200104.91
-12.42138337164067.888625.22080144.63200104.91
1.91864558164067.888625.22080144.63200104.91
14.31574274164067.888625.22080144.63200104.91
20.41414289164067.888625.22080144.63200104.91
67.4531762164067.888625.22080144.63200104.91
3.11778225164067.888625.22080144.63200104.91
53.5823431164067.888625.22080144.63200104.91
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_ANT_FLUO8_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as antagonists and decrease activity of the human M1 muscarinic receptor (CHRM1; M1) that have been pre-treated with a known agonist, with the end result being a decrease in intracellular calcium. In this assay, CHO-K1 cells stably expressing human M1 are loaded with the Fluo-8 calcium indicator dye. Compounds are added followed by treatment with the activator acetylcholine at a concentration that results in 80% activation (Ec80). As designed, compounds that act as CHRM1 antagonists will decrease calcium mobilization, resulting in decreased relative fluorescence of the indicator dye below that of the Ec80 of acetylcholine. Compounds are tested in singlicate at a final nominal concentration of 3 uM.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 ug/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 uL of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 uL of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were transferred to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470 - 495 nm excitation and 515 - 575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices) prior to all wells being treated with an EC80 concentration of acetylcholine. Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay.

Hits for this assay were determined according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read and,
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent inhibition was calculated from the median ratio as follows:

%_Inhibition = ( 1 - ( Ratio Test_Compound - Median_Ratio_High_Control ) / ( Median_Ratio_Low_Control - Median_Ratio_High_Control ) ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing Ec80 of acetylcholine and DMSO.
High_Control is defined as wells containing DMSO.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent inhibition of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter for each plate, i.e. any compound that exhibited greater % inhibition than that particular plate's cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed inhibition. Negative % inhibition values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-7, and for inactive compounds 80-0.

In this assay not all plates were run in the same batch. This resulted in batch-to-batch variation among the different batches of plates, thereby necessitating the use of a plate-based activity cutoff. For this reason the inactive and active scores overlap.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50 ug/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250mM (pH 8.0); (Sigma P8761)
Potentiator: Acetylcholine (50 mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 3 uM
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.47
6.47
6.47
6.47
6.47
6.47
6.47
6.47
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:Smad3 [Homo sapiens]
External ID: SMAD3101
Protocol: Suspensions of trypsinized HEPG2 CAGA-GFP cells were dispensed into white, tissue culture-treated, solid 1536-well plates at 5uL/well (1000 cells/well final concentration) in DMEM medium supplemented with 1% FBS. Plates were incubated at 37 degrees C for 2 hours, after which 23 nL of compounds or DMSO were delivered to each well using a pin tool. One uL of recombinant TGF-beta in DMEM (1% FBS) was then dispensed (500 pg/mL final concentration), and plates were incubated at 37 degrees C for 18 hours. The plates were measured on an Acumen eX3 Explorer plate reader for GFP fluorescence (ex488/em500-530). GFP values were calculated by determining the mean GFP fluorescence of individual cells, and compiling these values for each well to determine a total well GFP signal. The %Activity was determined from the corrected fluorescence values. A titration of the known TGF-B inhibitor SB431542 was included to monitor plate performance, while unstimulated HEPG2 (-TGF-B) control wells were used to normalize %Activity of identified inhibitors; unstimulated wells corresponded to 100%Activity (full inhibition), while stimulated cell controls (+DMSO) were used to normalize 0%Activity (no inhibition).

Concentration-response curves were fitted to the signals arising from the resulting fluorescence. The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity, and compounds were subsequently categorized based on their curve class. Active inhibitors showed concentration-dependent decreases in GFP fluorescence, concordant with a decrease in TGF-B/SMAD3-driven GFP expression. Inactive compounds showed no effect on fluorescence signal.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.018 uMActivity at 0.037 uMActivity at 0.074 uMActivity at 0.164 uMActivity at 0.369 uMActivity at 0.461 uMActivity at 0.737 uMActivity at 0.922 uMActivity at 1.840 uMActivity at 2.300 uMActivity at 3.690 uMActivity at 4.610 uMActivity at 9.231 uMActivity at 20.57 uMActivity at 46.10 uMActivity at 92.20 uMCompound QC
Inactive40 0 0 0 027.05699.939810.15150.16715.572127.0569QC'd by "Asinex Ltd."
Inactive40 0 0 0 1-4.9362-9.41412.0824-11.0493-7.696-4.9362QC'd by "Asinex Ltd."
Inactive40 0 0 0 15.95954.342-1.5624-2.6449-8.95385.9595QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-19.7473-1.4487.5701-38.1554-17.3097-19.7473QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-1.2351-5.5487-5.0573-16.62112.7653-1.2351QC'd by "Asinex Ltd."
Inactive40 0 0 0 07.1959-7.76824.48993.399213.37077.1959QC'd by "Asinex Ltd."
Inactive40 0 0 0 18.983315.3354.25354.1946-14.32368.9833QC'd by "Asinex Ltd."
Inactive40 0 0 0 07.9022-10.517413.4936-10.46867.23237.9022QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-11.834712.2839-2.7256-19.2666-5.8034-11.8347QC'd by "Asinex Ltd."
Inhibitor35.4813106.2444Single point of activity-4.454.44950.9934-109.7251-3.4808-30 0 0 0 0-84.6645-7.4849-2.0755-4.81140.1432-84.6645QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-3.6-2.07174.941415.4055-0.2463-3.6QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.7641028.345612.16980.90780.7641QC'd by "Asinex Ltd."
Inactive40 0 0 0 1-3.7338-9.95590.39868.925512.5033-3.7338QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-1.77973.8831.182-4.1851.7497-1.7797QC'd by "Asinex Ltd."
Inhibitor15.848938.9608Single point of activity-4.83.67720.9889-35.46083.5-30 0 0 0 0-32.8842.06775.8192.7318-1.3119-32.884QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-3.7978.4821-2.183612.765.4907-3.797QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-18.74991.02723.81520.51991.7606-18.7499QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.46409.4101-6.52060.90670.464QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.23719.7122-4.6112-6.6419-3.28890.2371QC'd by "Asinex Ltd."
Inactive40 0 0 0 13.67994.89241.7621-1.6686-4.49453.6799QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: APP-Toga-CHIKV-nsP2-f2-f9
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1.Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2.Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3.The plate was incubated at room temperature (protected from light) for 15 min
4.Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5.After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1.Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2.For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001943322 uMActivity at 0.0004169086 uMActivity at 0.0006184621 uMActivity at 0.00125 uMActivity at 0.00187 uMActivity at 0.00374 uMActivity at 0.00620 uMActivity at 0.011 uMActivity at 0.019 uMActivity at 0.034 uMActivity at 0.057 uMActivity at 0.103 uMActivity at 0.171 uMActivity at 0.309 uMActivity at 0.513 uMActivity at 0.958 uMActivity at 1.860 uMActivity at 2.874 uMActivity at 5.579 uMActivity at 8.623 uMActivity at 16.74 uMActivity at 25.51 uMActivity at 50.00 uMActivity at 83.33 uMActivity at 250.0 uMCompound QC
Inactive0004-3.9794-0.1198-7.062-11.5818-9.1944-3.8178-1.1441-5.6132-4.9511-5.5587-6.1624-3.9794QC'd by ACC
Inactive0-8.19790.30.608993140 0 0 0 0 0 0 0 0 0 010.172223.924224.655819.16521.660312.625318.76147.470919.892413.78158.189910.1722QC'd by Pharmaron
Activator8.955243.2190Partial curve; partial efficacy; poor fit-5.04791.3310.924736.0289-7.19012.40 0 0 0 0 0 0 0 0 0 029.4662-7.0776-6.47-9.2528-8.4641-9.2431-10.5751-5.22763.4595-2.881113.357829.4662QC'd by SIGMA
Inactive0-5.24790.40.3288-23.185-14.612940 0 0 0 0 0 0 0 0 0 0-20.7246-17.2155-15.3616-10.5108-18.084-14.0374-14.4678-15.7745-20.1988-20.9875-15.4123-20.7246QC'd by SIGMA
Activator7.113361.86540Partial curve; partial efficacy-5.14791.22210.985957.5474-4.3182.20 0 0 0 0 0 0 0 0 0 047.1053-2.7798-7.765-4.3513-5.9053-6.2870.5579-3.14590.608510.477728.702947.1053QC'd by Microsource
Inactive0-4.99790.60.627332840 0 0 0 0 0 0 0 0 0 026.108311.84129.28933.73345.70737.117815.20258.219319.316410.390817.592726.1083QC'd by Sequoia
Inactive0-5.74792.84730.9367-8.457912.540 0 0 0 0 0 0 0 0 0 0-9.131617.489614.59513.712112.150311.963210.01038.353810.3971-3.7628-7.349-9.1316QC'd by SIGMA
Inactive0-6.19790.60.544812-8.077540 0 0 0 0 0 0 0 0 0 1-5.6385-0.4717-21.3146-4.9131-1.5492-3.8745-4.9958-1.24894.18266.38268.2921-5.6385QC'd by Sytravon
Activator0.2832102.74350Partial curve; high efficacy-6.54791.78850.9885108.743562.10 0 0 0 0 0 0 0 1 1 1-95.91469.03367.02688.00912.495715.738721.831160.2571100.6884-22.8645-96.4497-95.9146QC'd by Sytravon
Inactive0-7.24790.50.705816240 0 0 0 0 0 0 0 0 0 17.40721.81285.59638.76350.293110.41188.75414.272511.851314.558914.81967.4072QC'd by Sytravon
Inactive0-6.09792.33320.5919-23.922-17.424240 0 0 0 0 0 0 0 0 0 0-24.9757-19.9067-14.6333-19.3926-16.8611-18.3099-13.2702-19.0908-20.4306-26.6017-20.1209-24.9757QC'd by Selleck
Activator2.523937.05290Partial curve; partial efficacy-5.59791.10.889926-11.05292.20 0 0 0 0 0 0 0 0 0 1-9.5741-14.2107-9.4787-6.7894-9.9383-13.1553-12.9138-4.80511.47322.279422.5785-9.5741QC'd by MedChem Express
Inactive0004-13.8524-9.282-5.697-4.2734-5.2179-3.3835-12.0959-4.84792.5228-14.939-6.0319-13.8524QC'd by Analyticon
Inactive0-5.65921.71370.8905-25.7583-14.342340 0 0 0 0 0 0 0 0 0 0-25.6319-16.1698-13.0793-14.8397-14.8495-13.9732-15.8115-12.3686-13.1319-19.083-21.7489-25.6319QC'd by Analyticon
Inactive0-7.50924.95490.619722.51340 0 0 0 0 0 0 0 0 0 19.598319.80839.92213.466214.199812.236423.007719.385826.190324.596918.43779.5983QC'd by Analyticon
Inactive0-7.84791.82650.8442-13.182-2.534240 0 0 0 0 0 0 0 0 0 0-17.235-1.6952-2.6747-4.1488-5.954-12.7639-12.1446-11.8915-10.8594-10.5634-16.1912-17.235QC'd by Analyticon
Inactive0004-17.7491-20.0995-21.9281-15.9595-15.8056-19.8756-17.2058-20.6448-14.277-20.5571-18.9876-17.7491QC'd by MedChem Express
Inactive0-6.44790.40.90323818.540 0 0 0 0 0 0 0 1 1 11.046919.221819.961723.310422.263624.416123.653128.414430.579620.197211.55121.0469QC'd by MedChem Express
Inactive0-5.25922.47290.682-17.827616.540 0 0 0 0 0 0 0 0 0 0-13.815121.03812.38782.682312.39217.096620.565119.339528.679215.0074.7718-13.8151QC'd by Analyticon
Inactive0-5.34791.10.676-42.4703-22.027640 0 0 0 0 0 0 0 0 0 0-37.2303-24.1889-23.1958-17.9964-27.2599-16.273-18.493-30.4886-23.3633-27.5267-38.9926-37.2303QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-f3_f16
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1a; Reagent; 3 uL; Papain in assay buffer.
1b; Reagent; 3uL; Assay buffer
2; Compound; 17 nL; Echo 655 acoustic dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature in the dark.
4: Reagent; 1 uL; Z-FR-AMC in assay buffer.
5; Incubation; 15 sec, 271g; centrifugation.
6; Detection; Fluorescence; time 0, Viewlux microplate reader (PerkinElmer) 355 nm excitation, 460 nm emission
7; Incubation; 10 min; room temperature
8; Detection; Fluorescence; time 10; ViewLux microplate reader (PerkinElmer), 355 nm excitation, 460 nm emission.

NOTES (numbers refer to sequence numbers above).
1a. Medium-binding black solid-bottom Greiner plates (cat. 789176-F). Dispense 3 uL of 1.33X papain in assay buffer (100 mM sodium acetate, pH 5.5, 5 mM dl-cysteine, 0.01% Tween-20 v/v) to columns 1, 2, 5-48 via Wako/Kalypsys dispenser. Papain (cat. P4762, Sigma) was dispensed to produce 5 nM final concentration. Enzyme solution kept on ice during experiment. Prepare papain as 50% glycerol (v/v) at final concentration of 10 mg/mL (427 uM, 100 U/mL). Sources: microplates (Greiner 789176-F), papain (Sigma P4762), sodium acetate (Bioworld 40120009-2), cysteine (Sigma 861677), Tween-20 (Sigma P1379), water (GIBCO 10977-015; Gibco).
1b. Dispense 3 uL of assay buffer (100 mM sodium acetate, pH 5.5, 5 mM dl-cysteine, 0.01% Tween-20 v/v) to columns 3 and 4 via Wako/Kalypsys dispenser. Assay buffer solution kept on ice during experiment.
2. Compound addition by single pin transfer (17 nL) using Wako pintool. Compound solutions in source plate: 169 nM to 10 mM DMSO stock solutions. Final concentrations: 0.664 nM to 39.2 uM, respectively. Final DMSO concentration: 0.5% (v/v).
3. RT incubation. Kalypsys lids used as microplate coverings. Protected from light.
4. Dispense 1 uL of 4x substrate mixture in assay buffer (100 mM sodium acetate, pH 5.5, 5 mM dl-cysteine, 0.01% Tween-20 v/v) to columns 1-48 via Wako/Kalypsys dispenser. Z-FR-AMC substrate was dispensed to produce 2 uM final concentration. Substrate solution kept on ice during experiment. Prepare Z-FR-AMC as 32.1 mM stock solution in DMSO. Source: Z-FR-AMC (HCl salt) (Bachem I-1160).
5. Centrifugation step to remove bubbles.
6. ViewLux microplate reader (PerkinElmer, Waltham, MA). Optics: excitation filter 340 (30) nm, emission filter 450 (20) nm. Energy = 2000. Exposure time = 2 sec.
7. RT incubation. Incubation time 10 min.
8. ViewLux microplate reader. Optics: excitation filter 340 (30) nm, emission filter 450 (20) nm. Energy = 2000. Exposure time = 2 sec.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008338173 uMActivity at 0.00124 uMActivity at 0.00249 uMActivity at 0.00373 uMActivity at 0.00749 uMActivity at 0.012 uMActivity at 0.023 uMActivity at 0.038 uMActivity at 0.069 uMActivity at 0.114 uMActivity at 0.206 uMActivity at 0.342 uMActivity at 0.619 uMActivity at 1.026 uMActivity at 1.916 uMActivity at 3.719 uMActivity at 5.749 uMActivity at 11.16 uMActivity at 17.25 uMActivity at 33.47 uMActivity at 51.01 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor2.5901109.960786Complete curve; high efficacy-5.58671.210.9897-108.96071-1.10 0 0 0 0 0 0 0 0 0 0-111.41171.55560.16860.5912-2.32080.5546-1.7222-9.4735-49.3194-78.617-90.0782-111.4117QC'd by Tocris
Inhibitor2.057490.645386Complete curve; high efficacy-5.686710.9996-95.4556-4.8103-1.10 0 0 0 0 0 0 0 0 0 0-91.4326-5.6107-5.4875-5.5173-5.2586-8.3832-11.5147-25.8607-48.4417-70.9035-84.9963-91.4326QC'd by SIGMA
Inhibitor2.590198.49686Complete curve; high efficacy-5.58674.0950.9994-101.9353-3.4393-1.10 0 0 0 0 0 0 0 0 0 0-102.3447-3.0022-2.6536-4.2124-2.3934-2.0327-2.9719-4.1726-25.8834-97.2501-101.4914-102.3447QC'd by NCGCChem
Inhibitor2.5901105.413785Complete curve; high efficacy-5.58670.80.9976-100.41375-1.10 0 0 0 0 0 0 0 0 0 0-90.95457.53544.46353.58863.2188-2.4359-10.3973-17.5405-39.749-63.8592-82.3674-90.9545QC'd by Tocris
Inhibitor12.98185.533582Complete curve; high efficacy-4.88674.95490.9967-87.5434-2.0099-1.10 0 0 0 0 0 0 0 0 0 0-85.325-1.8297-3.5602-3.91-1.0422-1.2527-1.4075-3.9675-0.4249-0.4411-70.6158-85.325QC'd by Sytravon
Inhibitor4.10593.343644Partial curve; partial efficacy-5.38670.70.9979-89.84363.5-2.20 0 0 0 0 0 0 0 0 0 0-77.65374.60332.57411.55570.6086-2.727-5.8785-14.7051-32.247-48.4602-62.0742-77.6537QC'd by APAC
Inhibitor9.189981.712442Partial curve; partial efficacy-5.03671.10.9987-84.3066-2.5942-2.20 0 0 0 0 0 0 0 0 0 0-72.9596-2.0933-3.4233-3.1998-2.8829-2.6472-1.7452-7.9092-14.2316-31.7647-56.8608-72.9596QC'd by Glixx
Inhibitor18.336272.984941Partial curve; partial efficacy-4.73672.04790.956-75.9849-3-2.20 0 0 0 0 0 0 0 0 0 0-70.3563-1.7343-12.6104-4.1714.03140.7429-2.4048-1.3619-5.566-12.2596-31.5981-70.3563QC'd by Princeton
Inhibitor18.336273.450741Partial curve; partial efficacy-4.73671.53860.9946-82.1193-8.6686-2.20 0 0 0 0 0 0 0 0 0 0-72.0345-7.7697-8.6785-9.0916-9.479-8.3494-7.2238-9.8284-10.1223-21.6905-41.8484-72.0345QC'd by Microsource
Inhibitor23.083988.658741Partial curve; high efficacy-4.63672.40640.9832-92.503-3.8444-2.10 0 0 0 0 0 0 0 0 0 0-90.6892-3.5026-2.9812-3.2189-4.6998-1.9536-5.3552-5.0547-4.555-8.1241-29.8904-90.6892QC'd by NCGCChem
Inhibitor2.906155.229123Complete curve; partial efficacy-5.53670.70.9915-52.22913-1.20 0 0 0 0 0 0 0 0 0 0-45.24942.53842.22822.66160.2019-1.9921-2.393-10.3912-22.8963-27.6273-41.5174-45.2494QC'd by MedChem Express
Inhibitor16.342181.36321Partial curve; partial efficacy-4.78671.28760.9793-77.8633.5-2.20 0 0 0 0 0 0 0 0 0 0-64.88584.62066.61036.34755.43191.9795-3.94211.1208-2.7854-12.2731-33.9047-64.8858QC'd by Microsource
Inhibitor18.336258.528921Partial curve; partial efficacy-4.73671.22210.9689-56.02892.5-2.20 0 0 0 0 0 0 0 0 0 0-46.69084.23963.60586.59553.80761.7487-1.2158-0.5062-1.333-10.3615-20.7839-46.6908QC'd by Microsource
Inhibitor18.336263.657421Partial curve; partial efficacy-4.73671.10.931-61.15742.5-2.20 0 0 0 0 0 0 0 0 0 0-50.96456.82263.13523.21093.8242.1658-3.03871.5869-9.9978-10.7579-20.2792-50.9645QC'd by MedChem Express
Inhibitor16.017653.680221Partial curve; partial efficacy-4.79541.10.9332-59.7413-6.061-2.20 0 0 0 0 0 0 0 0 0 0-47.4137-9.9147-8.0265-4.9002-7.74-1.7175-9.128-10.8321-13.0781-14.6739-24.7757-47.4137QC'd by Analyticon
Inhibitor11.273938.61321Partial curve; partial efficacy-4.94791.3310.9367-43.2673-4.6543-2.20 0 0 0 0 0 0 0 0 0 0-36.0561-3.0892-0.9619-5.6766-4.829-2.5548-6.7305-9.0092-6.7736-9.551-16.7432-36.0561QC'd by Analyticon
Inhibitor14.564967.495921Partial curve; partial efficacy-4.83671.10.983-68.9959-1.5-2.20 0 0 0 0 0 0 0 0 0 0-54.16350.8818-0.2331-1.50670.5982-1.1965-4.6761-8.0636-7.7637-15.5972-40.2452-54.1635QC'd by Glixx
Inhibitor16.342164.033421Partial curve; partial efficacy-4.78671.24750.987-60.03344-2.20 0 0 0 0 0 0 0 0 0 0-50.02786.60443.85072.66763.5393.9191.76213.45141.0614-12.3878-25.4689-50.0278QC'd by SIGMA
Inhibitor18.336270.455621Partial curve; partial efficacy-4.73671.62590.9803-68.95561.5-2.20 0 0 0 0 0 0 0 0 0 0-60.48735.82951.2932.17034.24110.8209-1.49341.094-2.4894-11.3309-27.749-60.4873QC'd by SIGMA
Inhibitor18.336252.926821Partial curve; partial efficacy-4.73671.41630.9896-55.8043-2.8775-2.20 0 0 0 0 0 0 0 0 0 0-46.5035-5.734-1.7587-1.7696-3.3881-1.8874-1.1479-3.8743-3.938-12.2677-26.0707-46.5035QC'd by Scientific Exchange
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-f
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Enzyme; 2 uL; 1,536-well solid-bottom, black plate (Greiner Bio One).
2; Compounds; 20 nL; Echo 655 acoustic dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature in the dark.
4: Reagent; 2 uL; Ac-DE-[Lys(5-TAMRA)]-EE-[Abu-psi(COO)Ala]-S-[Lys(ECLIPSE-7)]-amide.
5; Detection; Fluorescence; time 0, ViewLux microplate reader (PerkinElmer) 525 nm excitation, 598/25 nm emission
6; Incubation; 15 min; room temperature
7; Detection; Fluorescence; time 15; ViewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Two microliter of NS3-4A HCV enzyme solution (5 nM final concentration) in assay buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, with 0.01% Tween 20) were dispensed into a 1,536-well solid-bottom black plate (Greiner Bio One) using the Kalypsys Pintool Station.
2. Twenty nanoliter of compounds, positive control Aprotinin (50 uM final concentration), or neutral control DMSO were transferred to the assay plates. Compounds in counter-screen assays were tested at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
3. The assay plates were incubated in the dark for 15 min.
4. After incubation, 2 uL of 0.625 uM substrate (Ac-DE-[Lys(5-TAMRA)]-EE-[Abu-psi(COO)Ala]-S-[Lys(ECLIPSE-7)]-amide) in assay buffer (for NS3-4A assay) was added using the Kalypsys Pintool Station.
5-7. Plates were immediately read at time 0 then covered with stainless steel gasket lids and incubated for 15 min at room temperature in the dark. Fluorescence intensity in the assay plates were again read after incubation using the ViewLux imager equipped with Tamara fluorescence optics. The change in fluorescence intensity over the 15-min reaction period was normalized against DMSO and inhibitor controls as described below.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008333407 uMActivity at 0.00124 uMActivity at 0.00249 uMActivity at 0.00373 uMActivity at 0.00748 uMActivity at 0.012 uMActivity at 0.023 uMActivity at 0.038 uMActivity at 0.069 uMActivity at 0.115 uMActivity at 0.206 uMActivity at 0.344 uMActivity at 0.619 uMActivity at 1.033 uMActivity at 1.912 uMActivity at 3.719 uMActivity at 5.737 uMActivity at 11.16 uMActivity at 17.21 uMActivity at 33.48 uMActivity at 50.94 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor0.25992.105390Complete curve; high efficacy-6.58673.990.9964-92.10530-1.10 0 0 0 0 0 0 0 0 1 1000000-26.9057-94.1772-91.9507-86.4857-67.71240QC'd by GVK
Inhibitor0.205796.846490Complete curve; high efficacy-6.68670.50.9869-93.84643-1.10 0 0 0 0 0 0 0 0 0 0-88.36761.1189-13.0457-11.9936-16.2335-34.002-49.7919-58.5074-65.2049-76.2052-87.4254-88.3676QC'd by Cayman
Inhibitor0.81998.080488Complete curve; high efficacy-6.08674.95490.9998-98.08040-1.10 0 0 0 0 0 0 0 0 0 0-99.071100000-1.3807-18.4263-95.594-97.8277-98.7603-99.0711QC'd by SigmaAldrich
Inhibitor1.833690.267186Complete curve; high efficacy-5.736710.9788-90.7671-0.5-1.10 0 0 0 0 0 0 0 0 0 0-90.0467-11.97791.8615-1.11490.31450.4826-1.9658-28.8777-45.643-65.5697-80.455-90.0467QC'd by Sytravon
Inhibitor1.634297.729886Complete curve; high efficacy-5.78671.1110.9949-91.72986-1.10 0 0 0 0 0 0 0 0 0 0-91.54674.74716.6915.74934.61264.6496-4.2191-15.4016-52.1541-67.1067-83.4886-91.5467QC'd by Sytravon
Inhibitor1.634280.443285Complete curve; high efficacy-5.78671.41630.9844-82.9432-2.5-1.10 0 0 0 0 0 0 0 0 0 0-86.94260.0017-2.7057-0.96350.2371-10.9118-7.4073-13.1382-51.7572-66.8444-76.6984-86.9426QC'd by Sytravon
Inhibitor11.5693142.296983Complete curve; high efficacy-4.93674.95490.9843-146.2969-4-1.10 0 0 0 0 0 0 0 0 0 0-145.1358-11.1377-4.9584-14.1999-14.9851-11.52250000-127.65-145.1358QC'd by BOC Sciences
Inhibitor2.982882.380383Complete curve; high efficacy-5.52541.1110.9956-67.380315-1.10 0 0 0 0 0 0 0 0 0 0-66.408515.731216.408516.690113.75649.84876.8460.9994-27.4034-46.3695-59.0006-66.4085QC'd by ChemRoutes
Inhibitor5.167882.670583Complete curve; high efficacy-5.28671.69240.9917-84.1705-1.5-1.10 0 0 0 0 0 0 0 0 0 0-84.00242.33990.0403-2.9808-0.1304-2.852-3.4511-8.3788-9.4642-47.6561-71.3126-84.0024QC'd by ChemRoutes
Inhibitor0.579874.517767Complete curve; partial efficacy-6.23671.78850.9905-84.7108-10.1932-1.20 0 0 0 0 0 0 0 0 0 0-85.7922-6.411-13.187-13.2655-8.1855-13.3519-15.8017-54.0083-71.981-81.2068-87.6924-85.7922QC'd by Pharmaron
Inhibitor4.10572.3264Complete curve; partial efficacy-5.38671.50950.9933-89.4126-17.0927-1.20 0 0 0 0 0 0 0 0 0 0-90.3158-20.231-13.4106-18.193-17.5607-16.7098-16.5249-21.8958-32.2241-62.637-77.852-90.3158QC'd by Sytravon
Inhibitor10.311271.125562Complete curve; partial efficacy-4.98672.40640.9806-86.3626-15.2371-1.20 0 0 0 0 0 0 0 0 0 0-85.1702-13.7671-12.9532-14.248-25.2859-13.461-15.2839-12.6976-15.193-27.0044-68.8421-85.1702QC'd by Analyticon
Inhibitor9.189967.032862Complete curve; partial efficacy-5.03671.82650.9939-76.8664-9.8336-1.20 0 0 0 0 0 0 0 0 0 0-70.7322-10.7907-8.6988-8.6114-9.0149-11.4364-9.2773-12.7817-14.9845-27.5022-61.3355-70.7322QC'd by Chemdiv
Inhibitor8.1905106.357343Partial curve; high efficacy-5.08670.50.9661-114.4951-8.1378-2.10 0 0 0 0 0 0 0 0 0 0-86.7387-3.4482-13.2288-17.8624-15.8022-16.7275-16.6046-30.643-44.1175-47.0452-75.7003-86.7387QC'd by BIOMOL
Inhibitor11.5693128.704843Partial curve; high efficacy-4.93673.29750.9933-121.20487.5-2.10 0 0 0 0 0 0 0 0 0 0-121.6916-2.99137.44749.60127.73788.80399.956610.49748.9646-2.3207-89.0932-121.6916QC'd by NCGCChem
Inhibitor12.98167.215642Partial curve; partial efficacy-4.88671.10.9972-84.7948-17.5792-2.20 0 0 0 0 0 0 0 0 0 0-72.5718-16.8006-15.8993-18.304-17.8466-17.1874-19.286-19.9586-25.6491-34.807-56.3917-72.5718QC'd by Analyticon
Inhibitor16.3421132.313242Partial curve; high efficacy-4.78671.28760.9936-133.8132-1.5-2.10 0 0 0 0 0 0 0 0 0 0-111.511-1.0773-3.27710.19161.699-3.4092-5.8988-5.8666-5.6959-30.4121-64.6714-111.511QC'd by Life Chemicals
Inhibitor20.573598.567741Partial curve; high efficacy-4.68673.06540.9967-98.56770-2.10 0 0 0 0 0 0 0 0 0 0-96.6351.366200000000-36.802-96.635QC'd by APExBIO
Inhibitor23.0839122.554341Partial curve; high efficacy-4.63674.0950.8771-108.817213.7371-2.10 0 0 0 0 0 0 0 0 0 0-101.695-5.92085.54383.16447.27436.362713.609223.729537.428332.861-14.4157-101.695QC'd by NCGCChem
Inhibitor0.650655.936625Complete curve; partial efficacy-6.18672.72020.9428-55.43660.5-1.20 0 0 0 0 0 0 0 0 0 0-56.768000000-22.2431-60.7149-64.5173-39.0284-56.768QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-full-length
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL NSP2 full length enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008233323 uMActivity at 0.00124 uMActivity at 0.00246 uMActivity at 0.00377 uMActivity at 0.00739 uMActivity at 0.013 uMActivity at 0.023 uMActivity at 0.039 uMActivity at 0.069 uMActivity at 0.117 uMActivity at 0.206 uMActivity at 0.351 uMActivity at 0.618 uMActivity at 1.053 uMActivity at 1.927 uMActivity at 3.720 uMActivity at 5.782 uMActivity at 11.16 uMActivity at 17.34 uMActivity at 33.48 uMActivity at 50.65 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor1.0311106.093288Complete curve; high efficacy-5.986710.99-101.59324.5-1.10 0 0 0 0 0 0 0 0 0 0-98.4439.69810.004410.7127-6.9536-2.2974-11.3519-36.1756-62.6061-84.2015-97.0708-98.443QC'd by SigmaAldrich
Inhibitor0.919111.417488Complete curve; high efficacy-6.03671.10.9849-97.917413.5-1.10 0 0 0 0 0 0 0 0 0 0-96.36467.404918.91937.176321.7697-0.27442.4876-34.3663-61.0045-84.521-92.9929-96.3646QC'd by Selleck
Inhibitor1.4565108.77387Complete curve; high efficacy-5.83670.90.9912-101.2737.5-1.10 0 0 0 0 0 0 0 0 0 0-98.132810.07855.0453-2.210212.6454-0.7438-8.1305-26.4248-53.3465-74.5675-90.2675-98.1328QC'd by Selleck
Inhibitor1.2981107.823587Complete curve; high efficacy-5.886710.9927-101.32356.5-1.10 0 0 0 0 0 0 0 0 0 0-97.05321.48227.484311.22584.259-2.139-4.1769-31.5222-52.5312-85.691-92.9687-97.0532QC'd by Tocris
Inhibitor1.156992.80487Complete curve; high efficacy-5.93671.210.976-96.804-4-1.10 0 0 0 0 0 0 0 0 0 0-96.03577.5254-14.9467-7.974-2.01-12.1318-6.5988-36.504-61.4538-83.187-95.332-96.0357QC'd by SIGMA
Inhibitor1.456595.066587Complete curve; high efficacy-5.836710.9926-99.0665-4-1.10 0 0 1 0 0 0 0 0 0 0-95.99472.226-3.6974-10.351930.2584-11.8423-14.0904-31.1299-59.4844-78.33-91.9831-95.9947QC'd by NCGCChem
Inhibitor1.8336110.365186Complete curve; high efficacy-5.73671.24750.9945-99.365111-1.10 0 0 0 0 0 0 0 0 0 0-94.995815.797610.24626.95079.791910.4877.1488-16.8798-40.2744-77.7593-95.7275-94.9958QC'd by Microsource
Inhibitor2.0574107.49186Complete curve; high efficacy-5.68671.22210.9783-93.49114-1.10 0 0 0 0 0 0 0 0 0 0-92.234113.63262.353916.684313.807818.062618.6688-16.6338-34.2006-66.3978-87.0605-92.2341QC'd by Sytravon
Inhibitor2.0574110.033386Complete curve; high efficacy-5.68670.90.9865-101.53338.5-1.10 0 0 0 0 0 0 0 0 0 0-94.53752.57514.84352.581314.72980.6931-8.9626-15.325-43.8815-68.5449-89.3213-94.5375QC'd by Sytravon
Inhibitor1.4193104.591986Complete curve; high efficacy-5.84791.22210.9804-95.59199-1.10 0 0 0 0 0 0 0 0 0 0-91.56313.338212.1183.45719.685216.62987.975-15.319-22.3855-65.6932-86.2038-91.5631QC'd by Microsource
Inhibitor2.906193.574185Complete curve; high efficacy-5.53671.10.9812-95.0741-1.5-1.10 0 0 0 0 0 0 0 0 0 0-87.5452-10.254-2.4392-6.9481-0.21635.7988-1.9135-16.6748-36.4819-65.1695-80.976-87.5452QC'd by Sytravon
Inhibitor3.260799.032985Complete curve; high efficacy-5.48671.34430.9632-93.53295.5-1.10 0 0 0 0 0 0 0 0 0 0-91.6989-3.2822-3.856916.56124.99049.207314.3935-14.7708-21.951-60.88-83.1689-91.6989QC'd by Sytravon
Inhibitor4.10587.564284Complete curve; high efficacy-5.38671.34430.9761-91.5642-4-1.10 0 0 0 0 0 0 0 0 0 0-86.7085-6.111-5.8563-10.9621-8.20018.6265-8.333-8.9422-26.9277-56.1051-82.3696-86.7085QC'd by Sytravon
Inhibitor4.10594.757984Complete curve; high efficacy-5.38672.53340.9206-89.75795-1.10 0 0 0 0 0 0 0 0 0 0-94.487-2.0682-6.881818.97199.079426.6747-3.0833-13.5252-0.671-59.3912-82.4679-94.487QC'd by Sytravon
Inhibitor5.1678111.309384Complete curve; high efficacy-5.28671.1110.972-99.809311.5-1.10 0 0 0 0 0 0 0 0 0 0-90.123318.46670.454721.0592.25616.804310.3614-3.5838-12.6269-47.0769-77.3938-90.1233QC'd by Sytravon
Inhibitor4.7274110.237784Complete curve; high efficacy-5.32540.90.9989-105.23775-1.10 0 0 0 0 0 0 0 0 0 0-95.3244.46492.41734.84984.69613.5345-3.5636-16.4321-36.8529-65.4142-85.8945-95.324QC'd by ChemRoutes
Inhibitor6.6764102.715483Complete curve; high efficacy-5.175510.9925-85.715417-1.10 0 0 0 0 0 0 0 0 0 0-78.274524.400614.971411.383313.800814.663512.97462.3962-20.6265-48.4262-68.5588-78.2745QC'd by SigmaAldrich
Inhibitor6.505996.411583Complete curve; high efficacy-5.18671.98870.985-81.911514.5-1.10 0 0 0 0 0 0 0 0 0 0-82.35358.798114.34957.773819.733320.147916.82811.749112.1698-29.6807-65.7541-82.3535QC'd by Microsource
Inhibitor9.189994.261583Complete curve; high efficacy-5.03674.95490.984-98.2615-4-1.10 0 1 0 0 0 0 0 0 0 0-96.33483.9892-13.509951.244-3.2532-4.06541.2359-5.945-8.4138-9.4606-95.1238-96.3348QC'd by SIGMA
Inhibitor7.299894.557283Complete curve; high efficacy-5.13671.66040.9244-98.5572-4-1.10 0 0 0 0 0 0 0 0 0 0-91.766513.2607-14.95846.5402-15.1959-12.7095-5.0389-9.5867-19.5062-34.0351-85.2014-91.7665QC'd by Cayman
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-f18-cell-based
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1a; Cell Transfection; Lipofectamine 2000.
1b; Cell; 4 uL; Aurora 1536-well, white, tissue culture plate.
2; Incubation; 4 hr; 37C, 5% CO2, 95% humidity.
3; Compound; 20 nL; Echo 650 Liquid Handler.
4; Incubation; overnight; 37C, 55 CO2, 95% humidity.
5; Reagent; 4 uL; Nano-Glo Luciferase assay system.
6; Centrifugation; 2 sec.
7; Detection; Luminescence; ViewLux plate reader (PerkinElmer).

NOTES (numbers refer to sequence numbers above).
1a. For the 1,536-well assay, cells were transfected in T75 flasks using a reverse transfection procedure, where 9 mL of complexes containing 45 uL Lipofectamine 2000 (ThermoFisher Scientific), 20 ug nsP2 plasmid, and 0.2 ug Nluc reporter plasmid, were combined with 10 mL of HEK293T cell suspension (1x10^6 cells/mL, 10 million cells total). Complexes containing Transfection Carrier DNA (Promega) and Nluc reporter plasmid (also at 1:100 ratio) were used as a high-signal control. After 24h, cells were harvested by trypsinization and resuspended at a density of 1x10^6 cells/ml.
1b. Cells were dispensed (4 uL cell/well) into 1,536-well white plates (Aurora, cyclic olefin polymer, cat# EWB041000A) using a Multidrop Combi.
2-4. After 4 hours, compounds (20 nL) were subsequently pinned using an Echo 650 Series Liquid Handlers and incubated overnight at 37C.
5. Nano-Glo (Promega) reagent was added (4 uL /well) according to the manufacturer's recommendations.
6-7. The Plates were centrifuged and analyzed for luminescence intensity using a ViewLux reader.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008286089 uMActivity at 0.00124 uMActivity at 0.00248 uMActivity at 0.00373 uMActivity at 0.00744 uMActivity at 0.013 uMActivity at 0.023 uMActivity at 0.040 uMActivity at 0.069 uMActivity at 0.111 uMActivity at 0.206 uMActivity at 0.353 uMActivity at 0.624 uMActivity at 1.115 uMActivity at 1.930 uMActivity at 3.480 uMActivity at 5.807 uMActivity at 11.67 uMActivity at 17.60 uMActivity at 33.48 uMActivity at 51.06 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor1.412597.022587Complete curve; high efficacy-5.850.90.957-104.5706-7.5482-1.10 0 0 0 0 0 0 0 0 0 0-97.2822-11.2901-18.8772-11.6693-43.4765-44.248-44.8652-79.0266-84.1272-97.3439-97.9126-97.2822QC'd by GVK
Inhibitor1.4565126.346487Complete curve; high efficacy-5.83671.69240.9931-110.846415.5-1.11 0 0 0 0 0 0 0 0 0 0-107.409337.871713.682213.064213.776920.336416.8573-14.9483-55.8355-105.909-107.0903-107.4093QC'd by Chemdiv
Inhibitor0.4606100.414987Complete curve; high efficacy-6.33674.95490.928-79.296321.1186-1.10 0 0 0 0 0 0 0 0 0 0-80.69525.98363.899320.805713.096232.323152.0621-68.7904-68.3183-79.5773-81.684-80.6952QC'd by Chemdiv
Inhibitor2.0574127.04387Complete curve; high efficacy-5.68671.46410.9422-115.04312-1.10 0 0 0 0 0 0 0 0 0 0-108.296627.274827.23495.92651.1464-4.6804-0.5882-17.3408-29.4928-107.7134-107.9427-108.2966QC'd by NCGCChem
Inhibitor2.5901129.453786Complete curve; high efficacy-5.58671.82650.9531-115.953713.5-1.10 0 0 0 0 0 0 0 0 0 0-106.89125.29617.7047-2.168223.67114.5545-10.467319.514-32.1645-97.9389-107.1103-106.891QC'd by Sytravon
Inhibitor2.590197.869686Complete curve; high efficacy-5.58674.50450.9733-101.8696-4-1.10 0 0 0 0 0 0 0 0 0 0-102.3291-9.4766-13.236-4.3824-14.7087-2.633912.43521.8642-20.9241-97.3951-102.8986-102.3291QC'd by Chemdiv
Inhibitor2.0574116.348186Complete curve; high efficacy-5.68672.25260.9818-104.848111.5-1.10 0 0 0 0 0 0 0 0 0 0-99.988917.87645.414518.601721.38231.31256.6781-1.5616-36.6071-101.7374-101.5594-99.9889QC'd by NCGCChem
Inhibitor4.6058118.776985Complete curve; high efficacy-5.33673.990.9688-109.27699.5-1.10 0 0 0 0 0 0 0 0 0 0-107.319627.49919.9838-0.73770.5034-4.102211.125217.550211.1202-74.9358-107.3595-107.3196QC'd by Sytravon
Inhibitor5.6234109.163984Complete curve; high efficacy-5.251.88510.9652-105.16394-1.10 0 0 0 0 0 0 0 0 0 0-96.78411.62524.71273.4254-4.5143-4.9331-20.5877-16.0337-50.9533-98.0537-98.468-96.784QC'd by DC Chemicals
Inhibitor7.2998107.495784Complete curve; high efficacy-5.13671.22210.9783-111.4957-4-1.10 0 0 0 0 0 0 0 0 0 0-103.2367-13.2538-0.02672.0065-5.81943.6661-9.6857-15.95-22.7304-46.7644-84.8842-103.2367QC'd by NCGCChem
Inhibitor11.569397.536882Complete curve; high efficacy-4.93674.95490.9485-101.0368-3.5-1.10 0 0 0 0 0 0 0 0 0 0-99.6418-12.43523.0387-14.6153-12.22614.35122.43818.8048-13.72541.3125-89.3911-99.6418QC'd by Chembridge
Inhibitor11.569398.82882Complete curve; high efficacy-4.93674.50450.9121-102.828-4-1.10 0 0 0 0 0 0 0 0 0 0-102.6227-1.8731-15.5763-26.5166-12.5464-17.5339-1.8642-10.07279.9126-6.6647-86.3836-102.6227QC'd by Vitas
Inhibitor23.083979.475841Partial curve; partial efficacy-4.63674.0950.8235-82.9758-3.5-2.20 0 0 0 0 0 0 0 0 0 0-77.0049-11.7145-10.8602-14.62426.090818.6951-3.1322-12.0125-9.70796.7448-19.7584-77.0049QC'd by NCGCChem
Inhibitor20.573599.804841Partial curve; high efficacy-4.68671.71370.8734-98.30481.5-2.10 0 0 0 0 0 0 0 0 0 0-86.23230.8676-9.5389-7.5191.041115.211411.478716.8843-15.6741-12.7422-33.4839-86.2323QC'd by NCGCChem
Inhibitor20.573583.186341Partial curve; partial efficacy-4.68672.72020.8668-73.68639.5-2.20 0 0 0 0 0 0 0 0 0 0-73.338822.12982.3847-10.384210.49990.102319.660520.92419.88146.9673-17.4182-73.3388QC'd by NCGCChem
Inhibitor18.3362121.834541Partial curve; high efficacy-4.73672.78680.9485-108.334513.5-2.11 0 0 0 0 0 0 0 0 0 0-101.2702-23.8516-2.073330.62758.119614.1175.098717.920920.43917.8615-40.4645-101.2702QC'd by Chembridge
Inhibitor20.573584.41341Partial curve; partial efficacy-4.68672.33320.892-78.4136-2.20 0 0 0 0 0 0 0 0 0 0-72.8494-2.82072.460317.213514.93561.846412.4664-6.695915.6163-7.5679-24.6257-72.8494QC'd by NCGCChem
Inhibitor20.573592.825941Partial curve; high efficacy-4.68674.0950.9171-78.325914.5-2.10 0 0 0 0 0 0 0 0 0 0-73.226310.5264-3.15115.104918.850515.991227.25478.379713.951423.9589-13.1452-73.2263QC'd by NCGCChem
Inhibitor20.573583.187141Partial curve; high efficacy-4.68673.1320.8423-62.127821.0593-2.10 0 0 0 0 0 0 0 0 0 0-64.6929-2.536422.293214.267618.280420.7337.992716.454438.665223.812-8.8563-64.6929QC'd by NCGCChem
Inhibitor0.579833.910523Complete curve; partial efficacy-6.23674.44950.9281-32.91051-1.20 0 0 0 0 0 0 0 0 0 0-32.7721-6.1106-3.99926.126-3.02061.918710.2023-19.0021-31.9399-32.7413-33.1189-32.7721QC'd by Cayman
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-f5_f16-endo
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM endogenous NS2/3 peptide substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of endogenous NS2/3 peptide substrate (peptide 3: TMR-DELRLDRAGC/APSYR-K-QSY7; 2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008338173 uMActivity at 0.00124 uMActivity at 0.00249 uMActivity at 0.00373 uMActivity at 0.00749 uMActivity at 0.012 uMActivity at 0.023 uMActivity at 0.038 uMActivity at 0.069 uMActivity at 0.114 uMActivity at 0.206 uMActivity at 0.342 uMActivity at 0.619 uMActivity at 1.026 uMActivity at 1.916 uMActivity at 3.719 uMActivity at 5.749 uMActivity at 11.16 uMActivity at 17.25 uMActivity at 33.47 uMActivity at 51.01 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor0.81987.038587Complete curve; high efficacy-6.08671.34430.9961-84.53852.5-1.10 0 0 0 0 0 0 0 0 0 0-87.51391.114002.97934.2662-7.9466-33.2435-61.766-76.6432-81.3334-87.5139QC'd by SIGMA
Inhibitor1.634289.661386Complete curve; high efficacy-5.78670.80.9918-94.197-4.5357-1.10 0 0 0 0 0 0 0 0 0 0-90.227-2.5297-3.4679-9.635-7.1695-14.792-15.9048-29.4095-56.4408-69.3217-79.2648-90.227QC'd by APAC
Inhibitor1.833694.496186Complete curve; high efficacy-5.73671.86170.9989-94.9961-0.5-1.10 0 0 0 0 0 0 0 0 0 0-95.3776-1.3502-0.2066-2.42582.7774-1.6197-2.0908-11.2497-47.9814-82.942-94.0736-95.3776QC'd by Selleck
Inhibitor1.833698.758986Complete curve; high efficacy-5.73671.80790.9926-96.25892.5-1.10 0 0 0 0 0 0 0 0 0 0-96.17612.1633-3.0162-1.73913.83766.88923.9784-5.961-50.1564-79.4444-97.2312-96.1761QC'd by Chembridge
Inhibitor1.8336117.551786Complete curve; high efficacy-5.73671.1110.9917-104.051713.5-1.10 0 0 0 0 0 0 0 0 0 0-99.203816.02712.528420.739610.99283.40560.7171-11.6101-40.2962-81.8609-95.3712-99.2038QC'd by NCGCChem
Inhibitor4.105102.203385Complete curve; high efficacy-5.38672.78680.9963-102.20330-1.10 0 0 0 0 0 0 0 0 0 0-100.6552000.44662.61961.3014-7.0848-0.1399-9.5349-70.1791-102.6138-100.6552QC'd by Microsource
Inhibitor3.177496.712985Complete curve; high efficacy-5.49791.62660.9968-95.71291-1.10 0 0 0 0 0 0 0 0 0 0-88.623100.724301.163100-0.2194-6.346-40.8346-79.8345-88.6231QC'd by Analyticon
Inhibitor6.5059128.088785Complete curve; high efficacy-5.18671.53860.9928-132.0887-4-1.10 0 0 0 0 0 0 0 0 0 0-129.49870.1476-4.8849-6.6137-8.5236-3.9326-10.9532-8.9047-15.3414-65.574-105.6081-129.4987QC'd by Axon Medchem
Inhibitor2.906193.696885Complete curve; high efficacy-5.53671.82650.9956-91.69682-1.10 0 0 0 0 0 0 0 0 0 0-89.373104.594604.2711000.8493-27.8387-73.8967-86.3827-89.3731QC'd by Cayman
Inhibitor3.2607111.298885Complete curve; high efficacy-5.48672.04790.9948-99.298812-1.10 0 0 0 0 0 0 0 0 0 0-96.590715.559213.836617.029410.599911.54637.65512.3867-12.0459-71.5767-97.3518-96.5907QC'd by NCGCChem
Inhibitor3.658592.976984Complete curve; high efficacy-5.43671.69240.9965-92.47690.5-1.10 0 0 0 0 0 0 0 0 0 0-90.6636000003.988-8.3142-20.7831-59.875-87.9355-90.6636QC'd by SigmaAldrich
Inhibitor5.798495.974484Complete curve; high efficacy-5.23672.33320.9922-96.9744-1-1.10 0 0 0 0 0 0 0 0 0 0-93.0365-0.68670.424801.8559-0.4094-1.8277-5.021-11.0122-41.926-95.6355-93.0365QC'd by SIGMA
Inhibitor4.6058102.119684Complete curve; high efficacy-5.33673.92950.9779-94.61967.5-1.10 0 0 0 0 0 0 0 0 0 0-85.5338-0.64041.64322.67266.208310.280816.117412.58977.6496-60.847-103.7496-85.5338QC'd by Sytravon
Inhibitor4.6058107.458184Complete curve; high efficacy-5.33671.47810.992-98.95818.5-1.10 0 0 0 0 0 0 0 0 0 0-93.18098.83129.08824.19858.57956.83810.28788.55-19.9304-49.1765-88.9783-93.1809QC'd by Sytravon
Inhibitor5.798498.695684Complete curve; high efficacy-5.23671.1110.9913-96.69562-1.10 0 0 0 0 0 0 0 0 0 0-90.03320.44413.12146.06443.2241-5.00040-5.7269-22.3838-41.1315-74.3311-90.0332QC'd by Selleck
Inhibitor6.5059101.664984Complete curve; high efficacy-5.18671.28760.9986-106.4121-4.7472-1.10 0 0 0 0 0 0 0 0 0 0-99.6368-3.7525-4.5439-5.9657-1.8727-5.3345-7.423-10.2197-20.0785-51.0609-82.5103-99.6368QC'd by Analyticon
Inhibitor5.035990.647784Complete curve; high efficacy-5.29793.62720.9923-92.6477-2-1.10 0 0 0 0 0 0 0 0 0 0-92.46282.39754.229-3.4667-5.4432-3.7131-3.5860.2734-4.8695-11.6501-80.2351-92.4628QC'd by Prestwick
Inhibitor5.7984107.791584Complete curve; high efficacy-5.23671.92820.99-98.79159-1.10 0 0 0 0 0 0 0 0 0 0-95.174810.4673-0.8557.541910.130413.460114.96026.5091-1.1759-44.2917-87.5379-95.1748QC'd by Chemdiv
Inhibitor4.7166102.054884Complete curve; high efficacy-5.32641.86170.9952-99.55482.5-1.10 0 0 0 0 0 0 0 0 0 0-97.60283.9695-2.5222-0.88844.87277.42362.1813-0.4619-13.1259-55.3921-92.8344-97.6028QC'd by Vitas
Inhibitor5.1678114.21784Complete curve; high efficacy-5.28671.55790.995-99.71714.5-1.10 0 0 0 0 0 0 0 0 0 0-94.569816.45520.153114.577812.385915.02249.87235.3386-3.7884-44.983-85.8105-94.5698QC'd by Chemdiv
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsP2-f19-rhfurin
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Enzyme; 2 uL; 1,536-well solid-bottom, black plate (Greiner Bio One).
2; Compounds; 20 nL; Echo 655 acoustic dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature in the dark.
4: Reagent; 2 uL; pERTKR-AMC.
5; Detection; Fluorescence; time 0, Viewlux microplate reader (PerkinElmer) 355 nm excitation, 460 nm emission
6; Incubation; 15 min; room temperature
7; Detection; Fluorescence; time 15; ViewLux microplate reader (PerkinElmer), 355 nm excitation, 460 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Two micro-liter of furin enzyme solution (40 nM final concentration) in assay buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, with 0.01% Tween 20) were dispensed into a 1,536-well solid-bottom black plate (Greiner Bio One) using the Kalypsys Pintool Station.
2. Twenty nano-liter of compounds, positive control Aprotinin (50 uM final concentration), or neutral control DMSO were transferred to the assay plates. Compounds in counterscreen assays were tested at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
3. The assay plates were incubated in the dark for 15 min.
4. After incubation, 2 uL of 0.625 uM pERTKR-AMC substrate in assay buffer for the Furin assay was added using the Kalypsys Pintool Station.
5-7. Plates were immediately read at time 0 then covered with stainless steel gasket lids and incubated for 15 min at room temperature in the dark. Fluorescence intensity in the assay plates were again read after incubation using the ViewLux imager equipped with AMC fluorescence optics. The change in fluorescence intensity over the 15-min reaction period was normalized against DMSO and inhibitor controls as described below.

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003886644 uMActivity at 0.0008234935 uMActivity at 0.00124 uMActivity at 0.00246 uMActivity at 0.00377 uMActivity at 0.00739 uMActivity at 0.013 uMActivity at 0.023 uMActivity at 0.039 uMActivity at 0.069 uMActivity at 0.117 uMActivity at 0.206 uMActivity at 0.352 uMActivity at 0.618 uMActivity at 1.055 uMActivity at 1.924 uMActivity at 3.720 uMActivity at 5.772 uMActivity at 11.16 uMActivity at 17.32 uMActivity at 33.48 uMActivity at 50.62 uMActivity at 100.00 uMActivity at 166.7 uMActivity at 500.0 uMCompound QC
Inhibitor2.0574123.268587Complete curve; high efficacy-5.68672.40640.9964-118.26855-1.10 0 0 0 0 0 0 0 0 0 0-115.09082.8885.40046.58594.04132.80793.37932.2835-43.9445-114.475-115.9495-115.0908QC'd by SIGMA
Inhibitor2.0574120.450687Complete curve; high efficacy-5.68672.33320.9968-118.45062-1.10 0 0 0 0 0 0 0 0 0 0-116.81524.9144-0.21651.34233.41651.011-2.1306-5.6378-45.6943-113.1005-116.7151-116.8152QC'd by Bio Vision
Inhibitor4.105101.938684Complete curve; high efficacy-5.38672.84730.9578-98.43863.5-1.10 0 0 0 0 0 0 0 0 0 0-116.35774.70634.88514.14443.42941.8409-0.45260.3312-2.0485-70.9205-76.0559-116.3577QC'd by Adooq
Inhibitor7.299892.071783Complete curve; high efficacy-5.13671.88510.982-90.07172-1.10 0 0 0 0 0 0 0 0 0 0-80.90751.9866-0.00341.8592.45192.61364.709-0.0577-7.01-25.1697-83.0089-80.9075QC'd by APAC
Inhibitor9.1899126.48883Complete curve; high efficacy-5.03674.95490.9935-123.4883-1.10 0 0 0 0 0 0 0 0 0 0-120.35874.684812.69580.55870.49710.5341.43890.9107-0.7262-3.4411-118.5135-120.3587QC'd by MedChem Express
Inhibitor7.9813140.948544Partial curve; high efficacy-5.09791.1110.9968-139.44851.5-2.10 0 0 0 0 0 0 0 0 0 0-110.67346.12721.22021.4730.7797-1.90220.5033-2.5401-12.7365-32.4047-69.1492-110.6734QC'd by Selleck
Inhibitor11.5693133.590643Partial curve; high efficacy-4.93671.34430.998-128.59065-2.10 0 0 0 0 0 0 0 0 0 0-112.79886.13264.04794.49813.35553.74434.6172.9152-3.0749-34.911-75.3804-112.7988QC'd by BOC Sciences
Inhibitor8.9552108.061143Partial curve; high efficacy-5.04792.72020.9893-109.0611-1-2.10 0 0 0 0 0 0 0 0 0 0-113.6053-2.5498-0.0161-0.90541.549-1.6624-1.035-0.2871-3.0955-5.3823-47.9419-113.6053QC'd by Prestwick
Inhibitor14.5649127.955942Partial curve; high efficacy-4.83671.24750.9826-128.4559-0.5-2.10 0 0 0 0 0 0 0 0 0 0-105.98672.2922-1.30330.06040.33271.0331.7306-15.2556-2.8882-32.157-68.6091-105.9867QC'd by Microsource
Inhibitor14.949298.195442Partial curve; high efficacy-4.82541.210.9903-97.69540.5-2.10 0 0 0 0 0 0 0 0 0 0-86.60942.67262.2733-2.4477-0.1168-0.6014-1.3047-4.1854-5.4249-37.0086-59.94-86.6094QC'd by Analyticon
Inhibitor16.3421115.928742Partial curve; high efficacy-4.78671.41630.997-118.4287-2.5-2.10 0 0 0 0 0 0 0 0 0 0-99.18650.721-0.0234-3.3938-3.533-1.967-3.116-5.2659-9.9377-23.4562-59.675-99.1865QC'd by SIGMA
Inhibitor23.083990.567541Partial curve; high efficacy-4.63674.0950.9634-90.56750-2.10 0 0 0 0 0 0 0 0 0 0-83.39554.74497.57771.47721.30211.6670.6907-1.2401-5.9881-10.181-16.7566-83.3955QC'd by Specs
Inhibitor23.083975.77441Partial curve; partial efficacy-4.63674.0950.992-75.2740.5-2.20 0 0 0 0 0 0 0 0 0 0-69.52570.34681.32922.0132.5351.636-1.8741-0.19931.5465-2.9321-17.123-69.5257QC'd by MedChem Express
Inhibitor16.342192.057741Partial curve; high efficacy-4.78671.69240.9944-95.1547-3.097-2.10 0 0 0 0 0 0 0 0 0 0-84.8081-1.7048-2.7043-2.7328-3.1309-0.9142-2.2389-6.802-4.7221-18.0355-46.4212-84.8081QC'd by NCGCChem
Inhibitor25.900568.518740Partial curve; partial efficacy-4.58674.0950.9879-72.9929-4.4742-2.20 0 0 0 0 0 0 0 0 0 0-67.4188-3.157-0.3952-2.6752-3.6727-6.2029-4.4808-5.843-6.458-7.6543-12.7605-67.4188QC'd by Sequoia
Inhibitor18.336242.376921Partial curve; partial efficacy-4.73671.41630.9611-43.3769-1-2.20 0 0 0 0 0 0 0 0 0 0-38.05-3.369-1.8439-1.25460.0268-0.6973-0.09930.30380.0057-12.0993-17.8476-38.05QC'd by Microsource
Inhibitor20.573554.32321Partial curve; partial efficacy-4.68672.25260.9506-54.823-0.5-2.20 0 0 0 0 0 0 0 0 0 0-53.7485.10192.19790.06740.0829-1.10770.4012-3.1391-4.7207-8.4582-17.4267-53.748QC'd by Sytravon
Inhibitor18.336246.34721Partial curve; partial efficacy-4.73671.62590.9854-44.3472-2.20 0 0 0 0 0 0 0 0 0 0-38.90092.97871.94912.18482.73582.0412.25672.6921-0.4112-6.8174-16.7494-38.9009QC'd by Analyticon
Inhibitor14.564950.099621Partial curve; partial efficacy-4.83671.210.992-51.0996-1-2.20 0 0 0 0 0 0 0 0 0 0-41.74210.7762-0.4111-2.9919-2.3469-1.15660.2368-2.4226-3.9572-14.3837-27.3644-41.7421QC'd by Analyticon
Inhibitor20.573541.122920Partial curve; partial efficacy-4.68672.33320.9549-41.12290-2.20 0 0 0 0 0 0 0 0 0 0-40.31660.94294.30531.2929-3.02070.36030.3042-0.5695-2.7371-4.0541-12.0009-40.3166QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: Ebola screen2_EMI141217_green
Protocol: This 1536-well plate assay was adapted from the original 6-wells assay with a modification that eliminated cell wash steps. HeLa cells were plated at 750 cells/well in 3 microl of assay medium (DMEM + 10% FBS) in 1536-well assay plates and incubated for 16 hours at 37 degrees C and 5% CO2. Compounds in the 1536-well drug source plates were added to the 1536-well assay plates in a volume of 23 nl/well via a NX-TR pintool station (WAKO Scientific Solutions, San Diego, CA). Following 1-hour incubation at 37 degrees C with 5% CO2, 1 microl/well of VLP solution was added to the assay plates using a BioRapTR FRD dispenser (the VLP solution was diluted in Opti-MEM to a final concentration of 1:16). Plates were then spinoculated by centrifugation at 1500 rpm at 4 degrees C for 45 minutes followed by incubation at 37 degrees C with 5% CO2 for 4.5 hours. The CCF2-AM beta-lactamase substrate was prepared at 6x concentration following the manufacturer's instruction which was added to assay plates at 1 microl/well. Following a 2-hour incubation at room temperature, dual fluorescence intensities (Ex1 = 405+/-20, Em1 = 460+/-20, and Ex2 = 405+/-20, Em2 = 530+/-20 nm) were measured in an EnVision plate reader (PerkinElmer, Boston, MA). The ratio of fluorescence intensities (Em1/Em2) was calculated to represent the beta-lactamase activity that is proportional to the amount of VLP entry into the host cells.
Comment: The activity score was determined using both AC50, Efficacy and curve class. For a given compound j:
Activity is defined as the ability to inhibit viral entry.

If curve class = 4, activity score = 0 and outcome is set to 1. Compounds of this class have no significant activity points.
If efficacy is negative, activity score = 0 and outcome is set to 1. Compounds with negative efficacies, promote viral entry.

For all other curve classes:

Activity score(j) = [100*((max(Ac50)-Ac50(j))/(max(Ac50)-min(Ac50))) + 100*(1-(max(efficacy)-efficacy(j))/(max(efficacy)-min(efficacy))) ]/2

Compounds with Activity scores > 80% are deemed active, and the activity outcome is set to 2.

Refer to the following recent publication for more detail regarding active compounds:

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Jennifer Kouznetsova, Wei Sun, Carles Marti nez-Romero, Gregory Tawa, Paul Shinn, Catherine Z Chen,
Aaron Schimmer, Philip Sanderson, John C McKew, Wei Zheng and Adolfo Garci a-Sastre

Emerging Microbes and Infections (2014) 3, e84; doi:10.1038/emi.2014.88
NCGC sample numberSample NameSupplierAC50 (uM)Curve Class2EfficacyChannel
4trans-Aconitic acidSpecs0.6314-10.976Green
10NEROLMicrosource12.58934-28.228Green
3Phenol redLabotest0.7079419.263Green
4Aminoquinuride dihydrochlorideLabotest0.7079418Green
3Pyridoxamine DihydrochlorideBosche15.84894-11.767Green
7CarzenideLabotest0.631411.002Green
9PridinolSpecs102.236.664Green
3L-LeucineBosche0.8913414.333Green
6FenticlorVitas3.16234-28.657Green
6CHLORPROTHIXENE HYDROCHLORIDEMicrosource39.8107-3-98.319Green
8BenzbromaroneLabotest1.7783416.5Green
8Phosphonoacetic acidSIGMA14-15.333Green
17DomperidoneMicrosource25.11892.3125.472Green
4PifexoleBionet0.6314-9.778Green
15WY-14643SIGMA3.9811419.845Green
14OXAPROZINMicrosource39.8107418.153Green
6Topotecan hydrochloridePrestwick31.622851429.488Green
12AZELAIC ACIDMicrosource10417.221Green
13AmoxapineEnzo8.91252.394.86Green
14R-(+)-AtenololVitas104-16.344Green
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: Ebola screen2_EMI141217_ratio
Protocol: This 1536-well plate assay was adapted from the original 6-wells assay with a modification that eliminated cell wash steps. HeLa cells were plated at 750 cells/well in 3 microl of assay medium (DMEM + 10% FBS) in 1536-well assay plates and incubated for 16 hours at 37 degrees C and 5% CO2. Compounds in the 1536-well drug source plates were added to the 1536-well assay plates in a volume of 23 nl/well via a NX-TR pintool station (WAKO Scientific Solutions, San Diego, CA). Following 1-hour incubation at 37 degrees C with 5% CO2, 1 microl/well of VLP solution was added to the assay plates using a BioRapTR FRD dispenser (the VLP solution was diluted in Opti-MEM to a final concentration of 1:16). Plates were then spinoculated by centrifugation at 1500 rpm at 4 degrees C for 45 minutes followed by incubation at 37 degrees C with 5% CO2 for 4.5 hours. The CCF2-AM beta-lactamase substrate was prepared at 6x concentration following the manufacturer's instruction which was added to assay plates at 1 microl/well. Following a 2-hour incubation at room temperature, dual fluorescence intensities (Ex1 = 405+/-20, Em1 = 460+/-20, and Ex2 = 405+/-20, Em2 = 530+/-20 nm) were measured in an EnVision plate reader (PerkinElmer, Boston, MA). The ratio of fluorescence intensities (Em1/Em2) was calculated to represent the beta-lactamase activity that is proportional to the amount of VLP entry into the host cells.
Comment: The activity score was determined using both AC50, Efficacy and curve class. For a given compound j:
Activity is defined as the ability to inhibit viral entry.

If curve class = 4, activity score = 0 and outcome is set to 1. Compounds of this class have no significant activity points.
If efficacy is negative, activity score = 0 and outcome is set to 1. Compounds with negative efficacies, promote viral entry.

For all other curve classes:

Activity score(j) = [100*((max(Ac50)-Ac50(j))/(max(Ac50)-min(Ac50))) + 100*(1-(max(efficacy)-efficacy(j))/(max(efficacy)-min(efficacy))) ]/2

Compounds with Activity scores > 80% are deemed active, and the activity outcome is set to 2.

Refer to the following recent publication for more detail regarding active compounds:

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Jennifer Kouznetsova, Wei Sun, Carles Marti nez-Romero, Gregory Tawa, Paul Shinn, Catherine Z Chen,
Aaron Schimmer, Philip Sanderson, John C McKew, Wei Zheng and Adolfo Garci a-Sastre

Emerging Microbes and Infections (2014) 3, e84; doi:10.1038/emi.2014.88
NCGC sample numberSample NameSupplierAC50 (uM)Curve Class2EfficacyChannel
4trans-Aconitic acidSpecs40ratio
10NEROLMicrosource0.6314-18.609ratio
3Phenol redLabotest8.9125411.059ratio
4Aminoquinuride dihydrochlorideLabotest19.95262.395.842ratio
3Pyridoxamine DihydrochlorideBosche44.66844-13.116ratio
7CarzenideLabotest40ratio
9PridinolSpecs28.18382.3104.274ratio
3L-LeucineBosche0.79434-27.61ratio
6FenticlorVitas15.84892.459.259ratio
6CHLORPROTHIXENE HYDROCHLORIDEMicrosource3.16231.370.654ratio
8BenzbromaroneLabotest7.9433419.539ratio
8Phosphonoacetic acidSIGMA7.943349.28ratio
17DomperidoneMicrosource25.1189387.928ratio
4PifexoleBionet3.54814-20.543ratio
15WY-14643SIGMA3.9811-3-98.934ratio
14OXAPROZINMicrosource39.8107416.681ratio
6Topotecan hydrochloridePrestwick7.94332.183.464ratio
12AZELAIC ACIDMicrosource40ratio
13AmoxapineEnzo102.1101.678ratio
14R-(+)-AtenololVitas40ratio
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: Ebola screen2_EMI141217_blue
Protocol: This 1536-well plate assay was adapted from the original 6-wells assay with a modification that eliminated cell wash steps. HeLa cells were plated at 750 cells/well in 3 microl of assay medium (DMEM + 10% FBS) in 1536-well assay plates and incubated for 16 hours at 37 degrees C and 5% CO2. Compounds in the 1536-well drug source plates were added to the 1536-well assay plates in a volume of 23 nl/well via a NX-TR pintool station (WAKO Scientific Solutions, San Diego, CA). Following 1-hour incubation at 37 degrees C with 5% CO2, 1 microl/well of VLP solution was added to the assay plates using a BioRapTR FRD dispenser (the VLP solution was diluted in Opti-MEM to a final concentration of 1:16). Plates were then spinoculated by centrifugation at 1500 rpm at 4 degrees C for 45 minutes followed by incubation at 37 degrees C with 5% CO2 for 4.5 hours. The CCF2-AM beta-lactamase substrate was prepared at 6x concentration following the manufacturer's instruction which was added to assay plates at 1 microl/well. Following a 2-hour incubation at room temperature, dual fluorescence intensities (Ex1 = 405+/-20, Em1 = 460+/-20, and Ex2 = 405+/-20, Em2 = 530+/-20 nm) were measured in an EnVision plate reader (PerkinElmer, Boston, MA). The ratio of fluorescence intensities (Em1/Em2) was calculated to represent the beta-lactamase activity that is proportional to the amount of VLP entry into the host cells.
Comment: The activity score was determined using both AC50, Efficacy and curve class. For a given compound j:
Activity is defined as the ability to inhibit viral entry.

If curve class = 4, activity score = 0 and outcome is set to 1. Compounds of this class have no significant activity points.
If efficacy is negative, activity score = 0 and outcome is set to 1. Compounds with negative efficacies, promote viral entry.

For all other curve classes:

Activity score(j) = [100*((max(Ac50)-Ac50(j))/(max(Ac50)-min(Ac50))) + 100*(1-(max(efficacy)-efficacy(j))/(max(efficacy)-min(efficacy))) ]/2

Compounds with Activity scores > 80% are deemed active, and the activity outcome is set to 2.

Refer to the following recent publication for more detail regarding active compounds:

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Jennifer Kouznetsova, Wei Sun, Carles Marti nez-Romero, Gregory Tawa, Paul Shinn, Catherine Z Chen,
Aaron Schimmer, Philip Sanderson, John C McKew, Wei Zheng and Adolfo Garci a-Sastre

Emerging Microbes and Infections (2014) 3, e84; doi:10.1038/emi.2014.88
NCGC sample numberSample NameSupplierAC50 (uM)Curve Class2EfficacyChannel
4trans-Aconitic acidSpecs104-14.43blue
10NEROLMicrosource40blue
3Phenol redLabotest39.81074-13.607blue
4Aminoquinuride dihydrochlorideLabotest22.38722.395.429blue
3Pyridoxamine DihydrochlorideBosche40blue
7CarzenideLabotest40blue
9PridinolSpecs31.6228398.957blue
3L-LeucineBosche0.3981-1.4-35.007blue
6FenticlorVitas102.251.546blue
6CHLORPROTHIXENE HYDROCHLORIDEMicrosource3.16231.390.071blue
8BenzbromaroneLabotest11.2202418.74blue
8Phosphonoacetic acidSIGMA7.9433411.21blue
17DomperidoneMicrosource39.8107390.852blue
4PifexoleBionet3.54814-15.204blue
15WY-14643SIGMA3.9811-3-135.758blue
14OXAPROZINMicrosource44.668448.931blue
6Topotecan hydrochloridePrestwick0.6314-18.88blue
12AZELAIC ACIDMicrosource1.1224-15.036blue
13AmoxapineEnzo14.12542.190.875blue
14R-(+)-AtenololVitas40blue
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: Ebola screen2_EM141217_green
Protocol: This 1536-well plate assay was adapted from the original 6-wells assay with a modification that eliminated cell wash steps. HeLa cells were plated at 750 cells/well in 3 microl of assay medium (DMEM + 10% FBS) in 1536-well assay plates and incubated for 16 hours at 37 degrees C and 5% CO2. Compounds in the 1536-well drug source plates were added to the 1536-well assay plates in a volume of 23 nl/well via a NX-TR pintool station (WAKO Scientific Solutions, San Diego, CA). Following 1-hour incubation at 37 degrees C with 5% CO2, 1 microl/well of VLP solution was added to the assay plates using a BioRapTR FRD dispenser (the VLP solution was diluted in Opti-MEM to a final concentration of 1:16). Plates were then spinoculated by centrifugation at 1500 rpm at 4 degrees C for 45 minutes followed by incubation at 37 degrees C with 5% CO2 for 4.5 hours. The CCF2-AM beta-lactamase substrate was prepared at 6x concentration following the manufacturer's instruction which was added to assay plates at 1 microl/well. Following a 2-hour incubation at room temperature, dual fluorescence intensities (Ex1 = 405+/-20, Em1 = 460+/-20, and Ex2 = 405+/-20, Em2 = 530+/-20 nm) were measured in an EnVision plate reader (PerkinElmer, Boston, MA). The ratio of fluorescence intensities (Em1/Em2) was calculated to represent the beta-lactamase activity that is proportional to the amount of VLP entry into the host cells.
Comment: The activity score was determined using both AC50, Efficacy and curve class. For a given compound j:
Activity is defined as the ability to inhibit viral entry.

If curve class = 4, activity score = 0 and outcome is set to 1. Compounds of this class have no significant activity points.
If efficacy is negative, activity score = 0 and outcome is set to 1. Compounds with negative efficacies, promote viral entry.

For all other curve classes:

Activity score(j) = [100*((max(Ac50)-Ac50(j))/(max(Ac50)-min(Ac50))) + 100*(1-(max(efficacy)-efficacy(j))/(max(efficacy)-min(efficacy))) ]/2

Compounds with Activity scores > 70% are deemed active, and the activity outcome is set to 2.

Note that this scoring scheme only applies to the ratio of blue/green fluorescence intensities because it is this ratio that represents the activity of Bla inside cells. Separate uploads of blue and green data exist in this assay group but information on activity should not be derived from these.

Refer to the following recent publication for more detail regarding active compounds:

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Jennifer Kouznetsova, Wei Sun, Carles Marti nez-Romero, Gregory Tawa, Paul Shinn, Catherine Z Chen,
Aaron Schimmer, Philip Sanderson, John C McKew, Wei Zheng and Adolfo Garci a-Sastre

Emerging Microbes and Infections (2014) 3, e84; doi:10.1038/emi.2014.88
NCGC sample nbumberSample NameSupplierAc50Curve ClassEfficacyChannelChannel typeConc0Conc1Conc2Conc3Conc4Conc5Conc6Conc7Conc8Conc9Conc10Data0Data1Data2Data3Data4Data5Data6Data7Data8Data9Data10
10NEROLMicrosource12.589254124-28.228greenused to calculate ratio0.462.311.557.59.1270994759.61618564-3.7770449-15.60632145
3Phenol redLabotest0.707945784419.263greenused to calculate ratio0.462.311.557.5-9.385966028.828293685.796660949.22493965
4Aminoquinuride dihydrochlorideLabotest0.707945784418greenused to calculate ratio0.462.311.557.53.4615238822.8010761516.029539420.72614656
3Pyridoxamine DihydrochlorideBosche15.848931924-11.767greenused to calculate ratio0.462.311.557.53.2822761710.932088973.29047462-4.38930637
7CarzenideLabotest0.630957345411.002greenused to calculate ratio0.462.311.557.5-14.81373825-4.81206699-6.89129672-12.75493009
9PridinolSpecs102.236.664greenused to calculate ratio0.462.311.557.51.799217293.4608488822.2949210337.40401694
4ProcodazoleVitas0.6309573454-21.162greenused to calculate ratio0.462.311.557.511.00151234-9.702208834.56604819-14.71822198
3L-LeucineBosche0.891250938414.333greenused to calculate ratio0.231.155.7528.7-10.277274430.797956196.033257572.21607206
6FenticlorVitas3.162277664-28.657greenused to calculate ratio0.462.311.557.51.97467363-4.86579376-26.3812188411.38643713
6CHLORPROTHIXENE HYDROCHLORIDEMicrosource39.810717065-98.319greenused to calculate ratio0.462.311.557.58.229873113.4401888532.34629485-69.99258758
9Cyclobenzaprine hydrochlorideMicrosource15.848931922.1107.682greenused to calculate ratio0.462.311.557.5-15.91101847-4.2171917225.3285511382.99755874
8Phosphonoacetic acidSIGMA14-15.333greenused to calculate ratio0.462.311.557.57.40981797-5.05293193-1.67180124-11.11044314
17DomperidoneMicrosource25.118864322.1125.472greenused to calculate ratio0.462.311.557.5-10.68996778-0.4700079216.1055883196.36730961
4PifexoleBionet0.6309573454-9.778greenused to calculate ratio0.462.311.557.5-0.02107281-10.25290078-6.57120927-2.6114683
15WY-14643SIGMA3.981071706419.845greenused to calculate ratio0.462.311.557.5-1.53727228-0.6332131222.4891074413.55929131
14OXAPROZINMicrosource39.81071706418.153greenused to calculate ratio0.462.311.557.55.23106550.41003145-0.5438345216.85882561
6Topotecan hydrochloridePrestwick31.62277662.11429.488greenused to calculate ratio0.462.311.557.533.64911259138.5512222284.01020061141.705944
12AZELAIC ACIDMicrosource10417.221greenused to calculate ratio0.462.311.557.5-7.26743084-1.90015675-1.269343046.54169513
13AmoxapineEnzo8.9125093812.194.86greenused to calculate ratio0.462.311.557.5-4.771443380.0424582366.6559176193.16864781
14R-(+)-AtenololVitas104-16.344greenused to calculate ratio0.462.311.557.5-9.75671331-3.63184443-17.25199222-4.91153437
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: 5mMGluc_INS1E_InsulinRelease_40mMGluc_SP
Protocol: N/A
Comment: N/A
Activity at 2 uMActivity at 10 uM
1.051.35
-1.2-2.5
0.6-0.4
1.10
2.050.15
-1.2-0.5
1.150.95
-0.4-2
0.7-1.2
-2.3-2.4
0.50.9
1.91.9
-1.16.2
-0.9-0.3
2.24.1
2.61.85
35.9
2.60.5
17.6
0.80.8
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: hp70S6K1_LANCE_SP
Protocol: N/A
Comment: N/A
Activity at 0.2 uMActivity at 2 uMActivity at 20 uM
1.09-5.15-362.78
4.139.97-1.96
4.549.09-0.47
-1.19-3.81-128.25
-0.37-23.9228.99
-9.7327.02-2.62
8.436.870.21
2.3712.18-0.94
3.729.2229.89
0.947.143.8
11.8614.71.51
-10.831.09-2.9
-26.391.843.34
7.095.535.58
-6.6524.42-18.72
-8.345.01-4.08
-22.6230.4411.74
-6.222.73-9.45
-2.78-7.957.41
5.146.5-1.14
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR985
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-2.5265-7.1483-6.3353-8.6464-2.6851-3.55893.2191-3.1242-5.8134-5.6348-5.47660.4473-0.0628-2.5265QC'd by SIGMAInactive0-4.274510.6363
Inactive00043.9024-0.01911.091.23652.36520.00372.0670.4851-0.4224-1.0393-0.4413.17850.34623.9024QC'd by SigmaAldrichInactive0
Inactive00040.8889-4.98190.1870.7854-0.1677-2.0871-0.80150.24410.7043-8.80280.1379-2.37921.85830.8889QC'd by ChemServiceInactive0-7.06644.95490.4482
Inhibitor50.390553.327221Partial curve; partial efficacy-4.29773.06540.9802-53.3433-0.0161-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.8509-1.3968-0.7491.0621-2.87011.05283.12180.0760.9249-0.49840.7261-1.3704-19.9808-46.8509QC'd by SigmaAldrichInactive0
Inhibitor70.827737.733910Partial curve; partial efficacy; poor fit-4.14981.46410.7102-39.7339-2-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.77821.0091-5.79512.7551.2254-6.9293.33021.728-8.1392-0.7165-6.4259-8.7096-8.3826-29.7782QC'd by SigmaAldrichInhibitor70.827741.854910Single point of activity-4.14984.50450.8302
Inhibitor61.503849.916621Partial curve; partial efficacy-4.21113.1320.892-53.3018-3.3852-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-42.2741-8.1807-7.61190.23321.57810.17121.3858-3.7535-3.206-6.6036-4.2950.0288-15.3692-42.2741QC'd by SIGMAInactive0
Inhibitor52.384150.532421Partial curve; partial efficacy-4.28082.40640.9534-51.6847-1.1523-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-40.2915-0.3854-0.06330.2042-1.816-8.719-1.02010.9052-1.1643-1.4537-2.6853-2.4432-20.0028-40.2915QC'd by SIGMAInhibitor58.775939.524221Partial curve; partial efficacy-4.230810.8135
Inactive0004-9.709-4.4881-6.0445-8.8766-4.0388-0.5862-4.6549-8.3113-5.6134-4.8338-4.5642-0.5579-3.4555-9.709QC'd by Alfa AesarInactive0-4.15283.990.694
Inactive00041.66471.2462-0.14863.91093.85360.66890.332-0.85721.14780.26430.82850.06271.34331.6647QC'd by SV ChembiotechInactive0-4.16373.92950.6564
Inactive0-6.2164.95490.70982-6.490740 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5913-5.6041-9.9923-0.3428-7.6059-8.1832-4.6842-7.94470.1162.2630.2481.13570.77486.5913QC'd by SigmaAldrichInactive0
Inactive0-4.16644.95490.6737-25.7581-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.0484-0.84940.9603-8.21540.11392.05482.69681.41610.7927-9.70141.13732.2368-2.4398-21.0484QC'd by ChemServiceInactive0-4.36642.33320.8792
Inactive0-8.56773.1320.69960.5-9.217540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.1871-8.0979-1.72310.81240.29791.59360.956-0.5761.2867-4.1414-0.48432.01310.0104-0.1871QC'd by SIGMAInactive0
Inactive00045.07940.37572.19050.57630.92270.78453.46994.04961.90151.38273.96340.9117-0.60225.0794QC'd by SIGMAInactive0-4.96862.40640.6273
Inactive0-6.16074.95490.57915.5-2.430540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.1812-3.6421-0.044-0.36213.4152-5.3209-0.5383-7.85872.63685.21583.6992.344410.63857.1812QC'd by City ChemicalInhibitor54.870797.99941Partial curve; high efficacy-4.26071.78850.9628
Inactive0004-7.623-2.2142-5.4178-2.8594-1.2478-3.2961-1.8162-3.3949-3.2651-2.4468-13.60120.62040.0323-7.623QC'd by SIGMAInactive0
Inactive0-7.13754.0950.34570-4.700140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.0759-3.7616-3.6914-6.6307-6.3734-2.2758-1.4469-2.07440.5601-2.1426-0.4933-0.57645.1155-1.0759QC'd by SIGMAInactive0-4.58753.29750.926
Inactive0-6.92270.30.66969.5-12.317940 0 0 0 0 0 0 0 0 0 0 0 0 0 010.1368-8.154-8.9165-0.0326-1.7004-6.75864.0282-0.75942.5751-1.1314-0.72269.25986.41410.1368QC'd by SIGMAActivator26.751674.08270Partial curve; high efficacy-4.57272.18760.9777
Inactive0-8.31644.95490.36241-4.006940 0 0 0 0 0 0 0 0 0 0 0 0 0 00.262-4.04751.1113-0.82860.46322.60630.59311.42180.5483-1.23861.81471.70282.46480.262QC'd by SIGMAInactive0-8.81644.95490.6203
Inactive0-4.86070.50.827124-3.343540 0 0 0 0 0 0 0 0 0 0 0 0 0 10.3215-3.1196-2.8382-4.3087-0.9342-1.40680.1964-2.25525.21846.34245.162110.173116.8440.3215QC'd by LKT LabActivator9.757633.8970Complete curve; partial efficacy-5.01073.06540.9367
Inactive0-7.82850.70.757422.5-441 0 0 0 0 0 0 0 0 0 0 0 0 0 13.832412.68164.022614.57444.428120.650914.83922.328422.246920.362223.860820.325322.23313.8324QC'd by SIGMAInactive0-4.42850.80.8451
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR504
Protocol: Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Activator0.769618.541110Partial curve; partial efficacy; poor fit-6.11370.40.4771201.45892.40 0 0 0 0 0 0 0 0 0 1 1 1 1 18.43542.60297.16556.98426.77576.23584.39893.727414.10836.104412.34916.28710.24048.4354QC'd by SIGMAInactive0-7.46371.10.4107
Activator0.001518.544Complete curve; partial efficacy-8.81374.95490.845716.5-21.20 0 0 0 0 0 0 0 0 0 0 1 0 1 112.76338.520316.029918.960814.610214.569714.66815.484519.340417.405215.435716.74874.776812.7633QC'd by AcrosInactive0
Inactive040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.4538.53828.60629.13179.549110.755911.43756.467911.275510.13049.21297.3275-0.1191-11.453QC'd by SIGMAInactive0-4.36422.40640.8668
Inactive000417.43489.84064.73143.893717.43064.73392.71741.799421.142216.61518.79213.32233.134217.4348QC'd by Sigma DiscoveryCPRInactive0
Inactive000417.41599.11946.7603-2.39424.5125-5.07691.71712.688120.52570.113721.134-0.09350.75717.4159QC'd by EnamineInactive0-4.46372.35310.6137
Inactive0-8.51372.40640.34146.5-2.869340 0 0 0 0 0 0 0 0 0 0 0 0 0 09.2286-0.79294.86514.6489.82256.79684.62743.882111.065210.47076.49230.8715-0.7419.2286QC'd by SIGMAInactive0
Inhibitor3.063824.51160Complete curve; partial efficacy; poor fit-5.51374.95490.4049-18.61465.897-1.40 0 0 1 1 0 0 0 0 0 0 0 0 0 0-11.6821-3.038721.1044-20.78423.7169-18.207310.98469.041514.7886-15.2892-21.1562-17.0848-22.0042-11.6821QC'd by SIGMAInactive0
Activator0.001935.242610Complete curve; partial efficacy; poor fit-8.71424.95490.546629.4733-5.76921.40 0 0 0 0 0 0 0 0 0 0 1 1 1 1-35.059810.398831.296228.151536.89384.846829.689133.269131.780835.498622.02484.7913-29.1164-35.0598QC'd by SIGMAInactive0-4.31423.51170.6226
Inactive0004-0.31614.47693.98640.77972.2321.48744.16990.43690.07470.80680.3965-3.2133-3.9851-0.3161QC'd by SIGMAInactive0-4.71374.95490.3304
Inhibitor54.482733.50530Partial curve; high efficacy-4.26373.92950.9608-34.0053-0.5-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.00440.50840.4104-0.8948-3.2842-0.42840.0932-3.308-1.82040.56451.2561.479-9.8714-30.0044QC'd by Sigma DiscoveryCPRInhibitor68.589649.00410Single point of activity-4.16374.50450.9035
Inactive0-6.31374.95490.40220.5-2.854340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.9062-1.42020.2852-3.8028-4.0452-3.8452-3.7145-3.80550.63741.33431.7137-3.28390.5803-2.9062QC'd by MP BiomedicalsInactive0
Inhibitor61.130658.88120Partial curve; high efficacy-4.21373.19250.9781-59.7265-0.8453-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-47.5201-0.605-1.4306-2.7189-0.8465-0.0963-1.1087-1.55290.5068-0.225-0.0391-7.585-12.7325-47.5201QC'd by SIGMAInhibitor61.130669.99940Partial curve; partial efficacy-4.21373.990.9846
Inhibitor48.508455.41370Partial curve; high efficacy-4.31423.06540.992-53.97671.437-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.95211.59250.5164-0.94190.64010.73652.10781.92572.71730.23973.6782-1.5898-20.1662-46.9521QC'd by SIGMAInhibitor54.427380.68770Partial curve; high efficacy-4.26422.47290.9773
Inactive00041.1920.359-0.3975-0.251.0086-0.1111.15210.61861.1885-1.45780.6853-0.92120.6021.192QC'd by SIGMAInactive0
Inactive00040.2182-3.0991-1.93151.3572-2.42631.55190.1835-0.68480.605-0.3437-2.1085-0.74640.05991.72430.2182QC'd by LightBiologicalsInactive0
Activator68.589630.210110Single point of activity-4.16373.24750.923330-0.210130 0 0 0 0 0 0 0 0 0 0 0 0 0 021.8495-0.3001-1.0271-2.0701-0.01770.97450.4274-1.8475-0.9875-0.00953.49112.8063.96521.8495QC'd by SIGMAInactive0-4.46371.92820.7837
Activator17.228923.958720Partial curve; partial efficacy-4.76370.60.7544240.04132.20 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.99880.30040.8704-1.63220.2766.3859-0.80141.77834.025210.31816.43328.494618.8419-1.9988QC'd by LightBiologicalsActivator24.336535.974310Single point of activity-4.61374.0950.8673
Inactive00040.8624-0.4215-2.3373-2.43560.2408-1.76690.8666-1.7395-2.0022-1.4521-1.4395-0.981-0.53890.8624QC'd by LightBiologicalsInactive0-4.51374.95490.8869
Inactive0-4.11374.95490.654990.039740 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5998-0.8326-1.8287-1.08391.30271.03891.22330.81780.8549-1.37240.03750.73910.19056.5998QC'd by SIGMAInactive0-4.56374.95490.8448
Inactive0-4.56374.50450.4774.5-1.13740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.7168-1.8447-2.9517-3.0308-1.8846-0.48982.2361-1.7012-0.2024-2.7129-0.6292-0.32113.7485-3.7168QC'd by SIGMAInactive0-4.11374.95490.7344
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK554
Protocol: Assay Protocol Summary:

The medium for SNB-19 cells is composed of RPMI 1640 (ATCC, Cat.# 30-2001), 10% fetal bovine serum (FBS) (GE healthcare Life Sciences, Cat.# SH30071.03), and 1% Pen/Strep (Gibco, Cat.# 15140-122). The ATP content assay kit (PerkinElmer, Cat.# 6016731) was used to determine cell viability. The reagent was reconstituted and prepared as described by the manufacturer. Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 250 cells/well in 3ul medium for SNB-19 cells in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 72 hours, the reagent mixture of the ATP content assay kit was added to each well, followed by incubation at room temperature for 10 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV addition as a control of 100% viable cells and wells containing ZIKV infected cells as 100% cell death (completely reduced cell viability). The percentage inhibitions of the decreased cell viability by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002812903 uMActivity at 0.00113 uMActivity at 0.00153 uMActivity at 0.00281 uMActivity at 0.00542 uMActivity at 0.00844 uMActivity at 0.011 uMActivity at 0.022 uMActivity at 0.045 uMActivity at 0.070 uMActivity at 0.090 uMActivity at 0.180 uMActivity at 0.299 uMActivity at 0.374 uMActivity at 0.720 uMActivity at 1.388 uMActivity at 2.160 uMActivity at 2.888 uMActivity at 5.659 uMActivity at 11.50 uMActivity at 17.28 uMActivity at 23.76 uMActivity at 46.08 uMActivity at 88.34 uMActivity at 96.31 uMCompound QC
Activator1.945173.505784Complete curve; high efficacy-5.711110.864771.4361-2.06961.10 0 0 0 0 0 0 062.44071.09972.3066-1.2283-11.116133.491926.966474.277162.4407QC'd by NCGCChem
Activator0.6901104.858948Partial curve; high efficacy-6.16112.40640.989196.3182-8.54062.10 0 0 0 0 0 1 158.81-11.9933-12.901-0.2693-4.944744.915393.877430.337958.81QC'd by XcessBio
Activator1.545194.340846Partial curve; high efficacy-5.811110.961989.3318-5.0092.10 0 0 0 0 0 0 129.8027-12.9241-5.61338.94316.788419.00561.391976.233229.8027QC'd by SigmaAldrich
Activator6.151135.960845Partial curve; high efficacy-5.21111.98870.9616134.6285-1.33232.10 0 0 0 0 0 0 1-15.8163-11.2709-5.9111-3.999813.94233.743921.0254104.8508-15.8163QC'd by EMD Chemicals
Activator17.3358295.908844Partial curve; high efficacy-4.76112.40640.9897298.27212.36332.10 0 0 0 0 0 0 0271.65044.99913.474610.83796.77194.6648-17.293585.3651271.6504QC'd by Labotest
Activator19.4511248.209543Partial curve; high efficacy-4.71114.50450.9816252.5594.34952.10 0 0 0 0 0 0 0247.6069-12.6409-5.26158.811827.56591.20786.472525.0348247.6069QC'd by Microsource
Activator21.824478.644541Partial curve; high efficacy-4.66114.0450.888184.00025.35572.10 0 0 0 0 0 0 080.5557-5.2932-3.761223.97141.81112.43742.244610.747180.5557QC'd by SynKinase
Activator17.335895.086741Partial curve; high efficacy-4.76113.24750.980193.1618-1.92492.10 0 0 0 0 0 0 089.2354-4.5958-5.1705-3.4119-3.71638.7964-4.399417.689889.2354QC'd by Microsource
Activator24.4874155.112941Partial curve; high efficacy-4.61114.50450.8933161.95646.84342.10 0 0 0 0 0 0 0153.3678-2.3789-1.119716.1537-8.1009-9.199145.667312.5148153.3678QC'd by Tocris
Activator19.451182.501241Partial curve; high efficacy-4.71114.0950.95184.32161.82052.10 0 0 0 0 0 0 082.024-11.98323.8229-2.13496.01798.59695.282810.947582.024QC'd by SigmaAldrich
Activator31.622872.907340Partial curve; high efficacy-4.53.19250.896270.1279-2.77952.10 0 0 0 0 0 0 067.5623-8.2919-15.94161.28486.6829.0046-9.718916.950567.5623QC'd by Toronto Research
Activator35.5022106.477240Partial curve; high efficacy-4.44972.90230.9538108.70852.23132.10 0 0 0 0 0 0 095.3583-8.0506-5.3998-1.726312.559910.48045.024913.43895.3583QC'd by Tocris
Activator31.6228109.512140Partial curve; high efficacy-4.54.44950.9755111.58852.07642.10 0 0 0 0 0 0 0110.7029-1.2123-5.020214.43636.83371.1266-1.614422.5295110.7029QC'd by ACC
Activator0.122755.797226Complete curve; partial efficacy-6.91114.0950.995551.8366-3.96051.20 0 0 0 0 1 1 18.1729-0.8917-5.3838-4.06841.960950.820227.462211.18358.1729QC'd by SigmaAldrich
Activator0.974958.119424Partial curve; partial efficacy-6.01110.90.951351.372-6.74742.20 0 0 0 0 0 1 1-4.0359-10.237-7.51482.30574.826614.431139.02428.0221-4.0359QC'd by Toronto Research
Activator0.690157.515124Partial curve; partial efficacy-6.161110.989750.3227-7.19242.20 0 0 0 0 0 1 1-10.4437-7.7579-8.1592-0.25424.294220.83539.86761.266-10.4437QC'd by GVK
Activator0.774448.80223Partial curve; partial efficacy-6.11111.50950.992341.9173-6.88472.20 0 0 0 0 0 1 1-11.9147-7.0057-7.0552-6.99680.608414.385837.130310.2973-11.9147QC'd by Cayman
Activator5.011960.274522Partial curve; partial efficacy-5.31.24750.97258.7961-1.47852.20 0 0 0 0 0 0 1-10.47530.5441-6.64872.4060.707411.603327.523654.5192-10.4753QC'd by ChemAxon
Activator4.885965.955622Partial curve; partial efficacy-5.31111.69240.954257.5843-8.37132.20 0 0 0 0 0 0 110.9867-12.2279-0.5373-7.2202-14.0117-4.284911.365544.843710.9867QC'd by Tocris
Activator12.272835.39921Partial curve; partial efficacy-4.91111.88510.864635.56760.16852.20 0 0 0 0 0 0 032.7133-7.36620.59830.257810.0497-0.72841.46717.010932.7133QC'd by Pharmaron
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK726
Protocol: Assay Protocol Summary:

The medium for hNPCs consists of DMEM/F12, N2 supplement (ThermoFisher, Cat.# 17502048), NEAA (ThermoFisher, Cat. # 11140050), 2 ug/ml heparin, 2 uM cyclopamine, and B27 (ThermoFisher, Cat. # 17504044). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 350 cells/well in 3 ul medium for hNPCs in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002812903 uMActivity at 0.00113 uMActivity at 0.00153 uMActivity at 0.00281 uMActivity at 0.00542 uMActivity at 0.00844 uMActivity at 0.011 uMActivity at 0.022 uMActivity at 0.045 uMActivity at 0.070 uMActivity at 0.090 uMActivity at 0.180 uMActivity at 0.299 uMActivity at 0.374 uMActivity at 0.720 uMActivity at 1.388 uMActivity at 2.160 uMActivity at 2.888 uMActivity at 5.659 uMActivity at 11.50 uMActivity at 17.28 uMActivity at 23.76 uMActivity at 46.08 uMActivity at 88.34 uMActivity at 96.31 uMCompound QC
Inhibitor1.733681.5586Complete curve; high efficacy-5.76114.95490.9807-87.6509-6.1009-1.10 0 0 0 0 0 0 0-89.0761-13.3371-2.1783-3.8525-14.63641.9333-81.2861-86.412-89.0761QC'd by Toronto Research
Inhibitor1.227382.81786Complete curve; high efficacy-5.91111.210.9703-88.6497-5.8326-1.10 0 0 0 0 0 0 0-86.9114-17.75461.4148-9.1346-5.5937-37.1806-66.254-82.7137-86.9114QC'd by Vitas
Inhibitor1.227386.723586Complete curve; high efficacy-5.91111.96730.9781-87.5251-0.8015-1.10 0 0 0 0 0 0 0-87.8766-14.17825.00445.1387-1.1272-23.6216-74.9193-84.4245-87.8766QC'd by Vitas
Inhibitor1.227389.914886Complete curve; high efficacy-5.91112.84730.9993-88.64961.2652-1.11 0 0 0 0 0 0 0-89.54524.13051.40042.803-1.1845-14.6531-80.4721-88.0809-89.545QC'd by SigmaAldrich
Inhibitor1.733692.31886Complete curve; high efficacy-5.76113.51170.9943-87.80524.5128-1.10 0 0 0 0 0 0 0-88.15781.707412.12733.29180.71270.4037-74.3079-87.0979-88.1578QC'd by SigmaAldrich
Inhibitor1.37792.891786Complete curve; high efficacy-5.86111.62590.9971-90.00652.8852-1.10 0 0 0 0 0 0 0-90.91565.23262.53-2.20471.8088-21.1537-67.6567-86.4932-90.9156QC'd by SigmaAldrich
Inhibitor1.733690.046586Complete curve; high efficacy-5.76112.18760.9987-88.28861.7579-1.11 0 0 0 0 0 0 0-88.6431-21.5457-0.78453.77780.8549-8.9867-64.2607-87.5982-88.6431QC'd by NCGCChem
Inhibitor3.458999.240285Complete curve; high efficacy-5.46111.210.9731-98.22721.013-1.10 0 0 0 0 0 0 0-90.951210.3473-9.92082.50390-16.9769-37.713-82.6236-90.9512QC'd by Tocris
Inhibitor1.895590.225885Complete curve; high efficacy-5.72232.33320.9872-89.61640.6094-1.10 0 0 0 0 0 0 0-86.83767.0683-1.5319-7.19721.2273.1025-31.5106-85.8013-86.8376QC'd by GVK
Inhibitor2.448787.571285Complete curve; high efficacy-5.61113.1320.9757-88.073-0.5018-1.10 0 0 0 0 0 0 0-90.61019.7579-8.7306-0.0246-7.32643.5354-58.0742-83.0169-90.6101QC'd by NCGCChem
Inhibitor2.448785.7185Complete curve; high efficacy-5.61112.72020.982-83.49962.2104-1.10 0 0 0 0 0 0 0-85.378-7.466-0.03080.432910.41413.6225-47.9357-81.2576-85.378QC'd by SigmaAldrich
Inhibitor1.733692.563785Complete curve; high efficacy-5.76112.12110.9851-84.83557.7282-1.10 0 0 0 0 0 0 0-84.43531.69728.543718.60741.1045-5.058-62.8854-82.3356-84.4353QC'd by SigmaAldrich
Inhibitor1.945182.844485Complete curve; high efficacy-5.71111.210.9893-87.4538-4.6095-1.10 0 0 0 0 0 0 0-85.739-2.96780.3555-12.5932-11.0061-21.2007-56.3043-79.366-85.739QC'd by SigmaAldrich
Inhibitor3.88180.589384Complete curve; high efficacy-5.41111.82650.9826-77.43483.1544-1.10 0 0 0 0 0 0 0-75.34512.0815-3.05165.083311.5664-4.7481-26.6917-69.0474-75.3451QC'd by Toronto Research
Inhibitor3.981188.687784Complete curve; high efficacy-5.42.12110.9938-87.47531.2124-1.11 0 0 0 0 0 0 0-88.897727.08220.9136-3.3136.8541-9.9717-61.4568-83.8227-88.8977QC'd by SIGMA
Inhibitor4.354580.833784Complete curve; high efficacy-5.36111.82650.9833-84.4281-3.5943-1.10 0 0 0 0 0 0 0-82.08583.8577-3.4141-9.0998-8.3866-1.8515-31.1389-74.1649-82.0858QC'd by Bosche
Inhibitor4.354593.231684Complete curve; high efficacy-5.36111.66040.9716-84.89088.3408-1.10 0 0 0 0 0 0 0-86.38136.58215.11197.68273.578917.8788-28.2873-64.0961-86.3813QC'd by Tocris
Inhibitor3.88191.518484Complete curve; high efficacy-5.41111.62660.9749-85.23266.2858-1.10 0 0 0 0 0 0 0-83.12113.97125.544511.1633-2.37410.5328-34.646-67.4119-83.1211QC'd by GVK
Inhibitor3.458988.209984Complete curve; high efficacy-5.46111.10.9912-89.5747-1.3649-1.10 0 0 0 0 0 0 0-82.6324-7.35410.37261.0164-1.402-16.8774-41.1629-72.44-82.6324QC'd by XcessBio
Inhibitor4.8859103.228183Complete curve; high efficacy-5.31111.86170.9447-78.241624.9865-1.10 0 0 0 0 0 0 0-79.244221.759636.97215.079125.970234.419-7.1894-57.4678-79.2442QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK567
Protocol: Assay Protocol Summary:

The medium for hNPCs consists of DMEM/F12, N2 supplement (ThermoFisher, Cat.# 17502048), NEAA (ThermoFisher, Cat. # 11140050), 2 ug/ml heparin, 2 uM cyclopamine, and B27 (ThermoFisher, Cat. # 17504044). The ATP content assay kit (PerkinElmer, Cat.# 6016731) was used to determine cell viability. The reagent was reconstituted and prepared as described by the manufacturer. Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 350 cells/well in 3 ul medium for hNPCs in the tissue cultured treated/PDL coated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 72 hours, the reagent mixture of the ATP content assay kit was added to each well, followed by incubation at room temperature for 10 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV addition as a control of 100% viable cells and wells containing ZIKV infected cells as 100% cell death (completely reduced cell viability). The percentage inhibitions of the decreased cell viability by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002812903 uMActivity at 0.00113 uMActivity at 0.00153 uMActivity at 0.00281 uMActivity at 0.00542 uMActivity at 0.00844 uMActivity at 0.011 uMActivity at 0.022 uMActivity at 0.045 uMActivity at 0.070 uMActivity at 0.090 uMActivity at 0.180 uMActivity at 0.299 uMActivity at 0.374 uMActivity at 0.720 uMActivity at 1.388 uMActivity at 2.160 uMActivity at 2.888 uMActivity at 5.659 uMActivity at 11.50 uMActivity at 17.28 uMActivity at 23.76 uMActivity at 46.08 uMActivity at 88.34 uMActivity at 96.31 uMCompound QC
Activator7.743658.500310Single point of activity-5.11114.95490.820259.89871.398430 0 0 0 0 0 0 119.46163.65523.45855.0547-4.534414.6355-14.292852.705419.4616QC'd by GVK
Activator3.458941.955210Partial curve; partial efficacy; poor fit-5.46110.80.523447.955262.40 0 0 0 1 0 0 113.80616.428427.62092.17636.8529-24.385726.356136.532613.8061QC'd by Selleck
Activator10-7.811110.8756-51.5296-28.107750 0 0 0 0 0 0 0-54.056-31.3398-39.5219-43.2204-50.7338-54.1941-51.3849-45.9901-54.056QC'd by Selleck
Inactive0-5.4614.95490.8536-15.999711.540 0 0 0 0 0 0 0-14.416120.603516.50448.75884.65787.02939.2366-17.0831-14.4161QC'd by Prestwick Chemical; Inc.
Inactive0-5.21112.30310.6819-35.223810.995140 0 0 0 0 0 0 16.087611.693423.5104-7.772116.30029.9813.9998-26.44066.0876QC'd by Tocris
Inhibitor7.743652.43560Partial curve; partial efficacy-5.11112.78680.9365-47.93564.5-2.20 0 0 0 0 0 0 0-47.6628.2939-4.102714.92641.0442.11931.7971-34.9213-47.662QC'd by Tocris
Inhibitor56.234166.76620Single point of activity-4.254.95490.8455-73.9146-7.1484-30 0 0 0 0 0 0 0-68.9024-13.8049-18.85672.5816-4.0809-15.0271-19.5136-1.4868-68.9024QC'd by Toronto Research
Inhibitor4.354577.69930Complete curve; high efficacy; poor fit-5.36111.3310.8422-85.8007-8.1013-1.30 0 0 0 0 0 0 0-79.0157-21.8099-28.931.9977-8.22060.6965-43.2776-67.3217-79.0157QC'd by Toronto Research
Inhibitor17.335847.53650Single point of activity-4.76114.50450.9462-46.75760.7788-30 0 0 0 0 0 0 0-46.2786-4.6657-3.59865.9334.9801-1.92033.4427-6.1267-46.2786QC'd by APAC
Inactive0-8.46114.95490.3636-1-19.881540 0 0 0 0 0 0 1-8.4262-14.8249-0.34085.2591.29266.0598-14.9012-2.8941-8.4262QC'd by ACC
Inhibitor0.137782.25020Complete curve; high efficacy-6.86114.95490.9908-77.60434.6459-1.10 0 0 0 0 0 0 0-79.9161-2.96498.62547.8005-60.6439-73.5067-77.6531-78.9404-79.9161QC'd by Selleck
Inactive0-4.81111.0310.7705-19.9026940 0 0 0 0 0 0 0-13.252212.496214.28994.63351.399712.33453.181-2.2451-13.2522QC'd by Selleck
Inhibitor1.37772.24160Complete curve; high efficacy-5.86112.72020.9662-73.1605-0.9189-1.10 0 0 0 0 0 0 0-75.5794-3.4587-6.8595-6.106313.6092-12.7128-63.9802-70.8109-75.5794QC'd by ChemAxon
Inhibitor2.182436.04840Single point of activity-5.66113.990.7123-40.0484-4-30 0 0 0 0 0 1 1-1.9457-17.3668-3.9221.825-6.2771-1.2309-31.7070.1328-1.9457QC'd by Tocris
Inhibitor17.335886.3650Partial curve; high efficacy-4.76113.990.9311-82.7513.614-2.10 0 0 0 0 0 0 0-80.94744.06341.575612.3991-3.6901-8.458316.7716-10.4086-80.9474QC'd by NCGCChem
Inhibitor15.848938.78130Complete curve; partial efficacy; poor fit-4.84.95490.8508-36.39242.389-1.40 0 0 0 0 0 0 0-36.76215.4587-3.1878-7.80383.8851-1.3557.3218-31.052-36.762QC'd by ACC
Inhibitor17.782838.20450Partial curve; partial efficacy; poor fit-4.752.30310.8349-35.86332.3413-2.40 0 0 0 0 0 0 0-36.5329-5.53271.9501-3.48732.599716.6418-2.1763-22.5263-36.5329QC'd by ChemAxon
Inhibitor1.227384.05660Complete curve; high efficacy-5.91113.62720.9672-77.85516.2014-1.10 0 0 0 0 0 0 0-79.294814.3705-8.659616.67692.1334-5.1666-74.0838-76.8844-79.2948QC'd by EMD Chemicals
Inhibitor7.743659.07040Complete curve; high efficacy; poor fit-5.11114.95490.9731-64.7608-5.6904-1.30 0 0 1 0 0 0 0-64.5933-4.3213-12.3804-0.210132.6193-10.3584-1.2205-58.1285-64.5933QC'd by SynKinase
Inhibitor13.770333.46940Partial curve; partial efficacy; poor fit-4.86112.33320.6237-33.23020.2392-2.40 0 0 0 0 0 0 0-31.2245-13.7937-0.64479.3776-10.625511.38314.2981-14.3293-31.2245QC'd by SynKinase
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK304
Protocol: Assay Protocol Summary:

The medium for SNB-19 cells is composed of RPMI 1640 (ATCC, Cat.# 30-2001), 10% fetal bovine serum (FBS) (GE healthcare Life Sciences, Cat.# SH30071.03), and 1% Pen/Strep (Gibco, Cat.# 15140-122). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 250 cells/well in 3ul medium for SNB-19 cells in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002812903 uMActivity at 0.00113 uMActivity at 0.00153 uMActivity at 0.00281 uMActivity at 0.00542 uMActivity at 0.00844 uMActivity at 0.011 uMActivity at 0.022 uMActivity at 0.045 uMActivity at 0.070 uMActivity at 0.090 uMActivity at 0.180 uMActivity at 0.299 uMActivity at 0.374 uMActivity at 0.720 uMActivity at 1.388 uMActivity at 2.160 uMActivity at 2.888 uMActivity at 5.659 uMActivity at 11.50 uMActivity at 17.28 uMActivity at 23.76 uMActivity at 46.08 uMActivity at 88.34 uMActivity at 96.31 uMCompound QC
Inhibitor2.238789.761785Complete curve; high efficacy-5.653.1320.9798-91.7239-1.9621-1.10 0 0 0 0 0 0 0-92.6504-14.9776-2.82686.97092.5294-19.9355-89.5494-89.3969-92.6504QC'd by Toronto Research
Inhibitor2.4487105.737985Complete curve; high efficacy-5.61111.10.964-91.287714.4502-1.10 0 0 0 0 0 0 0-87.151617.47242.248328.45020.2899-3.8966-43.999-75.4993-87.1516QC'd by APAC
Inhibitor1.733671.148185Complete curve; high efficacy-5.76112.18760.9865-85.5846-14.4364-1.10 0 0 0 0 0 0 0-88.05-11.0286-13.1722-22.6166-11.6482-23.9564-67.5495-81.8454-88.05QC'd by Vitas
Inhibitor3.4589104.999285Complete curve; high efficacy-5.46111.96730.9619-94.639210.3601-1.10 0 0 0 0 0 0 0-93.59355.88010.92371.066428.289710.1673-33.3231-83.8664-93.5935QC'd by NCGCChem
Inhibitor0.2182100.649785Complete curve; high efficacy-6.66110.40.9042-48.908751.741-1.10 0 0 0 0 0 0 0-46.019636.048340.83292.32981.6403-13.2687-10.5332-28.8506-46.0196QC'd by Tocris
Inhibitor2.448787.352885Complete curve; high efficacy-5.61114.44950.9346-83.35174.0011-1.10 0 0 0 0 0 0 0-86.13113.0159-7.4847-1.9798-2.690728.1869-54.4602-81.0297-86.1311QC'd by SigmaAldrich
Inhibitor1.945188.884985Complete curve; high efficacy-5.71113.990.9976-88.0680.8169-1.10 0 0 0 0 0 0 0-88.9576-3.62320.982.3012.87380.3355-73.772-86.4882-88.9576QC'd by SigmaAldrich
Inhibitor3.0828109.714185Complete curve; high efficacy-5.51111.46410.9593-98.068111.646-1.10 0 0 0 0 0 0 0-90.9432-6.541725.516712.63029.46435.0841-40.5021-82.8978-90.9432QC'd by SigmaAldrich
Inhibitor3.458996.372685Complete curve; high efficacy-5.46111.96730.983-94.52751.8451-1.10 0 0 0 0 0 0 0-91.0669-6.7153-3.82114.49955.31915.4823-38.3842-89.4534-91.0669QC'd by NCGCChem
Inhibitor4.885991.980384Complete curve; high efficacy-5.31112.40640.977-88.30623.674-1.10 0 0 0 0 0 0 0-89.74213.47463.7694-0.8358-4.473315.2301-17.3952-75.5911-89.7421QC'd by Tocris
Inhibitor4.466895.808284Complete curve; high efficacy-5.354.95490.9805-89.76776.0405-1.10 0 0 0 0 0 0 0-91.787110.47785.3795-3.71350.987518.0399-71.8369-87.3281-91.7871QC'd by SIGMA
Inhibitor3.370788.649284Complete curve; high efficacy-5.47234.95490.9772-88.9248-0.2756-1.10 0 0 0 0 0 0 0-87.697-1.9772-9.5398-2.51674.3713-1.969110.0587-84.0919-87.697QC'd by GVK
Inhibitor4.354584.729584Complete curve; high efficacy-5.36111.46410.9635-91.2671-6.5376-1.10 0 0 0 0 0 0 0-88.4371-17.114-7.0154-1.0129-10.2535-0.6308-40.4239-74.3509-88.4371QC'd by XcessBio
Inhibitor3.458992.963384Complete curve; high efficacy-5.46111.88510.9823-90.13152.8318-1.10 0 0 0 0 0 0 0-88.36428.3178-0.0818-2.3812-1.72618.0541-39.6303-80.1311-88.3642QC'd by SigmaAldrich
Inhibitor4.885982.086684Complete curve; high efficacy-5.31111.210.958-90.6713-8.5847-1.10 0 0 0 0 0 0 0-83.491-15.9611-6.3092-13.82722.3555-20.7642-33.789-72.6017-83.491QC'd by SigmaAldrich
Inhibitor4.885987.426483Complete curve; high efficacy-5.31111.210.9619-84.51682.9096-1.10 0 0 0 0 0 0 0-78.58472.9372-7.187613.22334.6477-11.6811-22.524-64.0733-78.5847QC'd by Selleck
Inhibitor6.9015104.789983Complete curve; high efficacy-5.16112.30310.9648-86.939717.8502-1.10 0 0 0 0 0 0 0-85.837422.031811.074317.25596.538733.16412.8375-61.3006-85.8374QC'd by SIGMA
Inhibitor6.15187.670883Complete curve; high efficacy-5.21112.04370.9607-85.7661.9047-1.10 0 0 0 1 0 0 0-84.084311.86840.80467.2579-12.574629.0642-13.7532-67.4451-84.0843QC'd by Labotest
Inhibitor4.354594.391183Complete curve; high efficacy-5.36112.04790.9227-75.698118.6931-1.10 0 0 0 0 0 0 0-79.66435.764420.815216.094811.658640.9361-15.3703-57.615-79.6643QC'd by GVK
Inhibitor5.482166.533883Complete curve; high efficacy-5.26112.12110.9576-70.7385-4.2048-1.10 0 0 0 0 0 0 0-70.3847-16.43111.663-6.2016-1.50750.9096-19.0255-58.9929-70.3847QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK651
Protocol: Assay Protocol Summary:

The medium for astrocytes contains AM basal medium (ScienCell, Cat.# 1801), AGS (ScienCell, Cat.# 1801), 10% FBS, and 1% Pen/Strep. A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 350 cells/well in 3 ul medium for astrocytes in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002812903 uMActivity at 0.00113 uMActivity at 0.00153 uMActivity at 0.00281 uMActivity at 0.00542 uMActivity at 0.00844 uMActivity at 0.011 uMActivity at 0.022 uMActivity at 0.045 uMActivity at 0.070 uMActivity at 0.090 uMActivity at 0.180 uMActivity at 0.299 uMActivity at 0.374 uMActivity at 0.720 uMActivity at 1.388 uMActivity at 2.160 uMActivity at 2.888 uMActivity at 5.659 uMActivity at 11.50 uMActivity at 17.28 uMActivity at 23.76 uMActivity at 46.08 uMActivity at 88.34 uMActivity at 96.31 uMCompound QC
Inhibitor2.126798.290686Complete curve; high efficacy-5.67232.33320.989-94.61863.6721-1.10 0 0 0 0 0 0 0-92.22095.745712.695-0.4955-0.9426-0.004-23.8623-88.3104-92.2209QC'd by GVK
Inhibitor1.093885.970486Complete curve; high efficacy-5.96112.40640.9746-87.2021-1.2317-1.10 0 0 0 0 0 0 0-86.5101-4.826-11.49390.499610.8069-25.6751-82.9244-84.6842-86.5101QC'd by Toronto Research
Inhibitor1.7336103.944186Complete curve; high efficacy-5.76112.30310.9891-91.983511.9606-1.10 0 0 0 0 0 0 0-93.26493.766520.645814.58216.24942.3595-66.9639-90.5584-93.2649QC'd by SigmaAldrich
Inhibitor1.733699.285186Complete curve; high efficacy-5.76112.58840.9926-91.86437.4208-1.10 0 0 0 0 0 0 0-92.23329.90020.96482.900613.7785-0.3891-70.2185-90.9073-92.2332QC'd by SigmaAldrich
Inhibitor2.182482.189985Complete curve; high efficacy-5.66111.78850.966-83.6904-1.5005-1.10 0 0 0 0 0 0 0-85.5739.43192.4457-14.8764-4.9701-10.1524-53.7061-77.3664-85.573QC'd by APAC
Inhibitor1.945183.738385Complete curve; high efficacy-5.71112.25260.9866-90.0387-6.3005-1.10 0 0 0 0 0 0 0-91.5028-14.05931.5018-8.4839-5.4206-14.2252-67.204-85.585-91.5028QC'd by Vitas
Inhibitor1.945181.620185Complete curve; high efficacy-5.71113.990.994-85.8476-4.2275-1.10 0 0 0 0 0 0 0-86.7147-5.3956-0.96-10.1787-4.126-1.6685-71.9186-84.4646-86.7147QC'd by Vitas
Inhibitor2.4487102.603985Complete curve; high efficacy-5.61111.86170.9783-93.10239.5016-1.10 0 0 0 0 0 0 0-94.90595.98372.36855.112423.8641-0.4889-48.266-86.0562-94.9059QC'd by NCGCChem
Inhibitor2.747594.590685Complete curve; high efficacy-5.56112.33320.9719-88.26696.3237-1.10 0 0 0 0 0 0 0-89.1585-9.34847.070310.392316.2363.0405-42.787-84.922-89.1585QC'd by SigmaAldrich
Inhibitor2.747585.478285Complete curve; high efficacy-5.56111.41630.9706-87.5265-2.0483-1.10 0 0 0 0 0 0 0-87.878-11.3861-4.55672.54547.6047-17.4842-46.0156-75.511-87.878QC'd by SigmaAldrich
Inhibitor6.3096107.826384Complete curve; high efficacy-5.21.46410.9951-101.29416.5322-1.10 0 0 0 0 0 0 0-93.27266.6526.8647.22243.0047-1.642-49.0369-88.8736-93.2726QC'd by SIGMA
Inhibitor4.354593.540684Complete curve; high efficacy-5.36111.210.9916-91.46552.0752-1.10 0 0 0 0 0 0 0-86.61510.9960-0.15667.6334-10.6176-33.7688-68.9519-86.6151QC'd by XcessBio
Inhibitor4.3545114.247484Complete curve; high efficacy-5.36111.34430.9714-96.730917.5165-1.10 0 0 0 0 0 0 0-92.186128.617523.44171.717713.174610.1798-23.4073-72.7327-92.1861QC'd by SigmaAldrich
Inhibitor3.88186.852284Complete curve; high efficacy-5.41111.62660.9819-87.3695-0.5172-1.10 0 0 0 0 0 0 0-84.1712.34121.3774-7.31516.0015-11.9859-30.4165-77.1606-84.171QC'd by SigmaAldrich
Inhibitor3.881102.53984Complete curve; high efficacy-5.41112.40640.9598-94.15228.3868-1.10 0 0 0 0 0 0 0-94.43511.2112.95843.7145-4.604125.3762-24.3423-86.948-94.435QC'd by SigmaAldrich
Inhibitor3.881107.105484Complete curve; high efficacy-5.41112.25260.9366-98.6848.4214-1.10 0 0 0 0 0 0 0-94.7685-10.9643-2.261825.537322.78186.6323-29.0442-93.4381-94.7685QC'd by NCGCChem
Inhibitor5.482172.961883Complete curve; high efficacy-5.26111.96730.971-77.2318-4.2701-1.10 0 0 0 0 0 0 0-77.3964-10.9544-4.6765-6.0727-4.19395.3046-24.0277-61.7233-77.3964QC'd by Selleck
Inhibitor4.885992.130483Complete curve; high efficacy-5.31111.96730.974-82.83539.2952-1.10 0 0 0 0 0 0 0-82.820.47959.53240.17382.558411.0033-15.3175-66.887-82.8QC'd by Labotest
Inhibitor6.901579.065583Complete curve; high efficacy-5.16112.53340.9953-81.7895-2.7241-1.10 0 0 0 0 0 0 0-80.8236-2.9648-2.0732-6.4944-2.08321.4169-11.0939-65.172-80.8236QC'd by GVK
Inhibitor6.15184.657683Complete curve; high efficacy-5.21112.58840.9435-82.48892.1687-1.10 0 0 0 0 0 0 0-82.3972-4.6073-12.76319.44163.027815.9159-9.1577-67.6572-82.3972QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: VEGF_ADSC_ECFC_Angio_CD31_TubeArea_CRC
Protocol: N/A
Comment: N/A
IC50 qualifierIC50
>10
=2.3271
=1.4957
>10
>10
>10
=2.2736
>10
>10
>10
=0.0208
=4.5862
>10
>10
=4.9886
=0.001
=0.5236
=5.1845
>10
=0.405
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK159
Protocol: Assay Protocol Summary:

The medium for SNB-19 cells is composed of RPMI 1640 (ATCC, Cat.# 30-2001), 10% fetal bovine serum (FBS) (GE healthcare Life Sciences, Cat.# SH30071.03), and 1% Pen/Strep (Gibco, Cat.# 15140-122). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 250 cells/well in 3ul medium for SNB-19 cells in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inactive0-6.57924.95490.3504-2.229914.585140 0 0 0 0 0 0 0 0 0 0-5.356915.474625.14691.32891.457930.092112.8619-9.5062-12.2483-4.443920.4415-5.3569QC'd by BIOMOL
Inactive00040.140559.29224.527917.63713.780410.6882-1.5038-3.37094.203930.3994-1.99860.1405QC'd by BIOMOL
Inactive0-8.32924.95490.7822-3.268722.540 0 0 0 0 0 0 0 0 0 0-5.221915.927728.3896-3.44590.9788-0.6642-4.0601-8.14096.6432-8.9739-5.0251-5.2219QC'd by BIOMOL
Inactive0-7.17923.06540.4254932.145740 0 0 0 0 0 0 0 0 0 135.30295.277541.434433.152350.303620.24367.33299.210316.67199.450714.423135.3029QC'd by BIOMOL
Inactive0-8.37924.95490.35830.9315.540 0 0 0 0 0 0 0 0 0 119.319111.410119.1762-0.614-5.8917-0.005821.4835-3.85571.8137-0.8127-2.822419.3191QC'd by BIOMOL
Activator26.3506106.31810Single point of activity-4.57924.95490.950195.6321-10.685930 0 0 0 0 0 0 0 0 0 089.5669-8.1996-4.634-16.5004-16.3027-20.3551-20.1104-2.4639-1.956-4.3704-4.164789.5669QC'd by BIOMOL
Inactive0-9.02924.95490.39864-15.151240 0 0 0 0 0 0 0 0 0 011.3272-9.70937.84233.37613.399312.5003-0.1871-0.4744-2.70083.131-0.583111.3272QC'd by BIOMOL
Inactive0-4.47920.80.6034-34.4978-440 0 0 0 0 0 0 0 0 0 0-27.0815-0.6401-2.5148-2.2817-11.00811.0964-8.2348-11.6629-9.9639-6.098-9.2602-27.0815QC'd by BIOMOL
Inactive0004-0.534621.15938.357233.008610.588322.210240.91430.450915.303915.248315.763-0.5346QC'd by BIOMOL
Inactive0-7.37924.95490.72140.194224.863440 0 0 0 0 0 0 0 0 0 04.066615.530928.052423.038933.3812-2.1843-9.34578.111511.7564-7.393-1.86714.0666QC'd by BIOMOL
Inactive0004-29.782-16.4018-13.9219-14.5268-17.1479-18.872416.6048-0.8381-12.8788-19.3078-27.9636-29.782QC'd by BIOMOL
Inactive0004-9.6121-3.3856-4.2081-0.1463-6.8307-5.50433.9502-1.1496-1.2765-3.5332-1.7407-9.6121QC'd by BIOMOL
Activator0.331733.60330Complete curve; partial efficacy; poor fit-6.47920.70.714330.0135-3.58981.40 0 0 0 0 0 0 0 0 0 022.2786-3.1933-2.4551-4.04170.021512.07325.324119.20397.398643.355928.542722.2786QC'd by BIOMOL
Inactive0004-9.58580.041-18.54712.7931-0.1637-0.4717-3.0273-11.8154-12.2288-9.8437-6.1918-9.5858QC'd by BIOMOL
Inactive00043.544242.3006-2.999222.3937.6161-4.116332.17070.342-5.177242.8575-0.91733.5442QC'd by BIOMOL
Inactive0-6.37924.95490.3244-0.6421040 0 0 1 0 0 0 0 0 0 15.11119.82912.00793.113638.3079-0.532125.7035-1.3518-3.035-0.42124.22735.1111QC'd by BIOMOL
Inactive0-6.87924.95490.39070.6238.540 0 0 0 0 0 0 0 0 0 17.33186.6121-0.51588.08089.177318.9883-0.89744.13632.4077-2.3975-0.54117.3318QC'd by BIOMOL
Inactive0-7.62922.25260.46726-9.673540 0 0 0 0 0 0 0 0 0 04.0434-5.2371-12.2279-11.2597-1.22923.2718-0.865126.0229-0.0171-0.60298.95184.0434QC'd by BIOMOL
Inactive0004-0.5003-6.954428.7797-7.1636-6.6411.8449-16.4193-9.0529-12.5437-4.3363-10.7171-0.5003QC'd by BIOMOL
Inactive00049.9428-15.654318.1375-12.36-2.562816.0422-19.5863-8.3403-1.4148-7.26780.13079.9428QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: GSK3b_inh_pretreated_Viability_ATP_HCT116_SP
Protocol: N/A
Comment: N/A
Activity at 0.2 uMActivity at 2 uMActivity at 20 uM
-0.8-526.1
-4.15-1.1-7.2
-2-0.5-15.6
-6.4-13.6-13.4
-1.71.452.2
15.440.170
6.53.440.5
3.15-4.5-4.75
4.1-1.210.9
1.35-138.85
-0.51.6-14.3
-11.3-1039.1
7.0714.830.37
-1.8-1.57.5
19.1-3.9-10.9
13.90-5.5
-11.87.77.7
-10.05-4.15-2.95
5.51.32.6
-0.2-2.5-8.8
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK767
Protocol: Assay Protocol Summary:

The medium for astrocytes contains AM basal medium (ScienCell, Cat.# 1801), AGS (ScienCell, Cat.# 1801), 10% FBS, and 1% Pen/Strep. The ATP content assay kit (PerkinElmer, Cat.# 6016731) was used to determine cell viability. The reagent was reconstituted and prepared as described by the manufacturer. Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 350 cells/well in 3 ul medium for astrocytes in the tissue cultured treated/PDL coated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 72 hours, the reagent mixture of the ATP content assay kit was added to each well, followed by incubation at room temperature for 10 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV addition as a control of 100% viable cells and wells containing ZIKV infected cells as 100% cell death (completely reduced cell viability). The percentage inhibitions of the decreased cell viability by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002812903 uMActivity at 0.00113 uMActivity at 0.00153 uMActivity at 0.00281 uMActivity at 0.00542 uMActivity at 0.00844 uMActivity at 0.011 uMActivity at 0.022 uMActivity at 0.045 uMActivity at 0.070 uMActivity at 0.090 uMActivity at 0.180 uMActivity at 0.299 uMActivity at 0.374 uMActivity at 0.720 uMActivity at 1.388 uMActivity at 2.160 uMActivity at 2.888 uMActivity at 5.659 uMActivity at 11.50 uMActivity at 17.28 uMActivity at 23.76 uMActivity at 46.08 uMActivity at 88.34 uMActivity at 96.31 uMCompound QC
Activator7.7436251.405948Partial curve; high efficacy-5.11114.95490.9649256.16764.76172.10 0 0 0 0 0 0 116.3408-4.222-0.83564.737239.2766-8.74150.8296225.897316.3408QC'd by Labotest
Activator1.093891.011546Partial curve; high efficacy-5.961110.973187.9238-3.08782.10 0 0 0 0 0 0 146.5836-1.88210.21981.32081.295841.334956.841681.410946.5836QC'd by SigmaAldrich
Activator4.885959.090322Complete curve; partial efficacy-5.31114.95490.95557.2178-1.87251.20 0 0 0 0 0 0 048.802-4.2518-1.56346.456-1.9107-5.69710.86665.022848.802QC'd by SigmaAldrich
Activator31.622852.183820Partial curve; partial efficacy-4.52.12110.987752.4430.25922.20 0 0 0 0 0 0 047.49320.8385-3.09290.02593.6313-1.09781.395717.763947.4932QC'd by Toronto Research
Activator6.15137.698810Single point of activity-5.21113.06540.931538.25920.560530 0 0 0 0 0 0 14.02167.0265-2.68850.9817-3.28290.28344.136833.58754.0216QC'd by NCGCChem
Activator39.810738.970510Single point of activity-4.44.95490.993437.0057-1.964830 0 0 0 0 0 0 036.3163-2.288-4.5192-1.0857-1.0399-1.6354-1.8940.352736.3163QC'd by ACC
Activator63.095734.708310Single point of activity-4.24.95490.962634-0.708330 0 0 0 0 0 0 030.06680.4353-1.30873.164-3.0902-1.20751.4018-2.513130.0668QC'd by ChemAxon
Activator1.37782.566710Single point of activity-5.86114.44950.999679.2287-3.338130 0 0 0 0 0 1 1-9.1968-2.4762-4.4223-2.9029-3.15780.596276.204622.7521-9.1968QC'd by Microsource
Activator30.827835.224710Single point of activity-4.51114.95490.9143360.775330 0 0 0 0 0 0 031.7383-3.52062.04857.83410.5280.23630.2733-1.774131.7383QC'd by Vitas
Activator11.959631.059210Partial curve; partial efficacy; poor fit-4.92234.0950.9394320.94082.40 0 0 0 0 0 0 029.99793.3608-3.79931.5686-0.6674.5901-0.85222.352729.9979QC'd by SIGMA
Activator17.335835.616610Single point of activity-4.76113.19250.979233.5-2.116630 0 0 0 0 0 0 032.1022-2.0605-2.37042.1612-3.4305-2.9694-2.5865.638132.1022QC'd by GVK
Activator21.824435.103310Single point of activity-4.66114.50450.92535.46720.363930 0 0 0 0 0 0 034.4088.1938-0.3341-1.60980.3152-1.6427-3.03012.465134.408QC'd by SIGMA
Activator6.151186.50910Single point of activity-5.21113.990.9972185.349-1.1630 0 0 0 0 0 0 1-9.9898-1.7881-1.8274-6.91794.48711.02357.4273171.6194-9.9898QC'd by NCGCChem
Activator5.482136.268210Partial curve; partial efficacy; poor fit-5.26112.24810.975533.5-2.76822.40 0 0 0 0 0 0 1-9.6755-6.05680.0886-3.5093-2.3509-2.51424.240327.714-9.6755QC'd by Tocris
Activator5.482148.66110Single point of activity-5.26114.95490.966547.413-1.248130 0 0 0 0 0 0 1-10.3317-3.6187-3.4368-5.20674.52151.27550.647346.0144-10.3317QC'd by Selleck
Activator21.824440.12110Single point of activity-4.66114.50450.967341.35581.234730 0 0 0 0 0 0 039.83983.53892.07512.7318-4.38771.58393.02083.262239.8398QC'd by Carbosynth
Activator5.482181.285310Single point of activity-5.26113.990.992179.5097-1.775530 0 0 0 0 0 0 1-10.19192.2773-3.50471.0494-4.3992-4.11864.195775.531-10.1919QC'd by Tocris
Activator1.733651.212910Single point of activity-5.76114.95490.977950.2423-0.970530 0 0 0 0 0 1 1-1.5361.4091-2.3998-4.97543.3091-0.47646.606612.6681-1.536QC'd by SigmaAldrich
Activator17.335830.551710Single point of activity-4.76114.95490.962130.5-0.051730 0 0 0 0 0 0 030.2014-0.72973.27741.7456-3.37640.6024-2.24073.346930.2014QC'd by SigmaAldrich
Inactive00043.7857-0.65752.8452-4.4898-2.19140.76962.693.72033.7857QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK097
Protocol: Assay Protocol Summary:

The medium for hNPCs consists of DMEM/F12, N2 supplement (ThermoFisher, Cat.# 17502048), NEAA (ThermoFisher, Cat. # 11140050), 2 ug/ml heparin, 2 uM cyclopamine, and B27 (ThermoFisher, Cat. # 17504044). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 350 cells/well in 3 ul medium for hNPCs in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inhibitor1.177177.955893Complete curve; high efficacy-5.92924.44950.9941-184.5509-6.595-1.10 0 0 0 0 0 0 0 0 0 0-185.5575-4.6679-6.07642.0148-8.4168-11.0338-21.5021-2.901-155.7275-182.4713-186.415-185.5575QC'd by Toronto Research
Inhibitor1.1471185.207193Complete curve; high efficacy-5.94041.210.97-180.93524.2719-1.10 0 0 0 0 0 0 0 0 0 0-177.4789-1.8992-5.87563.952936.1181-2.14-22.9111-15.9848-71.7614-129.8809-162.4978-177.4789QC'd by Selleck
Inhibitor1.6626168.127491Complete curve; high efficacy-5.77923.1320.9837-169.0446-0.9171-1.10 0 0 0 0 0 0 0 0 0 0-168.1209-22.0426-2.082-5.32045.54071.319-1.450114.7212-89.7232-163.7665-168.7071-168.1209QC'd by Toronto Research
Inhibitor1.6626180.916791Complete curve; high efficacy-5.77923.06540.9946-179.00781.9089-1.11 0 0 0 0 0 0 0 0 0 0-184.164424.6062-0.25336.7266-4.25895.2703-6.96233.8251-93.9542-164.0777-181.1503-184.1644QC'd by Microsource
Inhibitor2.5119207.7491Complete curve; high efficacy-5.61.28761-191.831715.9083-1.10 0 0 0-186.97050.1857-67.9483-158.9713-186.9705QC'd by SIGMA
Inhibitor2.6351194.953890Complete curve; high efficacy-5.57923.1320.9719-181.527713.4261-1.10 0 0 0 0 0 0 0 0 0 0-182.0412-10.1591-4.327141.72652.806130.91214.291818.2215-27.3816-157.9177-180.8355-182.0412QC'd by Microsource
Inhibitor2.6351187.857190Complete curve; high efficacy-5.57921.96730.9892-184.8163.0411-1.10 0 0 0 0 0 0 0 0 0 0-185.5582-11.96489.2141-3.2711.099417.1828-3.5684-6.2672-52.0668-151.5101-173.32-185.5582QC'd by NCGCChem
Inhibitor1.049135.304590Complete curve; high efficacy-5.97921.210.9819-141.7236-6.4191-1.10 0 0 0 0 0 0 0 0 0 0-147.6287-12.4793-9.977-7.7012-7.9502-2.9377-8.1662-64.6761-88.8563-120.3966-133.137-147.6287QC'd by SantaCruz Bio
Inhibitor2.8184216.384690Complete curve; high efficacy-5.551.69240.9997-186.295930.0887-1.10 0 0 0-182.643124.865-42.6314-161.1067-182.6431QC'd by SIGMA
Inhibitor2.3485163.71489Complete curve; high efficacy-5.62922.25260.9797-163.7140-1.10 0 0 0 0 0 0 0 0 0 0-160.5039-3.8215-6.7268-7.215321.45223.6974-17.7659-0.4266-46.4433-147.1554-160.0245-160.5039QC'd by Chemscene
Inhibitor2.6351163.489589Complete curve; high efficacy-5.57922.90230.9893-160.83712.6524-1.10 0 0 0 0 0 0 0 0 0 0-164.4551-6.438912.37438.80558.37418.3794-11.7519-4.8192-29.5494-138.8745-157.2471-164.4551QC'd by NCGCChem
Inhibitor4.6859191.442587Complete curve; high efficacy-5.32923.1320.9826-168.314323.1281-1.10 0 0 0 0 0 0 0 0 0 0-166.876718.290114.40469.045234.10942.835721.691110.381325.2215-83.459-167.42-166.8767QC'd by Selleck
Inhibitor4.6859162.961287Complete curve; high efficacy-5.32922.24810.9856-169.2903-6.3291-1.10 0 0 0 0 0 0 0 0 0 0-177.4531-11.75413.3773-4.3533-18.2902-11.7259-2.3524-8.7407-13.4287-99.7645-147.5191-177.4531QC'd by XcessBio
Inhibitor3.7221126.784186Complete curve; high efficacy-5.42921.46410.957-135.7206-8.9365-1.10 0 0 0 0 0 0 0 0 0 0-142.2647-0.6771-6.2358-11.2121-16.6768-27.3011-0.3514-8.3109-35.4059-95.2772-106.0275-142.2647QC'd by Toronto Research
Inhibitor9.3495220.010985Complete curve; high efficacy-5.02922.33320.9927-186.75533.2559-1.10 0 0 0 0 0 0 0 0 0 0-173.508727.166126.046340.016235.561841.045434.729824.282529.7949-6.87-142.7818-173.5087QC'd by Selleck
Inhibitor10130.300384Complete curve; high efficacy-52.78680.9985-148.0456-17.7453-1.10 0 0 0-146.7041-67.4842-127.8599-147.7501-146.7041QC'd by SIGMA
Inhibitor10145.260384Complete curve; high efficacy-51.78850.9997-161.3387-16.0784-1.10 0 0 0-152.7828-41.646-82.1916-129.7354-152.7828QC'd by GVK
Inhibitor3.162382.146984Complete curve; high efficacy-5.52.18761-81.06551.0814-1.10 0 0 0-79.882-22.1789-55.8956-75.2948-79.882QC'd by SIGMA
Inhibitor10127.897283Complete curve; high efficacy-51.62590.9999-122.48425.4131-1.10 0 0 0-119.3803-48.5016-88.2414-110.9773-119.3803QC'd by SIGMA
Inhibitor9.349566.453582Complete curve; high efficacy-5.02922.25260.9036-65.87540.5781-1.10 0 0 0 0 0 1 0 0 0 0-62.9964-8.14449.52244.22022.849611.2227-15.585328.5669-1.4504-13.5243-50.6989-62.9964QC'd by Toronto Research
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK211
Protocol: Assay Protocol Summary:

The medium for SNB-19 cells is composed of RPMI 1640 (ATCC, Cat.# 30-2001), 10% fetal bovine serum (FBS) (GE healthcare Life Sciences, Cat.# SH30071.03), and 1% Pen/Strep (Gibco, Cat.# 15140-122). The ATP content assay kit (PerkinElmer, Cat.# 6016731) was used to determine cell viability. The reagent was reconstituted and prepared as described by the manufacturer. Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 250 cells/well in 3ul medium for SNB-19 cells in tissue culture treated plates. Compounds were added to cells and incubated for a specific time such as 6, 24, or 72 hours before addition of the reagent mixture of the ATP content assay kit at 1:1 ratio. After incubation at room temperature for 10 minutes, the luminescence intensity in assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without compound addition as a control of 100% viable cells and wells without cells as 0% cell viability (completely reduced cell viability). The percentage inhibitions of the decreased cell viability by small molecules were then calculated that indicate compound cytotoxicity.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002812903 uMActivity at 0.00113 uMActivity at 0.00153 uMActivity at 0.00281 uMActivity at 0.00542 uMActivity at 0.00844 uMActivity at 0.011 uMActivity at 0.022 uMActivity at 0.045 uMActivity at 0.070 uMActivity at 0.090 uMActivity at 0.180 uMActivity at 0.299 uMActivity at 0.374 uMActivity at 0.720 uMActivity at 1.388 uMActivity at 2.160 uMActivity at 2.888 uMActivity at 5.659 uMActivity at 11.50 uMActivity at 17.28 uMActivity at 23.76 uMActivity at 46.08 uMActivity at 88.34 uMActivity at 96.31 uMCompound QC
Inactive0-4.954.95490.7301-28.1197-2.317340 0 0 0 0 0 0 0-25.2569-1.598712.3919-9.5676-10.9165-2.3501-1.4521-30.7808-25.2569QC'd by Toronto Research
Cytotoxic1.545169.635285Complete curve; high efficacy-5.81111.50950.9413-71.1032-1.468-1.10 0 0 0 0 0 0 0-73.7747-5.65321.1494-13.549910.9055-21.7206-50.3617-65.4108-73.7747QC'd by Toronto Research
Cytotoxic24.487442.947420Partial curve; partial efficacy-4.61111.62660.8852-52.3258-9.3783-2.20 0 0 0 0 0 0 0-41.1559-16.6387-4.4819-7.8307-13.8113-7.2563-12.5026-19.0583-41.1559QC'd by APAC
Inactive0-8.41114.95490.57876-17.312240 0 0 0 0 0 0 013.6138-13.593513.17620.07934.9462.8313-2.34910.390213.6138QC'd by ACC
Inactive0-6.36114.95490.37675-5.662540 0 0 0 0 0 0 03.2816-5.15547.7491-6.7695-18.05215.52627.40883.18853.2816QC'd by Tocris
Cytotoxic0.015587.431393Complete curve; high efficacy-7.81111.13410.99-79.19158.2398-1.10 0 0 0 0 0 0 0-81.19591.406-32.3557-58.0304-70.3274-77.6375-79.962-80.5907-81.1959QC'd by Selleck
Inactive0-6.24974.95490.53191-10.158340 0 0 0 0 0 0 1-23.6662-4.5014-5.0336-17.6319-13.9665.357-4.39541.6721-23.6662QC'd by Tocris
Cytotoxic4.354583.264684Complete curve; high efficacy-5.36111.210.9911-85.7814-2.5168-1.10 0 0 0 0 0 0 0-79.00111.1666-6.846-0.8138-7.9871-8.4594-33.9635-66.5727-79.0011QC'd by ChemAxon
Inactive0-5.16114.95490.64247-11.092540 0 0 0 0 0 0 05.3323-19.24370.1334-11.6067-7.6189-10.1426-16.98137.69395.3323QC'd by Tocris
Inactive0-5.86114.95490.382-15.706-0.540 0 0 0 0 0 0 0-25.17178.0806-3.9886-14.29482.19634.7323-20.3153-0.9191-25.1717QC'd by NCGCChem
Inactive0-8.154.95490.34569-12.200240 0 0 0 0 0 0 11.4762-7.250114.26194.93650.241120.8735-2.000415.80491.4762QC'd by ACC
Inactive0-4.954.95490.52347.5-6.404840 0 0 0 0 0 0 04.0754.4894-1.9309-10.1412-7.688-14.9206-8.885210.73264.075QC'd by ChemAxon
Cytotoxic4.885958.468883Complete curve; high efficacy-5.31113.1320.9263-65.727-7.2581-1.10 0 0 0 0 0 0 0-63.1804-9.5143-14.8752-0.6791-20.6238-10.9557-14.1399-65.1114-63.1804QC'd by EMD Chemicals
Inconclusive5.482139.090710Complete curve; partial efficacy; poor fit-5.26112.84730.81837.7925-1.29821.40 0 0 0 0 0 0 037.4341-13.78516.3344-3.179111.974-7.38884.909933.535637.4341QC'd by SynKinase
Inactive0-8.41114.95490.31575.5-12.2640 0 0 0 0 0 0 08.4705-9.490612.2592-0.9384.258213.7445-9.89.19068.4705QC'd by SynKinase
Cytotoxic8.912580.374482Complete curve; high efficacy-5.053.1320.9528-80.5181-0.1437-1.10 0 0 0 0 0 0 0-78.963312.47416.5639-13.0419-7.61931.3512-17.9499-77.9639-78.9633QC'd by Cayman
Inactive0-8.16113.06540.60717.5-11.991140 0 0 0 0 0 0 010.0664-10.8263.806713.119412.7767-2.43242.91049.448410.0664QC'd by Cayman
Inactive0-5.11114.95490.51114.50.439340 0 0 0 0 0 0 13.7494-7.13396.23411.44524.96150.472-2.518812.74863.7494QC'd by Toronto Research
Inactive0-8.21111.85790.3859-11.890940 0 0 0 0 0 0 013.4975-7.82574.64472.009222.42520.97520.887712.047713.4975QC'd by Pharmaron
Cytotoxic19.451137.771820Single point of activity-4.71113.57220.6413-41.2055-3.4337-30 0 0 0 0 0 0 0-39.7269-15.23467.1378-14.2159-10.88252.33989.61-8.9369-39.7269QC'd by Pharmaron
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: hNCI-H716_GLP1_Secretion_SP
Protocol: N/A
Comment: N/A
Activity at 2 uMActivity at 10 uM
0.4-0.1
2.11.1
0.31
-1.90.3
-2.42
1.63.4
-3.4-1.5
0.51.4
1.38.5
1.13.3
-0.5-0.7
2.32.6
2.80.1
2.26
0.83.1
2.6-0.1
-21-21
0.4-1.1
10.5
01.9
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Southern Research Institute 靶标:CFTR
External ID: CF Folding
Protocol: A high throughput 384-well microplate based fluorescence assay was developed using HeLa cells engineered to express F508del-CFTR. Cells were maintained in cell culture media (High Glucose DMEM (Gibco) supplemented w/ 10% FBS (Gibco)). For the assay, cells were trypsinized (0.25% Trypsin-EDTA solution (Gibco)) and resuspended in assay media (cell culture media + 1% Pen/Strep (Gibco)) at a density of 320,000 cells per ml. Cells were dispensed to the assay plates (Corning 3712) in 25 ul using a Wellmate (Matrix/Thermo). Plates were incubated overnight at 37C, 5% CO2 and high humidity. The next day, compounds were prepared by making a dilution in assay media to a concentration of either 150 uM or 60 ug/ml (6x) depending on the library being screened. Then 5 ul of the diluted compound was transferred to the assay plate containing the cells. Assay plates were incubated for 24 hours 37C, 5% CO2 and high humidity. Following incubation with the compounds, relative cell number was determined by adding 3 ul of alamarBlue (TREK Diagnostics) and incubating the plates at 37C, 5% CO2 and high humidity, until cell control values reached ~4 million, as measured with a fluorescent intensity protocol on an Envision multimode plate reader (Perkin Elmer) (excitation 535 nm, emission 595 nm wavelengths) . Following the alamarBlue read, the media was removed and the cells were fixed with the addition of 13 ul of 4% paraformaldehyde in PBS (pH 7.4) and incubated for 10 minutes at room temperature. Plates were washed twice with PBS to remove the fixative. Cells were permeabilized with the addition of blocking solution (PBS, 0. 1% Triton X-100, 10 mg/ml BSA) and incubated at room temperature for 30 minutes. The blocking solution was removed and the primary antibody mixture was added in 13ul (Antibodies UNC570 and UNC596; CFF Therapeutics, Inc., Bedford, MA) at a 1/5000 dilution of each antibody in blocking solution. Plates were then incubated over night at 4oC. Primary antibody was removed by washing three times with 50 ul of wash solution (PBS, 0.1% Triton X-100) with at least 5 minutes between wash cycles. Secondary antibody (Alexa 488 anti-mouse IgG Invitrogen) was then added in a volume of 13 ul (1/1000 dilution in blocking solution) and incubated for two hours at room temperature in the dark. To remove excess secondary antibody, plates were washed three times with 50 ul of wash solution and one time with 50 ul of PBS. Plates were read from the bottom using a fluorescent intensity protocol on an Envision multimode plate reader (485 nm excitation and 535 nm emission).
To minimize the disruption of the cell monolayer during the numerous washes, the following process was used. The removal of media or other reagents for the wells of the microtiter plate was done using a Biomek FX (Beckman, Fullerton CA) with a 384 tip multichannel head. Aspiration was done at a slow rate following the liquid level with the tip positioned in the top right corner of the well. All solution additions, starting with the fixative, were done with a Matrix Wellmate. Again to avoid disturbing the cell monolayer, the plate offset was adjusted so that the liquid dispensed to the left wall of the well rather than directly on the cell monolayer.
For the screen, approximately ten thousand compounds from a mix of FDA and diverse libraries (MicroSource Pharmacon-1600 (FDA), Enzo (FDA), Selleck (FDA) and Enamine) were tested at a final concentration 25 uM (Enzo, Selleck & MS Pharmakon) or 10 ug/ml (Enamine 30K diversity set). The proteasome inhibitor ALLN was used as the positive control (50 uM) and 100 uM Hyamine was used as a viability control on all microtiter plates. All wells including the cell controls contained 0.5% DMSO. In-plate controls were used to normalize the data and results were reported as fold increase above the cell control and normalized to relative cell number derived from the alamarBlue data.
Ninety six compounds identified in the single dose screen were evaluated further in dose response. Compound high dose was twice the screening concentration and a ten point series of two fold dilutions were done for each compound. DMSO concentration was 1% for in all wells. Compounds were evaluated in both the immunostain assay and in the cell viability assay.

Data Analysis: Thirty two control wells containing cells only, 24 wells containing Hyamine and 8 wells containing ALLN were included on each assay plate and used to calculate Z' value for each plate and to normalize the data on a per plate basis. Data were analyzed using the IDBS Activity Base software. Results were expressed as Fold Increase (FI) for the immunostain assay and cell viability (V) for the alamarBlue assay. Final data was reported as Normalized fold increase (NFI). Data was analyzed as follows FI=DataValue/Median cell control, V= (DataValue-median Hyamine control)/(median cell control -median Hyamine control) and NFI=FI/V.

For the immunostain dose response assay, IC50 values were calculated for active compounds by plotting the FI for each concentration, and using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0. Similarly, EC50 values were calculated for the cell viability dose response assay, plotting the % Viability at each concentration and also using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0 and the maximum limit set at 100.

Outcome- From the primary screen, compounds selected as Active were those that met one of the following two criteria: (1) Fold Induction >/= 1.5, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/= 1.5; or (2) Fold Induction >/= 1, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/=1.75. While 101 compounds met this criteria, 96 were ultimately selected for confirmatory screening. For the dose response screen, compounds were labeled as "Active" if they showed at least 8 fold increase over the ALLN control at any concentration.
Comment: Possible Artifacts: Possible artifacts in this assay include, but are not limited to, compounds that are fluorescent, absorb at the excitation or emission wavelengths, or non-specifically upregulate protein expression
IC50 ModifierIC50IC50 Fit Hill SlopeIC50 Fit NormChi2IC50 Fit StDevMax Fold IncreaseConc @Max Fold IncreaseEC50 ModifierEC50EC50 Fit Hill SlopeEC50 Fit NormChi2EC50 Fit StDevFold Increase @50 uM Rep1Fold Increase @25 uM Rep1Fold Increase @12.5 uM Rep1Fold Increase @6.25 uM Rep1Fold Increase @3.13 uM Rep1Fold Increase @1.56 uM Rep1Fold Increase @0.78 uM Rep1Fold Increase @0.39 uM Rep1Fold Increase @0.2 uM Rep1Fold Increase @0.09 uM Rep1Fold Increase @20 ug/ml Rep1Fold Increase @10 ug/ml Rep1Fold Increase @5 ug/ml Rep1Fold Increase @2.5 ug/ml Rep1Fold Increase @1.25 ug/ml Rep1Fold Increase @0.63 ug/ml Rep1Fold Increase @0.31 ug/ml Rep1Fold Increase @0.156 ug/ml Rep1Fold Increase @0.078 ug/ml Rep1Fold Increase @0.039 ug/ml Rep1Fold Increase @50 uM Rep2Fold Increase @25 uM Rep2Fold Increase @12.5 uM Rep2Fold Increase @6.25 uM Rep2Fold Increase @3.13 uM Rep2Fold Increase @1.56 uM Rep2Fold Increase @0.78 uM Rep2Fold Increase @0.39 uM Rep2Fold Increase @0.2 uM Rep2Fold Increase @0.09 uM Rep2Fold Increase @20 ug/ml Rep2Fold Increase @10 ug/ml Rep2Fold Increase @5 ug/ml Rep2Fold Increase @2.5 ug/ml Rep2Fold Increase @1.25 ug/ml Rep2Fold Increase @0.63 ug/ml Rep2Fold Increase @0.31 ug/ml Rep2Fold Increase @0.156 ug/ml Rep2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: VEGF_ADSC_ECFC_Angio_CD31_TubeArea_SP
Protocol: N/A
Comment: N/A
Activity at 2 uMActivity at 10 uM
-6.5-1.2
6.2-8.1
-22.1-8.2
-5.67.4
-6.63.5
2.7-8.6
5.2-10.7
21.82.7
-10.59.6
-13.31.9
-10.4-4.4
2.314.1
2.12.1
1.45.9
5.70.3
-7.1-9.6
-5.8-11.2
-1-36.8
-4.2-12.4
-12.2-9
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK375
Protocol: Assay Protocol Summary:

The medium for hNPCs consists of DMEM/F12, N2 supplement (ThermoFisher, Cat.# 17502048), NEAA (ThermoFisher, Cat. # 11140050), 2 ug/ml heparin, 2 uM cyclopamine, and B27 (ThermoFisher, Cat. # 17504044). The ATP content assay kit (PerkinElmer, Cat.# 6016731) was used to determine cell viability. The reagent was reconstituted and prepared as described by the manufacturer. Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 350 cells/well in 3 ul medium for hNPCs in the tissue cultured treated/PDL coated plates. Compounds were added to cells and incubated for a specific time such as 6, 24, or 72 hours before addition of the reagent mixture of the ATP content assay kit at 1:1 ratio. After incubation at room temperature for 10 minutes, the luminescence intensity in assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without compound addition as a control of 100% viable cells and wells without cells as 0% cell viability (completely reduced cell viability). The percentage inhibitions of the decreased cell viability by small molecules were then calculated that indicate compound cytotoxicity.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002812903 uMActivity at 0.00113 uMActivity at 0.00153 uMActivity at 0.00281 uMActivity at 0.00542 uMActivity at 0.00844 uMActivity at 0.011 uMActivity at 0.022 uMActivity at 0.045 uMActivity at 0.070 uMActivity at 0.090 uMActivity at 0.180 uMActivity at 0.299 uMActivity at 0.374 uMActivity at 0.720 uMActivity at 1.388 uMActivity at 2.160 uMActivity at 2.888 uMActivity at 5.659 uMActivity at 11.50 uMActivity at 17.28 uMActivity at 23.76 uMActivity at 46.08 uMActivity at 88.34 uMActivity at 96.31 uMCompound QC
Cytotoxic28.183857.977620Partial curve; partial efficacy-4.551.96730.9819-55.82612.1514-2.20 0 0 0 0 0 0 0-50.62591.11451.931.56856.3454-2.55832.4351-21.2508-50.6259QC'd by Toronto Research
Cytotoxic3.458988.330984Complete curve; high efficacy-5.46111.46410.9722-88.05330.2776-1.10 0 0 0 0 0 0 0-85.8219-6.2995-7.27596.40210.87740.2166-42.2058-70.0716-85.8219QC'd by Toronto Research
Cytotoxic19.451147.575321Partial curve; partial efficacy-4.71112.30310.9153-47.8271-0.2517-2.20 0 0 0 0 0 0 0-41.93923.50615.5779-5.19711.9739-8.0807-0.4595-11.3757-41.9392QC'd by APAC
Inactive0-8.21113.1320.62964.5-18.008340 0 0 0 0 0 0 1-7.7761-16.25691.078813.63025.56182.8914-6.36126.589-7.7761QC'd by ACC
Inactive00045.01735.67670.9345-2.8901-5.053516.80202.83845.0173QC'd by Tocris
Cytotoxic0.690163.446685Complete curve; high efficacy-6.16111.62590.9905-64.2941-0.8474-1.10 0 0 0 0 0 0 0-60.92691.4444-5.48541.5354-8.0911-32.9046-59.4023-66.939-60.9269QC'd by Selleck
Cytotoxic35.502234.413120Single point of activity-4.44972.84730.8592-37.4131-3-30 0 0 0 0 0 0 0-32.8443-8.456-3.8001-3.89186.4235-5.3159-2.8216-6.9183-32.8443QC'd by Tocris
Cytotoxic1.945181.131785Complete curve; high efficacy-5.71111.62590.9849-81.7382-0.6065-1.10 0 0 0 0 0 0 0-83.5769-0.9757-5.3124-2.4177.4877-16.4965-54.7072-74.7257-83.5769QC'd by ChemAxon
Inactive00041.2764-2.4572.1363-0.06124.7465.15913.8213-1.22711.2764QC'd by Tocris
Cytotoxic13.770333.50820Partial curve; partial efficacy; poor fit-4.86111.34430.9007-34.508-1-2.40 0 0 0 0 0 0 0-29.17331.0669-3.8778-6.35283.30492.4028-6.6547-14.7598-29.1733QC'd by NCGCChem
Inactive0-7.81.10.35077.5-13.08940 0 0 0 0 0 0 06.2174-9.24082.03480.68414.852125.49471.17591.50576.2174QC'd by ACC
Inactive0-6.54.95490.36531.5-4.281440 0 0 0 0 0 0 1-9.5304-7.67453.2382-8.1512-0.48891.97360.33591.9503-9.5304QC'd by ChemAxon
Cytotoxic1.733693.775386Complete curve; high efficacy-5.76111.37230.9973-91.04172.7336-1.10 0 0 0 0 0 0 0-89.25656.07130.49750.2643-1.0544-18.4277-58.0582-87.4106-89.2565QC'd by EMD Chemicals
Inactive0-5.36114.95490.679-15340 0 0 0 0 0 0 0-9.01034.01663.5936-1.2145-3.804711.96050.6106-21.25-9.0103QC'd by SynKinase
Inactive0-4.51114.95490.4969-17.0242040 0 0 0 0 0 0 0-15.0202-12.21962.30.56622.42310.65646.37920.2322-15.0202QC'd by SynKinase
Cytotoxic3.981168.728883Complete curve; high efficacy-5.44.95490.9891-67.62891.0999-1.10 0 0 0 0 0 0 0-68.17490.5349-6.40021.00075.82583.5832-58.1119-66.8594-68.1749QC'd by Cayman
Inactive0-8.31112.35310.64864.5-14.833240 0 0 0 0 0 0 01.0331-10.69432.26792.624712.01034.23917.9786-0.50111.0331QC'd by Cayman
Inactive0-6.26114.95490.94865-7.10940 0 0 0 0 0 0 04.6078-5.4009-5.7935-6.9992-9.25752.41456.8163.90884.6078QC'd by Toronto Research
Inactive0-6.711110.6219-3.19639.540 0 0 0 0 0 0 0-5.132610.09546.333810.25340.17274.4314-8.91362.2597-5.1326QC'd by Pharmaron
Cytotoxic13.770341.617221Partial curve; partial efficacy-4.86111.96730.9642-43.2746-1.6574-2.20 0 0 0 0 0 0 0-39.602-2.99371.9719-3.5811-3.9687-2.48521.5083-20.0659-39.602QC'd by Pharmaron
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: Basal_Viability_ATP_SW480_SP
Protocol: N/A
Comment: N/A
Activity at 0.2 uMActivity at 2 uMActivity at 20 uM
18.418.217.1
16.67.823.6
-2.53.616.2
19.434.522.8
15.624.6125.8
48.875.790.3
27.314.323.3
6.1528.859.1
21.212.649.7
-6.47.611.9
0.2-0.4-16.3
3-1.5-2.4
46.1-3.51.7
10.115.25.3
-36.65.815
13.2-5.516.6
-28.60.2-24.3
1.4-13.240.9
12.3534.45132.2
1320.8-14.2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK808
Protocol: Assay Protocol Summary:

The medium for astrocytes contains AM basal medium (ScienCell, Cat.# 1801), AGS (ScienCell, Cat.# 1801), 10% FBS, and 1% Pen/Strep. The ATP content assay kit (PerkinElmer, Cat.# 6016731) was used to determine cell viability. The reagent was reconstituted and prepared as described by the manufacturer. Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 350 cells/well in 3 ul medium for astrocytes in the tissue cultured treated/PDL coated plates. Compounds were added to cells and incubated for a specific time such as 6, 24, or 72 hours before addition of the reagent mixture of the ATP content assay kit at 1:1 ratio. After incubation at room temperature for 10 minutes, the luminescence intensity in assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without compound addition as a control of 100% viable cells and wells without cells as 0% cell viability (completely reduced cell viability). The percentage inhibitions of the decreased cell viability by small molecules were then calculated that indicate compound cytotoxicity.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002812903 uMActivity at 0.00113 uMActivity at 0.00153 uMActivity at 0.00281 uMActivity at 0.00542 uMActivity at 0.00844 uMActivity at 0.011 uMActivity at 0.022 uMActivity at 0.045 uMActivity at 0.070 uMActivity at 0.090 uMActivity at 0.180 uMActivity at 0.299 uMActivity at 0.374 uMActivity at 0.720 uMActivity at 1.388 uMActivity at 2.160 uMActivity at 2.888 uMActivity at 5.659 uMActivity at 11.50 uMActivity at 17.28 uMActivity at 23.76 uMActivity at 46.08 uMActivity at 88.34 uMActivity at 96.31 uMCompound QC
Cytotoxic15.848956.978321Partial curve; partial efficacy-4.80.70.9406-46.188410.7899-2.20 0 0 0 0 0 0 0-36.28627.452216.61317.68547.5757-4.8329-3.7753-20.1291-36.2862QC'd by Toronto Research
Cytotoxic2.747574.265684Complete curve; high efficacy-5.56111.53860.9458-73.70730.5583-1.10 0 0 0 0 0 0 0-73.8499-6.9415-6.81272.856815.5674-12.2779-38.6533-64.8451-73.8499QC'd by Toronto Research
Cytotoxic21.824446.474620Partial curve; partial efficacy-4.66111.96730.9543-50.6821-4.2075-2.20 0 0 0 0 0 0 0-41.80460.2706-8.4595-5.5308-7.8659-5.2709-3.8936-14.9406-41.8046QC'd by APAC
Inactive0-8.46114.95490.39376.5-2.814640 0 0 0 0 0 0 1-1.3182-0.678812.21422.83177.39339.0983.17164.4375-1.3182QC'd by ACC
Inactive0-6.16113.990.560113.5-1.530940 0 0 0 0 0 0 1-0.9187-1.8319-8.35911.1261-6.7857.035914.816311.9755-0.9187QC'd by Tocris
Cytotoxic0.137758.399587Complete curve; high efficacy-6.86111.88510.9807-60.6296-2.2301-1.10 0 0 0 0 0 0 0-58.9668-0.9979-6.9268-4.176-42.0514-54.0167-58.9732-66.3237-58.9668QC'd by Selleck
Inactive0-4.29974.95490.6081-21.5209-340 0 0 0 0 0 0 0-18.3507-3.12461.7244-5.698-3.93211.0222-11.43650.9634-18.3507QC'd by Tocris
Cytotoxic3.458988.035884Complete curve; high efficacy-5.46111.10.9763-84.85893.1768-1.10 0 0 0 0 0 0 0-78.3022-3.27894.77073.54388.1609-16.4308-31.4464-69.9583-78.3022QC'd by ChemAxon
Inactive0-7.61114.95490.6036-6.63152.540 0 0 0 0 0 0 11.2385-2.51397.3716-7.9669-2.4984-7.8119-6.4841-8.02621.2385QC'd by Tocris
Inactive0-5.11114.95490.69274-10.053540 0 0 0 0 0 0 1-8.4264-6.3764-9.5878-10.1935-14.2113-6.8809-14.10982.172-8.4264QC'd by NCGCChem
Inactive0-8.154.95490.707912-17.805440 0 0 0 0 0 0 012.8185-11.504519.72580.601814.380112.065913.43911.648712.8185QC'd by ACC
Inactive0-6.44.44950.33994.5-1.446440 0 0 0 0 0 0 1-0.26192.6885-5.372-2.36540.980210.9592-0.72062.7046-0.2619QC'd by ChemAxon
Cytotoxic1.227358.520285Complete curve; high efficacy-5.91113.92950.9693-65.2567-6.7365-1.10 0 0 0 0 0 0 0-67.3304-17.66380.0346-7.5539-4.1906-12.4058-64.1835-62.0797-67.3304QC'd by EMD Chemicals
Inconclusive21.824440.13210Single point of activity-4.66111.80790.549139.3369-0.795130 0 0 0 0 0 0 030.98524.81538.943810.642-19.5763-10.50763.08418.683230.9852QC'd by SynKinase
Inactive0-8.41114.95490.4487-6.852910.540 0 0 0 0 0 0 16.27547.3998-7.123-9.23455.3063-8.1132-7.1251-14.46076.2754QC'd by SynKinase
Cytotoxic8.912574.741282Complete curve; high efficacy-5.053.51170.9614-73.08931.6519-1.10 0 0 0 0 0 0 0-71.69711.4726-6.9455-0.412-5.192210.7966-13.0091-72.0082-71.697QC'd by Cayman
Inactive0-7.96111.69240.77169-14.696140 0 0 0 0 0 0 05.5961-12.6634-2.43416.26911.42287.74512.644917.40545.5961QC'd by Cayman
Inactive0-7.36110.20.400916-26.37940 0 0 0 0 0 0 014.5767-18.64924.582-13.39884.7001-5.51229.1952-3.546114.5767QC'd by Toronto Research
Inactive0-8.16113.51170.611410-9.123940 0 0 0 0 0 0 010.0418-8.43666.991516.36766.875216.43520.239910.666410.0418QC'd by Pharmaron
Cytotoxic12.272846.625920Partial curve; partial efficacy; poor fit-4.91111.210.7951-46.9293-0.3035-2.40 0 0 0 0 0 0 0-39.27167.26478.7632-15.5306-2.6441-2.0334-5.997-23.0142-39.2716QC'd by Pharmaron
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:846 靶标:N/A
External ID: Basal_Viability_ATP_HCT116_SP
Protocol: N/A
Comment: N/A
Activity at 0.2 uMActivity at 2 uMActivity at 20 uM
3.22.511.9
32.316.2-36.7
-4.92.5-0.4
-33.90.62.4
-2.32.438.9
-27.323.859.6
1.12.134.3
8.5-0.8-5.3
1.44.933.6
8-0.11.5
-32.6-5.40.6
-15.8-1211.7
10.79.1525.9
40.810.8
-4.66.89.4
-1.2-3.6-6.4
2.12.20.6
-13.8-26.98.9
-26.2-2.810
-31.84.26.6
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: ERR163
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00043.0633-0.75412.1391.5904-0.3839-1.1415-0.39720.3007-0.97562.17540.8962-0.70775.67143.0633QC'd by ACCInactive0-4.475110.3403
Inactive0-4.47512.58840.5668.5-0.350840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.86480.1037-0.8896-0.4598-1.86570.62930.11860.461.3225-4.0423-0.7584-0.26931.61755.8648QC'd by ACCInactive0-4.87510.96410.6959
Inconclusive26.603243.928410Partial curve; high efficacy-4.57511.75290.950842-1.92842.10 0 0 0 0 0 0 0 0 0 0 0 0 0 032.0411-4.94030.1803-1.7907-1.04840.7187-2.0655-1.6464-0.9268-3.163-1.69577.805612.275332.0411QC'd by ACCInconclusive14.960143.862810Partial curve; partial efficacy-4.82511.96730.9669
Inactive0-4.77511.17050.46487-2.090540 0 0 0 0 0 0 0 0 0 0 0 0 0 05.8087-2.6379-0.128-0.3535-5.64580.03570.6444-4.5926-6.7421-1.9435-0.94861.98431.17355.8087QC'd by ACCInactive0-9.12514.95490.3263
Inactive00041.42561.18570.65356.04820.39286.34775.07265.4272.92610.04150.34843.0231-0.03451.4256QC'd by RTIInactive0
Inactive0004-1.88582.35057.09190.33143.3965-1.34684.203-0.8178-0.3747-1.06299.6715-2.4181-0.776-1.8858QC'd by RTIInactive0
Inactive0410.19018.95610.325512.63911.810913.69999.62495.66968.687812.306313.512815.91738.562510.1901QC'd by RTIInactive0
Inactive0004-0.41364.053-1.44611.85171.21114.06523.09290.81280.93140.5931-2.12422.4304-0.681-0.4136QC'd by RTIInactive0
Inactive00040.842-0.47542.86752.25690.4215-1.5297-2.07673.62060.9619-1.5025.02941.288-1.44990.842QC'd by RTIInactive0
Inconclusive0.00215.510Complete curve; partial efficacy; poor fit-8.70534.50450.795614-1.51.40 0 0 0 0 0 0 0 0 0 0 1 1 0 1-9.16440.693913.915611.436716.139211.324915.416415.994911.157614.795712.415311.295913.1797-9.1644QC'd by RTIInactive0-4.10534.95490.806
Inactive0004-6.75480.2459-1.60532.34130.73913.9972-1.3651-1.7233-3.4099-1.711.5906-2.29334.2594-6.7548QC'd by RTICytotoxic74.351433.63620Partial curve; partial efficacy; poor fit-4.12874.0450.7048
Cytotoxic40.421673.990940Partial curve; high efficacy-4.39342.25260.9604-70.17013.8208-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-61.09312.03564.92412.49064.22714.26826.20750.1594-0.95685.63330.0103-1.2879-37.614-61.0931QC'd by RTICytotoxic50.887883.280741Partial curve; high efficacy-4.29342.40640.9709
Cytotoxic69.171880.051341Partial curve; high efficacy-4.16014.50450.9543-74.39445.6568-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-62.67343.72427.29138.5895.08398.48319.02366.00472.81232.47474.97363.2009-4.4556-62.6734QC'd by RTICytotoxic69.171870.875120Single point of activity-4.16014.95490.9592
Inactive00045.1373.18785.21485.1644.96454.2219-0.33642.43436.57815.74133.06254.20694.86615.137QC'd by RTIInactive0
Cytotoxic78.824137.545620Single point of activity-4.10334.95490.8973-36.54561-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.20472.52230.11410.250.7493-2.2911-0.3071-0.86864.6455-1.007-1.8243.89684.0876-29.2047QC'd by RTICytotoxic78.824134.719820Partial curve; partial efficacy; poor fit-4.10334.95490.8207
Cytotoxic54.894739.278640Partial curve; high efficacy-4.26053.1320.9761-38.27861-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-33.1488-1.31041.12321.8921-0.72281.240.11850.53022.330.65950.21212.9868-14.3497-33.1488QC'd by RTICytotoxic54.894761.362221Partial curve; partial efficacy-4.26052.18760.9745
Inactive00043.14233.21915.8769-1.7146-0.4681-0.26044.11687.43091.98552.08331.94551.2669-1.29783.1423QC'd by RTIInactive0
Inactive0004-2.77945.33392.168-2.2813-0.6736-2.0788-16.89162.24013.5698-1.00744.02973.9198-1.0474-2.7794QC'd by RTIInactive0-4.79590.40.487
Inactive0004-0.88360.18994.02715.7421-2.1210.15651.51726.95692.32841.27492.76063.93542.593-0.8836QC'd by RTIInactive0
Inactive0-6.964110.3333-0.776340 0 0 0 0 0 0 0 0 0 0 0 0 0 13.24412.13982.31925.45162.7289-2.13923.47190.2244-0.6655-1.88570.9391.8723-2.31343.2441QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:firefly luciferase
External ID: LUC790
Protocol: Tox21 Assay Protocol Summary:

3 ul of substrate mix (containing 50 mM Tris acetate, pH 7.6, 13.3 mM Mg acetate, 10uM D-luciferin, 10uM ATP, 0.01% Tween, 0.05% BSA and dH2O ) is dispensed into each well of a Greiner white, solid-bottom 1536-well format plate using a flying reagent dispenser (FRD). These assay plates were then treated with 23nL of compound or DMSO using a Kalypsys pin tool, which allows for delivery of a 6-point interplate titration of each compound to the assay plate (quantitative HTS.) 1 uL of firefly luciferase mix (containing 50 mM Tris acetate, pH 7.6, 0.04 uM P. pyralis luciferase, 0.01% Tween, 0.05% BSA and dH2O) was then delivered by FRD to each well. Luciferase activity was then measured using a ViewLux CCD imager.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000074871 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000679832 uM-Replicate_1Activity at 0.0001616562 uM-Replicate_1Activity at 0.0003744726 uM-Replicate_1Activity at 0.0007728037 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00651 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.2010.90.8471131.115440 0 0 0 0 0 0 0 0 0 0 0 0 0 09.54731.4227-0.0927-0.73721.51692.33370.74961.98550.53323.45031.33282.53683.90686.069.5473QC'd by LightBiologicalsActivator70.63415.92510Partial curve; partial efficacy; poor fit-4.1510.90.7402
Inactive00043.83132.48656.35684.00543.84138.25791.63143.11833.93691.19885.93977.44213.27273.8313QC'd by LightBiologicalsInactive0
Inhibitor27.540425.239720Partial curve; partial efficacy-4.563.06540.9464-24.23971-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.86643.54850.58071.273.5792-1.0506-0.74551.82640.64041.29330.55871.0439-10.0294-21.8664QC'd by LightBiologicalsInactive0-4.364.50450.8982
Inhibitor70.574761.494341Partial curve; high efficacy-4.15142.30310.9936-61.34170.1527-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.84970.69220.24130.03541.62351.4902-0.6178-0.2576-0.1338-0.7741-1.5037-5.7105-17.9277-46.8497QC'd by LightBiologicalsInhibitor62.899858.392741Partial curve; high efficacy-4.20143.1320.9871
Inactive0-4.39890.90.710380.988440 0 0 0 0 0 0 0 0 0 0 0 0 0 11.7160.31890.18581.95122.60040.67990.14231.73831.70660.79292.27513.9265.04871.716QC'd by LightBiologicalsInactive0
Inactive0004-1.2464-0.1277-3.31990.07610.0272-0.171-0.9426-1.275-0.8314-1.0122-0.1704-0.7926-0.2083-1.2464QC'd by LightBiologicalsInactive0
Inactive00049.0594-4.22375.94818.69258.92016.96137.5769-4.56141.7618.73328.6084-3.34-3.90129.0594QC'd by LightBiologicalsInactive0
Inactive00041.81981.5048-2.86521.29632.0381-3.75161.90181.93420.96122.92531.90792.69043.8991.8198QC'd by LightBiologicalsInactive0-4.19893.92950.4592
Inactive00041.0427-2.9040.2976-1.36752.4811.58460.60181.9111.8233-2.31412.7932-0.1252-3.80621.0427QC'd by LightBiologicalsInactive0
Inactive00041.81572.32444.23827.73370.21471.78012.640.32671.7625.77573.74973.61055.36231.8157QC'd by LightBiologicalsInactive0-4.51490.50.3892
Inhibitor89.358431.923510Single point of activity-4.04894.95490.9445-30.92351-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.10290.8105-1.44111.7887-0.1850.69522.96312.16590.03891.2506-0.78660.32282.6099-24.1029QC'd by LightBiologicalsInhibitor89.358427.433610Single point of activity-4.04894.95490.9335
Inactive0-6.39480.90.42680.05953.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.61711.84673.25183.75243.33334.00713.8712-0.9505-1.43963.0690.48362.44510.1858-1.6171QC'd by LightBiologicalsInactive0
Inactive00040.0907-0.4901-3.2387-0.7092-0.3212-0.94770.426-0.2568-0.3555-0.5594-0.8083-0.44290.5340.0907QC'd by LightBiologicalsInactive0
Inactive00040.8222.29930.05141.4340.8292-3.84692.04270.53252.7743.15713.841.89041.86440.822QC'd by LightBiologicalsInactive0
Inhibitor79.640758.055341Partial curve; high efficacy-4.09893.62720.9858-58.8675-0.8123-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.8693-1.39271.2532-1.8476-3.00891.0377-0.085-0.0864-1.0068-0.2868-1.8043-4.6859-9.7906-46.8693QC'd by LightBiologicalsInhibitor70.979924.628520Partial curve; partial efficacy-4.14893.57220.9379
Inactive0-4.04894.50450.8551-8.6034140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.33621.44610.98591.11170.77190.52781.33360.63411.98470.66550.3564-1.19960.4705-6.3362QC'd by LightBiologicalsInactive0-4.24891.46410.7616
Inhibitor31.705522.975520Partial curve; partial efficacy-4.49892.09370.9159-21.97551-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.22960.1079-1.25660.0804-0.4464-0.9265-0.24241.22035.1564-0.16970.1335-8.2794-14.2156-21.2296QC'd by SIGMAInhibitor39.914927.035120Partial curve; partial efficacy-4.39891.47870.9029
Inactive00041.68681.80593.04642.90412.6745-1.14845.3851.35853.20093.01323.66774.258211.12191.6868QC'd by SIGMAInactive0
Inactive0004-0.01532.91587.60184.7593.8923-5.03062.21774.13765.41963.00133.93875.23166.3628-0.0153QC'd by SIGMAInhibitor89.358418.599210Partial curve; partial efficacy; poor fit-4.04894.95490.8509
Inactive00043.7853-0.6681.31811.1372-0.42441.41111.52592.25831.1924-5.84795.2943-0.63157.19593.7853QC'd by SIGMAInactive0